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Cystic fibrosis (CF) is caused by mutations in the cystic fibrosis transmembrane 
conductance regulator (CFTR) Cl- channel. The licensing of the CFTR potentiator 
ivacaftor (VX-770, Vertex Pharmaceuticals Inc.), provided proof of concept for the use 
of small molecules to treat CF. However, the mechanism of action of ivacaftor is not 
well understood. Studies exploiting species differences in CFTR pharmacology have 
previously been used to identify binding sites of CFTR modulators. We hypothesised 
that differences in the response of CFTR orthologues to ivacaftor may be used to 
determine regions of the protein involved in its mechanism of action. 
 
CFTR orthologues from human, pig, sheep, ferret, mouse and zebrafish were studied 
using single-channel patch-clamp recordings. These studies identified differences in 
the single-channel current amplitude (i) and open probability (Po) of CFTR 
orthologues. Single-channel recordings also demonstrated that the Po of mouse 
F508del-CFTR after rescue of its plasma membrane expression was not reduced 
compared to mouse wild-type (WT)-CFTR and channel activity remained stable at 37 
°C in contrast to human F508del-CFTR. Furthermore, neither mouse WT-CFTR nor 
rescued mouse F508del-CFTR were potentiated by ivacaftor. We therefore developed 
a high-throughput assay utilising automated whole-cell patch-clamp recording to test 
a selection of human-mouse CFTR chimeras for their response to ivacaftor. From 
these studies, we identified five sequence alterations from the human to the mouse 
sequence, A326T, L327V, K329N, I332V and A349S, located in the third extracellular 
loop (ECL3) and on transmembrane helix 6 (TM6), that when expressed in human 
CFTR prevented potentiation by ivacaftor. These experiments were further supported 
by single-channel recordings of human-mouse CFTR chimeras. 
 
In conclusion, this study has identified structural regions within the transmembrane 
helices of CFTR that may be targeted for the development of novel CFTR potentiators 
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a.a. = amino acid 
AAV = adeno-associated virus 
AMPK = 5’ adenosine monophosphate-activated protein kinase 
Apo = unbound 
ATP = adenosine triphosphate 
ADP = adenosine diphosphate 
AQP = aquaporin 
ASL = airway surface liquid 
BHK = baby hamster kidney 
bp = base pair 
cAMP = cyclic adenosine monophosphate 
CF = cystic fibrosis 
CFTR = cystic fibrosis transmembrane conductance regulator 
CHO = Chinese hamster ovary 
DMEM = Dulbecco’s modified Eagle’s medium 
DMSO = Dimethyl sulphoxide 
DPBS = Dulbecco’s phosphate-buffered saline 
ECl = equilibrium constant for chloride 
EGTA = ethylene glycol-bis(β-aminoethyl ether)-N,N,N',N'-tetra acetic acid 
EM = electron microscopy 
EMA = European Medicines Agency 
ENaC = epithelial sodium channel 
ER = endoplasmic reticulum 
ERAD = endoplasmic reticulum associated degradation 
ERQC = endoplasmic reticulum quality control 
F = the Faradays constant (9.648533 x104 C∙mol-1) 
FABP = fatty acid binding protein 
FACS = fluorescence activated cell sorting 
FBS = foetal bovine serum 
fCFTR = ferret CFTR 
FDA = U.S. Food and Drug Administration 
FSK = forskolin 
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GTA = gene transfer agent 
hCFTR = human CFTR 
HDX = hydrogen/deuterium exchange mass spectrometry 
HEPES = 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
KCN = potassium channel 
MCC = mucociliary clearance 
mCFTR = mouse CFTR 
NHE1 = Na+/H+ antiporter 1 
NKCC1 = Na+, K+, Cl—cotransporter 
NMDG = N-Methyl-D-glucamine 
NPPB = 5-nitro-2-(3-phenylpropylamino) benzoate 
pCFTR = pig CFTR 
pEGFP-N1 = Enhanced green fluorescent protein N1 plasmid 
PKA = protein kinase A 
PKC = protein kinase C 
PM = plasma membrane 
PPi = Pyrophosphate 
PTC = premature termination codon 
R = universal gas constant (8.314472 J∙K-1∙mol-1) 
RD = regulatory domain 
RI = regulatory insertion 
sCFTR = sheep CFTR 
SD = Standard deviation 
SEM = Standard error of the mean 
T = temperature 
TES = N-tris[hydroxymethyl]methyl-2-aminoethanesulphonic acid 
TM = transmembrane helix 
TMD = transmembrane domain 
TMEM16A = Ca2+-activated Cl- channel 
WA = Walker A site 
WB = Walker B site 
z = valency 
zCFTR = zebrafish CFTR 
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1.1 Aetiology and epidemiology of cystic fibrosis 
 
Cystic fibrosis (CF) is one of the most common life-shortening autosomal recessive 
disorders among Caucasians with an estimated incidence of 1 in 2,000-3,000 births in 
European-derived populations, corresponding to a carrier frequency of up to 1 in every 
26 individuals (Romeo et al., 1989; Farrell, 2000; Bobadilla et al., 2002). Whilst 
incidence of CF within European countries is variable (ranging from 1 in 1,400 in 
Ireland and 1 in 2,400 in the UK to 1 in 25,000 in Finland), it is much lower in non-
European populations (e.g. 1 in 15,000 in African Americans and 1 in >100,000 in 
Asians) (O'Sullivan & Freedman, 2009; Bell et al., 2015). Once considered to be 
primarily a paediatric disease due to low life expectancy, in recent decades advances 
in evidence-based care and, more recently, the development of small molecule CFTR 
modulators that target the underlying defect in CF have extended average life 
expectancy beyond ~40 years (Elborn et al., 1991; Burgel et al., 2015; Elborn, 2016; 
Ramsey & Welsh, 2017). However, there is still no cure for the disease. 
 
CF disrupts fluid movement across epithelial membranes throughout the body, 
including the respiratory, gastro-intestinal and reproductive systems, and can lead to 
diverse organ pathologies that may include respiratory disease, pancreatic 
insufficiency, intestinal obstruction and male infertility (Frizzell & Hanrahan, 2012; 
Wang et al., 2014b). However, airway disease resulting from defective transport of 
fluid across the respiratory epithelia and the build-up of thick, dehydrated mucus, 
represents the major cause of mortality in patients with CF (Ratjen et al., 2015). 
Effective fluid secretion across the airway epithelium is necessary to ensure that 
mucus lining the airways is sufficiently fluid to enable clearance via ciliary beating 
(Quinton, 1999). This process of mucociliary clearance (MCC) is required for the 
effective removal of potentially harmful bacteria such as Staphylococcus aureus and 
Pseudomonas aeruginosa as well as other pathogens including viruses and fungi (e.g. 
Aspergillus spp.) from the respiratory system (Gilligan, 1991). In patients with CF 
however, disruption of fluid movement across this epithelium results in a build-up of 
viscous mucus that cannot be cleared, increasing the risk of infection. Repeated and 
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chronic pulmonary infections in the CF lung can therefore lead to scarring and 
progressive deterioration in lung function, reducing the capacity of the CF lung for 
normal gaseous exchange and eventually leading to pulmonary failure (Gilligan, 1991; 
Rowe et al., 2005). 
 
In the early 1980s, Quinton (1983) determined that reduced Cl- permeability in the 
sweat ducts of CF patients was the cause of poor NaCl reabsorption. Riordan et al. 
(1989) identified the gene involved in CF, a region spanning over 250 kb on 
chromosome 7 and consisting of 27 exons that encode a protein with 1480 amino 
acids (a.a.) with a molecular mass of 168,138 Daltons. The protein in question was 
found to share structural similarities with the mammalian multi-drug resistance protein 
P-glycoprotein, a member of the ATP-binding cassette (ABC) transporter family of 
membrane transporters (Juliano & Ling, 1976; Riordan et al., 1989; Senior & Gadsby, 
1997). These similarities included 2 repeated motifs, each with a transmembrane-
spanning domain (TMD) and a nucleotide-binding domain (NBD), although CFTR also 
includes an additional regulatory domain (RD) between these two motifs that is unique 
to CFTR (Figure 1.1) (Riordan et al., 1989). For this reason, Riordan et al. (1989) 
hypothesised that the protein in question was likely to be involved in membrane 
transport, and so named it the Cystic Fibrosis Transmembrane Conductance 
Regulator (CFTR), although it’s role as an ion channel at that time was not known. 
CFTR is now known to belong to the C subfamily of the ABC transporter superfamily 
of membrane proteins and as such has been given the designation ABCC7 (Holland, 
2003; Jordan et al., 2008). However unlike other ABC transporters, which utilise the 
energy derived from ATP hydrolysis to actively transport substrates across the plasma 
membrane, CFTR is unique, functioning as a low conductance (6 - 10 pS), ATP-
regulated anion-selective channel with channel gating regulated by binding of ATP at 
the NBDs and phosphorylation of consensus phosphorylation sites located within the 




Figure 1.1: Schematic cartoon indicating the domain arrangement of CFTR. The CFTR protein 
shares many structural similarities with other members of the ABC-transporter family of membrane 
proteins and consists of two repeated motifs, each comprising a membrane bound transmembrane 
domain (TMD) and a nucleotide-binding domain (NBD). These two repeated domains are connected 
via a fifth, regulatory domain (RD), phosphorylation of which is involved in regulating the gating 
behaviour of CFTR (Riordan et al., 1989). EXT = extracellular, INT = intracellular. 
 
CFTR plays an important role in controlling fluid flux across epithelial membranes, 
principally via regulation of Cl- secretion, which establishes both the electrochemical 
and osmotic driving forces for Na+ and H2O movement (Frizzell & Hanrahan, 2012). In 
addition, CFTR facilitates HCO3- secretion, which has an antibacterial role, is important 
for neutralising mucosal pH and contributes to the physiochemical properties of the 
mucosal layer (Frizzell & Hanrahan, 2012; Shamsuddin & Quinton, 2014; Stoltz et al., 
2015). The key role of CFTR in epithelial fluid flux underlies the diverse pattern of 
organ dysfunction observed in CF (Wang et al., 2014b). Historically, treatment of CF 
has primarily been targeted at the symptoms of the disease, including physiotherapy 
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to aid clearance of lung mucus, combined with antibiotics to target infection, anti-
inflammatories and where possible surgery and lung transplant (Fajac & De Boeck, 
2017). However, since identification of the gene involved in CF, the CF research 
community has focussed on the development of targeted therapies for CF that treat 
the root cause of the disease. Such approaches have included the use of small 
molecule pharmacological compounds that restore function to mutant CFTR (Becq et 
al., 2011), gene therapy (Griesenbach et al., 2015; Alton et al., 2016), or bypassing 
the need for CFTR altogether by targeting alternative Cl- transporters (Li et al., 2016; 
Li et al., 2017). However, in addition to the need to overcome a multitude of organ 
pathologies, the task of developing successful treatments for CF is further complicated 
by the diversity of mutations that lead to the disease. Since its discovery, over 2,000 
mutations have now been identified in CFTR that can cause cystic fibrosis and a 
continually updated database of these mutations is maintained by the Cystic Fibrosis 
Mutation Database at http://genet.sickkids.on.ca/app. The vast majority of these 
mutations are rare, with many being identified in only one individual, however the 
major exception to this is the deletion of phenylalanine at position 508, commonly 
referred to as F508del (Kerem et al., 1989). As many as 90% of CF patients are 
thought to carry at least one copy of the F508del allele, with ~70% patients 
homozygous for the mutation worldwide (Bobadilla et al., 2002; Bell et al., 2015). 
 
1.2 Role of CFTR in epithelial fluid transport 
 
Effective epithelial fluid secretion is essential for the healthy function of multiple organ 
systems and CFTR plays a pivotal role in this process in conjunction with other ion 
channels and transporters (Frizzell & Hanrahan, 2012; Saint-Criq & Gray, 2017). This 
involvement of CFTR is demonstrated by the multiple organ pathology observed in CF 
patients, with defective CFTR function contributing to impaired epithelial transport in 
the lungs, exocrine pancreatic insufficiency, impaired intestinal secretion (resulting in 
blockage of ducts and demonstrated by meconium ileus, obstruction of the small 
intestine in some newborn babies with CF), male infertility and ‘salty sweat’ (Rowe et 
al., 2005; Wang et al., 2014b). In the airways, the movement of H2O and formation of 
the airway surface liquid (ASL) layer at the apical surface of airway epithelia is 
regulated via the coordination of a network of ion transport pathways, principally 
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involving Na+, Cl-, HCO3-, Ca2+, and K+. Figure 1.2 provides an overview of the ion 
channels, transporters and pathways that are known to be involved in mediating fluid 
secretion and maintaining the ASL. The extent to which these pathways contribute to 
epithelial fluid transport may vary between organ systems, as well as between different 
species (Ostedgaard et al., 2007; Frizzell & Hanrahan, 2012; Stahl et al., 2012). As 
progressive deterioration in lung function as a result of defective fluid secretion is the 
main cause of death in patients with CF, ion channels and transporters involved in this 
process have the potential as therapeutic targets for CF (Li et al., 2017). 
 
As shown in Figure 1.2, movement of water across epithelia may occur by either the 
paracellular pathway or the transcellular route through aquaporins. This movement is 
dependent upon an osmotic gradient from the basolateral to the apical side of the 
epithelial cell layer. The net movement of Na+ and Cl- is a major factor involved in 
establishing this gradient (Frizzell & Hanrahan, 2012). Na+ ions pass via the 
paracellular pathway in response to the electrochemical driving force established by 
the transport of other ions, key to which is the transcellular transport of Cl- (Frizzell & 
Hanrahan, 2012). Whilst a number of pathways are available for the apical transport 
of Cl-, for example via the SLC26A9 Cl- channel and the Ca2+-activated chloride 
channel TMEM16A, CFTR is the predominant pathway for apical Cl- movement in 
human airway epithelia (Frizzell & Hanrahan, 2012) (Figure 1.2). Furthermore, as 
CFTR gating is dependent upon both binding of ATP at the NBDs and phosphorylation 
of the RD, the role of CFTR in apical movement of Cl- facilitates regulation of fluid 
movement via the cAMP/PKA signalling pathway (Riordan et al., 1989; Vergani et al., 
2005a). Absorption of Na+ occurs via the amiloride-sensitive epithelial sodium channel 
(ENaC), and it has been proposed that specific regions of airway epithelia are 
specialised for either absorption or secretion (Shamsuddin & Quinton, 2012). The 
apical absorption of Na+ via ENaC is enhanced in patients with CF and there appears 
to be a reciprocal relationship between CFTR-mediated Cl- efflux and ENaC activity, 
suggesting a mechanism of interaction between CFTR and ENaC, either directly or 




Figure 1.2: Schematic of the pathways involved in epithelial fluid transport.  Net secretion of Cl- 
establishes a gradient for the transepithelial movement of Na+ via paracellular pathways and this in turn 
establishes an osmotic gradient favouring the secretion of H2O via the paracellular pathway or 
transcellular pathway through aquaporins (AQP) such as AQP3 (Frizzell & Hanrahan, 2012; Saint-Criq 
& Gray, 2017). At the basolateral membrane, Cl- transport occurs primarily via cotransport with Na+ and 
K+ by the NKCC1 cotransporter. This is driven by the electrochemical gradient established by the 
Na+/K+ATPase, which exchanges Na+ for K+, and subsequent K+ efflux via KCN channels (e.g. KCNQ1, 
KCNE2, KCNE3 and KCNN4). Basolateral Cl- transport is supplemented by the Na+-independent anion 
exchanger AE2 (SLC4A2) in exchange for HCO3-. Cellular pH is regulated by basolateral transport of 
HCO3- via the electrogenic sodium bicarbonate cotransporter 1 (NBC1/SLC4A4) in conjunction with Na+ 
and via the conversion of CO2 and H2O to HCO3- and H+ as catalysed by carbonic anhydrase. H+ efflux 
at the basolateral membrane occurs via the sodium-hydrogen antiporter 1 (NHE1/SLC9A1). At the 
apical membrane, Cl- efflux into the airway surface liquid (ASL) layer occurs principally via CFTR. Apical 
Cl- efflux is also supplemented via the Ca2+-activated Cl--channel TMEM16A and SLC26A9. Absorption 
of Na+ at the apical membrane occurs via the epithelial sodium channel (ENaC) and is enhanced in 
patients with CF, contributing to ASL dehydration. Figure adapted from Frizzell and Hanrahan (2012) 
and Saint-Criq and Gray (2017). 
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The primary route for Cl- entry to epithelial cells at the basolateral membrane is via the 
Na+, K+, Cl--cotransporter (NKCC1), the driving force for which, the inward 
electrochemical gradient of Na+, is established by the active transport of Na+ and K+ 
via the Na+/K+-ATPase. The Na+/K+-ATPase transports three Na+ ions out of the cell 
in exchange for two K+ ions, the energy for which is derived from the conversion of 
one molecule of ATP to ADP (Skou, 1957, 1965, 1998). K+ ions that have entered the 
cell are then able to exit via KCN channels in the basolateral membrane, the identity 
of which varies between cell type, but in airway epithelia includes the cAMP-activated 
KCNE1,2 and KCNQ1 channels, as well as Ca2+-activated KCNN4 (Liao et al., 2005; 
Frizzell & Hanrahan, 2012; Saint-Criq & Gray, 2017). This efflux of K+ is a major 
determinant of the negative-inside basolateral membrane potential. Splice variants of 
KCNN4 have also been identified at the apical membrane where they are able to 
enhance the driving force for Cl- secretion following activation by elevated Ca2+ (Joiner 
et al., 2003; Nanda Kumar et al., 2010; Frizzell & Hanrahan, 2012; Saint-Criq & Gray, 
2017). Additional basolateral Cl- transport may occur in exchange for HCO3- via the 
Na+-independent anion exchanger AE2 (SLC4A2), which is highly expressed in gut 
epithelial cells and has also been identified in cultured human airway epithelial cells 
(Calu-3) (Loffing et al., 2000; Gawenis et al.,2004; Garnett et al. 2011; Shan et al., 
2011; Frizzell & Hanrahan, 2012; Huang et al., 2012; Haq et al., 2016). 
 
Intracellular pH is a further determinant of epithelial anion secretion. Intracellular pH 
is primarily controlled by the co-ordination of the basolateral Cl-/HCO3- and Na+/H+ 
exchangers AE2 and NHE1 (Novak & Young, 1986; Pirani et al., 1987; Haq et al., 
2016), basolateral HCO3- entry via the Na+/HCO3- cotransporter 1 (NBC1) and the 
conversion of intracellular CO2 and H2O to HCO3- and H+ as catalysed by carbonic 
anhydrase (Frizzell & Hanrahan, 2012; Saint-Criq & Gray, 2017). CFTR also plays an 
important role in the secretion of HCO3- which is important for maintaining the pH of 
the ASL and secretions in other organs including the pancreas (Poulsen et al., 1994; 
Shamsuddin & Quinton, 2014). Maintenance of correct pH is important for the action 
of antibacterial defence mechanisms and maintaining the correct mucosal structure 
(Shamsuddin & Quinton, 2014). 
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1.3 CFTR structure and function 
 
1.3.1 Structure of CFTR 
CFTR shares many structural similarities with other members of the ABC transporter 
family. As shown in Figure 1.3, CFTR forms a largely symmetrical protein, with two 
transmembrane domains (TMD1 and 2), each consisting of six transmembrane helices 
(TM1-12) that together form the transmembrane pore of the protein, and two 
cytoplasmic nucleotide-binding domains (NBDs) (Liu et al., 2017). As their name 
suggests, the NBDs contain two ATP-binding sites, each formed by the Walker A (WA) 
and Walker B (WB) sites on the ‘head’ of one NBD and the ABC-specific signature 
sequence (LSGGQ) located on the ‘tail’ of the opposing NBD (Figures 1.3 and 1.4) 
(Vergani et al., 2005b). An additional domain, the regulatory domain (RD) is unique to 
CFTR among the ABC transporter family and consists of a ~200 a.a. region linking the 
C-terminus of NBD1 with the N-terminus of TMD2. The RD contains consensus protein 
kinase A (PKA) phosphorylation sites as well as sites for phosphorylation by protein 
kinase C (PKC) and 5’ adenosine monophosphate-activated protein kinase (AMPK) 
(Riordan et al., 1989; Dahan et al., 2001; Moran, 2017). More recently, the use of 
electron cryo-microscopy (cryo-EM) has revealed an additional structure formed by 
the N-terminal region of TMD1, termed the lasso motif (LM) due to its resemblance to 
a lasso, that appears to lie perpendicular to the TM helices of TMD1 (Zhang & Chen, 
2016; Liu et al., 2017) (Figure 1.3). The functional importance of this motif is as yet 
unclear, although there is evidence that interaction between the LM and NBD1 is 
involved in regulating ATPase activity (Ehrhardt et al., 2016). The transmembrane 
helices of the TMDs are linked by four intra- and six extracellular loops (ICLs and 
ECLs, respectively) as shown in the cartoon in Figure 1.3B. Of these, the ICLs are 
much larger, extending well below the plasma membrane into the cytoplasm where 
they form coupling helices with the NBDs. The ECLs are considerably smaller than 
the ICLs. However, ECL4 is larger than the others and undergoes co-translational N-
glycosylation at two sites, N894 and N900 (McClure et al., 2016). 
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Figure 1.3: Structure of the human CFTR ion channel. A Structure of human CFTR based upon 
cryo-EM data, PDB: 5UAK (Liu et al., 2017). Structures include lasso motif (LM, red), transmembrane 
domains (TMD1, cyan; TMD2, green) and nucleotide-binding domains (NBD1, magenta; NBD2, purple). 
The structure of the regulatory domain (RD, grey) has not yet been observed distinctly from cryo-EM 
studies. However, a helical structure thought to correspond to part of the RD has been observed located 
within the intracellular vestibule between the TMDs and is shown here. The NBD sequences 
corresponding to the LSGGQ, Walker A and Walker B consensus sequences, which are involved in 
binding and hydrolysis of ATP are highlighted here in yellow, orange and dark orange, respectively. 
The grey shaded area represents the predicted location of the plasma membrane. The location of F508 
has been highlighted. B Cartoon indicating the domain structure of CFTR. Branched structures in ECL4 
represent sites of N-glycosylation. 
 
For many years, the lack of a high-resolution structure of CFTR, confounded by the 
challenges associated with expressing and purifying sufficient quantities of the protein, 
provided a major barrier to CF research (Pollock et al., 2015). Whilst x-ray 
crystallography enabled determination of the structure of the NBDs at an atomic level 
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(Lewis et al., 2004; Atwell et al., 2010; Lewis et al., 2010), a high-resolution structure 
of the TMDs and RD remained elusive until advances were made in cryo-EM. Prior to 
this, high-resolution structures obtained for related ABC transporters including the 
multidrug resistance transporter P-glycoprotein (Pgp) (Aller et al., 2009), the bacterial 
transporter Sav1866 (Dawson & Locher, 2006, 2007) and bacterial lipid flippase MsbA 
(Ward et al., 2007) provided the best approximation of CFTR structure. These 
homologues provided the basis for a number of CFTR models that could be used to 
make inferences about CFTR structure-function relationships (Mornon et al., 2008; 
Serohijos et al., 2008; Dalton et al., 2012; Corradi et al., 2015). 
 
The first high-resolution structure of the entire CFTR protein itself was obtained using 
the zebrafish CFTR orthologue in the inactive (closed) ATP-free, unphosphorylated 
state (Zhang & Chen, 2016), closely followed by the human CFTR structure as shown 
in Figure 1.3A (Liu et al., 2017). Despite only sharing 55% amino acid identity, the 
resulting structures of these two CFTR orthologues were remarkably similar (Liu et al., 
2017; Zhang et al., 2017). These structures identified a number of unique features that 
had not been predicted using homology models. One such feature was the presence 
of a novel interfacial motif termed the ‘lasso-motif’ due to its morphological 
resemblance to a rope lasso and possible involvement in mediating protein-protein 
interactions (Ford, 2017). In addition, a break in the secondary structure of TM8 was 
observed, possibly enabling interaction of main-chain residues with ions and water 
within the channel pore (Zhang et al., 2017). To date however, cryo-EM models have 
not succeeded in showing a consistent structural feature that can be attributed to the 
RD, likely due to a largely disordered organisation of this domain, which would fail to 
be resolved in cryo-EM images (Zhang & Chen, 2016). However, as shown in Figure 
1.3A, an α-helical region was identified that occupies the intracellular vestibule of the 
channel pore between the ICLs, and this structure has been proposed to correspond 
to a section of the RD (Zhang & Chen, 2016). As the structure solved by Zhang and 
Chen (2016) was obtained using the non-phosphorylated closed configuration of the 
channel, it was suggested that the RD appears to occupy the space between the ICLs 
and NBDs in this state, preventing tight dimerisation of the NBDs. This observation 
suggests the possibility that phosphorylation of the RD may be required in order to 
expose the ATP-binding sites for interaction with ATP and allow NBD dimerisation 
(Baker et al., 2007), in line with experimental data for human CFTR that show 
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decreased CFTR ATPase activity in the absence of phosphorylation (Li et al., 1996; 
Eckford et al., 2012). 
 
1.3.2 Control of CFTR gating 
Gating of CFTR is strongly linked to ATP binding and hydrolysis at the NBDs (Vergani 
et al., 2003; Vergani et al., 2005b; Jih & Hwang, 2012, 2013), which as with many 
other ABC transporters form a head-to-tail dimer with two ATP-binding sites located 
in-between them (Lewis et al., 2004) (Figure 1.4). As mentioned above, these ATP-
binding sites are each formed by the WA and WB sites on the head of one NBD and 
the corresponding ABC-specific “LSGGQ” signature sequence on the tail of the other 
(Smith et al., 2002; Higgins & Linton, 2004). Channel closing is linked to the 
dissociation of the NBD dimer, and is therefore dependent upon hydrolysis of ATP at 
the site formed by the WA and WB of NBD2 (Carson et al., 1995a; Gunderson & 
Kopito, 1995; Vergani et al., 2005b) (Figure 1.4). At the time of writing, a high 
resolution cryo-EM structure of the fully open CFTR channel has not yet been 
obtained, however the Chen group have published a structure of the zebrafish CFTR 
channel in the phosphorylated, ATP-bound, NBD dimerised conformation (Zhang et 
al., 2017). In order to achieve this, a mutated version of the zebrafish CFTR channel 
was used (E1372Q, equivalent to E1371Q in the human sequence) where a glutamic 
acid residue located within the WB consensus site of NBD2 was switched to a 
glutamine residue, abolishing ATP hydrolysis at this site and prolonging pore closure 
(Vergani et al., 2005b; Zhang et al., 2017). In this case, the pore itself remains 
occluded at the apical, extracellular opening due to the configuration of the 
extracellular loops, however the structure does show some important structural 
changes that occur as result of NBD dimerisation. 
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Figure 1.4: ATP-binding and hydrolysis at the CFTR nucleotide-binding domains.  CFTR gating 
is linked to binding of ATP in binding pockets located at the interface between NBD1 and NBD2. In 
common with other members of the ABC transporter superfamily of membrane proteins, each binding 
pocket is formed by the association of the Walker A and B (WA and WB) sites located within the ‘head’ 
region of one NBD and the ABC-specific signature sequence LSGGQ located within the tail of the 
opposite NBD. Whilst ATP may remain bound for several minutes at the so-called ‘degenerate’ site at 
the head of NBD1, channel closing is linked to the hydrolysis of ATP at the hydrolytic site formed by the 
head of NBD2 (Vergani et al., 2005a; Vergani et al., 2005b). CFTR gating is further dependent upon 
phosphorylation of consensus sequences located within the regulatory domain by both PKA and PKC 
(Riordan et al., 1989; Chappe et al., 2003; Seavilleklein et al., 2008). 
 
In contrast to the structures obtained for the ATP-free CFTR channels from human 
and zebrafish, the structure of the phosphorylated, ATP-bound zebrafish channel does 
not show any density that could correspond to the RD, suggesting that on 
phosphorylation the RD becomes completely disordered and no longer occupies the 
region between the ICLs and NBDs (Zhang et al., 2017). It is proposed that this 
disengagement of the RD facilitates NBD dimerisation by the binding of ATP at the 
two ATP-binding sites, leading to changes in the structural conformation that follow 
the longitudinal axis of the protein via the ICLs to the TMDs and subsequent opening 
of an ion conductance pathway (Sorum et al., 2015; Zhang et al., 2017). In the past 
this conformational change has been described as a “flip” between an inwardly facing, 
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closed configuration of the channel with a larger, inward facing intracellular vestibule 
formed between the ICLs, and an outward facing configuration, much like that 
observed for other homologous members of the ABC transporter family (Corradi et al., 
2015; Sorum et al., 2017). However, the Chen model suggests a more subtle, 
rotational movement of two halves of the CFTR channel towards the molecular core. 
These two halves consist of TMs 1-3, 6, 10 and 11 plus NBD1 on the one side, and 
TMs 4-5, 7-9 and 12, plus NBD2 on the other (Zhang et al., 2017). The rotational 
movement of these TM helices facilitates the opening of an ion conductance pathway 
lined with positively charged amino acid residues through the channel (Li et al., 2018). 
However as tight dimerisation of the NBDs itself occludes the direct central ion 
conductance pathway at the intracellular end, the cytoplasmic entry point to the 
pathway is likely to involve at least one ‘lateral portal’ between the ICLs that is 
surrounded by positively charged residues that facilitate anion entry (Li et al., 2018). 
Using patch-clamp recordings in conjunction with mutagenesis of several amino acids 
within the ICLs with positively charged side chains, Li et al (2018) have proposed a 
potential location for this lateral pore adjacent to residues R248 (ICL2) and K370 
(located within the C-helix between TM6 and the regulatory insertion RI). 
 
Due to the dependence upon ATP-binding at the NBDs, it has been proposed that 
gating of the CFTR channel can be considered to act in accordance with the del 
Castillo-Katz mechanism for agonist-activated gated ion channels, where intracellular 
ATP acts as the agonist for CFTR activity (del Castillo & Katz, 1957; Colquhoun, 1998; 




In the above mechanism, CFTR can be considered to fulfil the role of the ligand-
activated receptor ‘R,’ with ‘R*’ representing the open channel following activation by 
binding of the ligand ‘A,’ in this case ATP. From this equation, the agonist equilibrium 
constant K-1/K+1 represents the affinity of ATP binding to CFTR whilst β/α represents 
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the equilibrium constant between open and closed states of CFTR (i.e. ATP efficacy) 
(Colquhoun, 1998; Scott-Ward et al., 2007). However, gating of CFTR relies upon 
further processes, i.e. binding of two molecules of ATP, phosphorylation of the RD and 
hydrolysis of ATP at the second ATP-binding site. Due to this asymmetry, CFTR gating 
is not reversible as described by the del Castillo-Katz mechanism for most ion 
channels, and so the equation must be modified to apply to CFTR. The scheme shown 
in Figure 1.5 below is an extension of the gating cycle of CFTR that has been proposed 
by Jih and Hwang (2013). In this representation, O1 and O2 represent stable and 
unstable open channel configurations, respectively, whilst C1 and C2 represent stable 
and unstable closed states (Jih & Hwang, 2013). According to this model, each stage 
in the cycle is reversible and equilibrium constants may be calculated by the rate 
constants indicated by the Greek letters. The stable closed, non-ATP-bound, non-
phosphorylated channel is represented in this scheme by C1. The rate of transition 
from C2 to C1 is slow for CFTR and rare in the presence of ATP (Jih & Hwang, 2013). 
Binding of one molecule of ATP and phosphorylation of the RD (C2ATP) is normally 
required to result in channel opening. Binding of a second ATP molecule (C2ATP2) and 
NBD dimerisation (C2ATP2*) leads to CFTR opening and the more stable open state 
(O12ATP*). Following ATP hydrolysis at the hydrolytic ATP binding site formed by WA 
and WB on the head of NBD2 it is proposed that CFTR may enter a brief less stable 
open state (O2) which will either proceed rapidly back to the closed state C2 or revert 
back to the stable O1 state via re-entry of ATP at the hydrolytic ATP binding site. This 





Figure 1.5: The proposed gating cycle for CFTR, adapted from Jih and Hwang (2013). In this 
model, CFTR may proceed from a stable closed state (C1) to a less stable closed state (C2) by binding 
of ATP at the non-hydrolytic site formed by WA and WB sites on the head of NBD1. Binding of ATP at 
the second, hydrolytic ATP binding site results in channel opening and the more stable O1 open state. 
Following hydrolysis of ATP at the second ATP binding site the channel enters the less stable O2 open 
state which will either revert back to the less stable C2 state or may return to O1 following re-entry of 
ATP at the hydrolytic site. This re-entry process is represented by the dashed box. Rate constants for 
each transition are represented by Greek letters (see text for further information). 
 
1.4 Classification of CF causing mutations 
 
CF-causing mutations have traditionally been classified into six groups according to 
their effects on channel production, processing, function, and membrane stability 
(Welsh & Smith, 1993; Zielenski & Tsui, 1995; Rowe et al., 2005). The purpose of this 
classification system was to group CF-causing mutations according to potential 
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therapeutic strategies with the aim of developing mutation-specific personalised 
medicines (Amaral, 2015). This scheme for classification is summarised in Figure 1.6 
with common example mutations from each class summarised in Table 1.1. Some 
mutations, such as the gating mutation G551D can be neatly categorised into just one 
of these classes, however other mutations may result in multiple defects and belong 
to more than one group. For this reason, it may be more appropriate to consider 
mutations according to their phenotype when developing therapeutic strategies (Veit 
et al., 2016), although the traditional classification scheme remains useful for 
descriptive purposes. One such mutation is F508del, which results in defective CFTR 
processing, gating and stability at the plasma membrane (PM) and therefore can be 
described as a class II, III and VI mutation (Veit et al., 2016). Such mutations pose a 
problem for the development of treatments for cystic fibrosis as multiple defects must 
be addressed for clinical benefit (Wang et al., 2014b). 
 
Figure 1.6: Classification of CF-causing mutations. Over 2,000 CFTR mutations have been 
identified that may result in a CF phenotype (http://www.genet.sickkids.on.ca/cftr/app). These mutations 
may be classified according to their effects on channel production (Class I), processing (Class II), 
regulation (Class III), conduction (Class IV), synthesis (Class V) and membrane stability (Class VI) 
(Welsh & Smith, 1993; Zielenski & Tsui, 1995; Rowe et al., 2005). Figure previously published in (Bose 
et al., 2015). 
 
 17 
• Class I mutations result in defective channel production leading to either 
complete absence or a severe reduction in the amount of CFTR protein 
produced. Class I mutations may include premature termination codons 
(PTCs), splicing, frameshift or nonsense mutations (Welsh & Smith, 1993; 
Zielenski & Tsui, 1995; Veit et al., 2016). 
 
• Class II mutations include changes that result in defective channel processing 
and biogenesis. A classic example of a class II mutation is F508del, which 
results in protein misfolding and premature degradation via the endoplasmic 
reticulum quality control system (ERQC). Class II mutations result in a reduction 
in the availability of mature CFTR, leading to a deficit in the amount of active 
CFTR expressed at the cell membrane (Welsh & Smith, 1993; Zielenski & Tsui, 
1995; Veit et al., 2016). 
 
• Class III mutations lead to defective channel regulation, primarily impacting 
channel gating and typically resulting in a reduction in channel activity by 
prolonging channel closures and decreasing the proportion of time that 
channels occupy the stable open configuration (O1 in Figure 1.5) (Welsh & 
Smith, 1993; Zielenski & Tsui, 1995; Veit et al., 2016). 
 
• Class IV mutations impact the ion permeability pathway through the CFTR 
protein, resulting in a decrease in channel conductance and a reduction in the 
overall rate of cellular anion efflux (Sheppard et al., 1993; Welsh & Smith, 1993; 
Zielenski & Tsui, 1995; Hämmerle et al., 2001; Veit et al., 2016). 
 
• Class V mutations reduce CFTR expression levels, for example by affecting 
promoter sequences or via splice mutations. Class V mutations, e.g. A455E 
(Sheppard et al., 1995) and P574H (Ostedgaard et al., 1999) differ from Class 
I mutations as they do not affect CFTR structure itself, but regulate CFTR 
expression (Highsmith et al., 1994; Zielenski & Tsui, 1995; Highsmith et al., 
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1997; Veit et al., 2016). Silent single nucleotide polymorphisms (sSNPs) that 
affect translation rate such as T2562G may also belong to class V (Kirchner et 
al., 2017). 
 
• Class VI mutations lead to a destabilisation of CFTR in post ER-compartments 
or at the PM, either by decreasing conformational stability (Haardt et al., 1999) 
or by promoting internalisation (Silvis et al., 2003; Veit et al., 2016). This is well 
demonstrated by the thermal instability exhibited by corrected F508del-CFTR 
at the plasma membrane at 37 °C (Wang et al., 2011b). 
The classification system discussed above has become well established over past 
decades. However, these classifications do have some limitations, particularly as 
many of the most common and severe CF-causing mutations, including F508del, may 
result in defects that apply to multiple classes. As such the system is frequently under 
review and a more combined approach may need to be taken when determining the 
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Table 1.1: Example CF-causing mutations according to classification and potential therapeutic 
strategies. Abbreviations: AON, antisense oligonucleotides; VX-770, ivacaftor and VX-809, lumacaftor. 
This table is adapted from Amaral (2015). 
 
1.5 Current landscape in the treatment of CF 
 
In 2015 an important milestone was reached that highlights advances in the 
development of CF therapy in recent decades. For the first time in the US, the number 
of adult patients (aged over 18) outnumbered the number of children with the disease 
(Burgel et al., 2015). This remarkable statistic highlights both the dramatic leap in life 
expectancy that has resulted from decades of CF research, improved understanding 
of the disease and development of novel therapies for the disease and evidence-
based care. However, it also highlights how much further there is to go in searching 
for a cure for the disease. Despite the work that is still to be done, there is great 
encouragement to be had from the fact that CF patients in 2018 can now expect to 
live long enough to have careers and families. This success is due to the development 
of therapeutic strategies that target both the symptoms of the disease (i.e. 
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physiotherapy and antibiotics) and the underlying cause of the disease, including 
pharmacological modulators of CFTR (Quon & Rowe, 2016). Since the discovery of 
the gene involved in the disease, there has been a shift in the direction of research 
into treatments for CF with a focus on targeting the root cause of the disease. Part of 
this effort has been to produce treatments that aim to target each of the classes of 
defect highlighted in Section 1.4 with the aim of developing either mutation-specific 
treatments or mutation-independent treatments that will be suitable for a wider range 
of patients regardless of the mutation involved. Recent years have seen the licensing 
of such compounds, including small molecule CFTR modulators such as ivacaftor and 
Orkambi (Vertex), and promising clinical trials of other strategies including antisense 
oligonucleotides (AONs) and gene therapy are currently in progress (Fajac & De 
Boeck, 2017). Table 1.2 summarises CF therapies that are currently either approved 
or undergoing clinical trials. Although a complete cure for CF is still the goal, the 
progress that has been made, including the licensing of ivacaftor and Orkambi, 
provides a proof of concept that CF may be treated using small molecule therapies. 
Furthermore, as CF is the most common autosomal recessive disorder among 
Caucasian populations, the research and treatment strategies that have been, or are 
being developed for CF provide hope for the treatment of other, less common 










Table 1.2 (opposite page): Key non-symptomatic treatments for cystic fibrosis. Key treatments 
either approved or in development aiming at correcting the underlying defects in CFTR resulting in CF. 
Treatments are grouped according to their type as discussed in Section 1.5. Information in this Table 
is derived in part from Fajac and De Boeck (2017) with updated information on the development phase 
accessed at https://clinicaltrials.gov (accessed June 2018). FDA = U.S. Food and Drug Administration, 
EMA = European Medicines Agency. 
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Phase IIb (In combination) 
Riociguat (Adempas) Bayer Phase II 
GLPG2222 Galapagos/AbbVie Phase II 
FDL169 Flatley Discovery Lab Phase I (Complete) 
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1.5.1 Symptomatic treatments for cystic fibrosis 
Since the 1960s, treatments that targeted the organ-specific symptomatic defects of 
CF rather than specific defects caused by CFTR mutations formed the major strategy 
for patients with CF (Cohen-Cymberknoh et al., 2011; Quon & Rowe, 2016; Fajac & 
De Boeck, 2017). The general approach for the symptomatic treatment of CF involves 
a combination of antibiotics to guard against and treat existing bacterial infections, 
treatment of inflammation, and the use of physiotherapy and other treatments to aid 
mucociliary clearance (Fajac & De Boeck, 2017). Mucociliary clearance in the airways 
may be facilitated through the use of inhaled treatments including dornase alfa (Fuchs 
et al., 1994), hypertonic saline (Elkins et al., 2006) and mannitol (Bilton et al., 2013; 
Quon & Rowe, 2016). Whilst focus since the identification of the CFTR gene has been 
on treating the underlying defects of CF, it is important to note that symptomatic 
treatments must continue to be developed alongside targeted medicines. Not only is 
this important until a cure for CF has been developed, but also for patients for whom 
these targeted treatments have come too late to prevent existing conditions from 
taking hold. Furthermore, as life expectancy for CF patients is extended through the 
development of novel therapies, it may be necessary to develop therapies for 
alternative organ defects and diseases that may result from CFTR dysfunction and 
have hitherto been under reported due to the limited life expectancy of the disease. 
 
1.5.2 Small molecule modulators of CFTR: Correctors and potentiators 
CFTR potentiators enhance the activity of CFTR present in the PM by favouring the 
stable open state of the channel and are targeted for the treatment of class III and 
class IV mutations (Figure 1.6 and Table 1.1) (Amaral, 2015; De Boeck & Amaral, 
2016). The CFTR potentiator ivacaftor (VX-770; Kalydeco®, Vertex Pharmaceuticals) 
was the first small molecule modulator of CFTR to be approved by the FDA (Van Goor 
et al., 2009; Ramsey et al., 2011). Ivacaftor was initially licensed for the treatment of 
patients carrying the third most common CF-causing class III mutation worldwide 
G551D, which results in a severe gating defect (Cai et al., 2006; Bompadre et al., 
2007). However, its use has since been extended to cover a range of 38 other 
mutations including S549R and G1349D, as well as the class IV mutation R117H 
(Moss et al., 2015; Sheppard et al., 2017). However, CFTR potentiators rely on an 
existing pool of CFTR protein that is already present at the PM and as such are 
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unsuitable for use in patients carrying mutations that affect CFTR expression, 
including F508del, unless used in combination with other compounds. To date, despite 
benefits to many patients, combination therapies such as Orkambi and Symdeko 
(discussed below) have not succeeded in demonstrating the degree of efficacy 
demonstrated by ivacaftor for patients with pure class III mutations like G551D. For 
this reason, there remains a requirement for the development of CFTR potentiators 
that have a greater efficacy. As shown in Table 1.2, a number of candidates are 
currently in clinical trials including QBW251 (Novartis), CTP-656 (Concert 
Pharmaceuticals) and GLPG1837 (AbbVie/Galapagos), (Quon & Rowe, 2016; Fajac 
& De Boeck, 2017). One hurdle to the development of such compounds is that the 
mechanism of action of existing potentiators, including ivacaftor, is currently poorly 
understood. A better understanding of the mechanism by which existing CFTR 
potentiators work could benefit the development of novel potentiator compounds with 
greater efficacy for a wider range of mutations; they may also be more effective when 
used in combination with other compounds such as correctors. Identification of 
potentiators that act via different regions of the CFTR protein to correctors, for example 
via the TMDs rather than the NBDs, may increase efficacy. In addition, identification 
of multiple CFTR potentiators with different sites of action may aid the development of 
potentiator combinations that could be used in conjunction with correctors for 
mutations such as F508del. 
 
CFTR correctors work to correct abnormal folding and processing of class II (and 
potentially class V) CFTR mutant channels such as F508del, increasing the number 
of channels that are successfully processed and therefore expressed at the PM (Quon 
& Rowe, 2016). CFTR mRNA is translated at the ER and the majority of tertiary folding 
occurs at this stage co-translationally (Kleizen et al., 2005). Wild-type (WT) CFTR 
undergoes additional post-translational folding and is trafficked to the PM via the Golgi 
apparatus where glycans that have been added to the CFTR channel undergo further 
modification before the mature channel is expressed (Cheng et al., 1990; Mijnders et 
al., 2017). Class II mutations such as F508del however result in protein misfolding at 
the point of co-translational folding (Hoelen et al., 2010). In this case, misfolded protein 
is recognised by ERQC factors and targeted to proteasomes for endoplasmic 
reticulum associated degradation (ERAD) (Lukacs et al., 1994; Ward et al., 1995). 
CFTR corrector compounds may therefore work by a number of mechanisms. Firstly, 
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they may act as a pharmacological chaperone by binding to the developing CFTR 
protein itself as it is translated at the ER and facilitating correct folding, preventing 
targeting to ERAD. Secondly, they may interact with misfolded CFTR post-
translationally to correct the folded structure. Alternatively, they may function as 
proteostasis modulators, interacting with non-CFTR proteins that are part of the CFTR 
interactome and are involved in determining correct protein folding and trafficking of 
CFTR to either the Golgi or the proteasome (Balch et al., 2008; Balch et al., 2011). 
Lumacaftor (VX-809, Vertex Pharmaceuticals) is a corrector that is thought to interact 
with residues in TMD1 to stabilise mutant CFTR and correct folding early in biogenesis 
(Loo et al., 2013; Ren et al., 2013; Fajac & De Boeck, 2017). 
 
F508del is by far the most common CF mutation with ~70% patients homozygous for 
this variant of the disease, (Bobadilla et al., 2002) and as such the development of 
small molecule therapies for CF that demonstrate efficacy for patients with F508del is 
a key priority. In WT-CFTR, residue F508 is located in NBD1 at the interface between 
NBD1 and ICL4 of TMD2 (Figure 1.3) (Serohijos et al., 2008; Hoelen et al., 2010). 
Whilst F508del affects structural folding of NBD1, the correct folding of NBD2 is also 
reliant upon integrity of NBD1 and as a result, the mutation appears to indirectly affect 
the correct folding of NBD2, leading to recognition of misfolded CFTR by ERQC and 
subsequent degradation (Hoelen et al., 2010). WT-CFTR is a relatively inefficiently 
folded protein, with only around 30-50% successfully reaching the PM depending upon 
cell type (Lukacs et al., 1994; Ward & Kopito, 1994; Kleizen et al., 2005). As CF is an 
autosomal recessive disorder and heterozygous carriers of the F508del mutation are 
asymptomatic, it is considered that 50% rescue of CFTR expression would be 
sufficient to provide enough CFTR protein at the PM for normal function. However, 
patients expressing just 5 – 14% of normal levels of CFTR exhibit a relatively mild CF 
phenotype and as such the actual amount of corrected CFTR protein required may be 
less than this (Ramalho et al., 2002; Van Goor et al., 2011). The requirement for a 
relatively low level of correctly processed CFTR provides strong rationale for the use 
of correctors in combination with potentiators to treat F508del patients. Orkambi, 
approved by the FDA in 2015 is one such combination therapy, combining ivacaftor 
and lumacaftor with the aim of achieving this goal (Okiyoneda et al., 2013; Wainwright 
et al., 2015). Lumacaftor alone has demonstrated correction of F508del-CFTR 
processing to levels 14% of WT (Van Goor et al., 2011), a level that should 
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theoretically be sufficient to restore near normal levels of CFTR function to patients 
when used in combination with a potentiator (Ramalho et al., 2002). However, by itself 
lumacaftor was without clinical benefit for CF patients homozygous for F508del 
(Clancy et al. 2012). Moreover, whilst the benefits of Orkambi proved sufficient to 
warrant FDA approval, they were relatively limited for F508del homozygous CF 
patients, equating to a 4.3 – 6.7% increase in the forced expiratory volume in 1 s 
(FEV1) with a high percentage of patients discontinuing use of the drug due to side 
effects (Wainwright et al., 2015). This compared to a 10.6% increase in FEV1 and an 
incidence of adverse events that was lower than placebo for patients carrying the 
G551D mutation treated with ivacaftor alone (Ramsey et al., 2011). In 2018, the FDA 
have approved a second combination therapy from Vertex Pharmaceuticals, 
Symdeko, which combines ivacaftor with the corrector tezacaftor (VX-661) taken in 
combination with additional doses of ivacaftor alone (Taylor-Cousar et al., 2017). 
Combination of ivacaftor with tezacaftor rather than lumacaftor resulted in similar 
levels of restoration in FEV1 compared to Orkambi, but improved levels of tolerance 
(Taylor-Cousar et al., 2017). The relatively low level of improvements in FEV1 resulting 
from these double-therapy strategies may be improved however by the use of multiple 
corrector compounds with different mechanism of action or binding sites, as has been 
shown recently for the triple combination of MCG1516A, RDR1 and VX-809, three 
corrector compounds that interact with different sites on NBD1 (Carlile et al., 2018). 
Furthermore, the results from two recent phase II trials for such therapies, involving 
the use of either VX-659 or VX-445 in combination with ivacaftor and tezacaftor, have 
shown increases in FEV1 of 13.3% (VX-659) and 13.8% (VX-445), respectively 
(Davies et al., 2018; Keating et al., 2018). This level of response exceeds that of 
ivacaftor for patients with G551D (Ramsey et al., 2011) and it is hoped that levels of 
tolerance for these therapies will be comparable to those shown by Symdeko (Davies 
et al., 2018; Keating et al., 2018). 
 
1.5.3 Genetic medicine strategies for cystic fibrosis 
Due to the variety of defects that can lead to CF, targeted medicines such as small 
molecule modulators that can correct specific classes of CF mutation may be limited 
to identified populations with certain mutations. Furthermore, as the vast majority of 
CF mutations are rare, often only reported in one individual, this presents challenges 
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for both the FDA and clinicians in terms of determining the potential efficacy and 
tolerance of treatments for such rare mutations. Whilst great advances are being made 
in developing assays that can test the likely efficacy in individuals (Oliver et al., 2017; 
Cholon & Gentzsch, 2018), it is hoped that gene therapy may hold the key to a 
mutation-independent approach for treating CF. 
 
As the most common autosomal recessive disease in Western populations, discovery 
of the gene involved in CF led to the hope that successful correction of the disease 
through gene therapy would pave the way for similar success with other rare genetic 
disorders and since 1989 there have been a total of 27 clinical trials in CF gene therapy 
(Alton et al., 2016). The primary aim has been to restore the production of functional 
CFTR in the epithelial tissue of the CF lung. Several approaches have been attempted, 
including the introduction of the corrected CFTR DNA sequence into the cell nucleus, 
mRNA therapy, which bypasses the need to introduce the whole CFTR gene into the 
nucleus, gene editing (e.g. via CRISPR/Cas9) and mRNA repair using antisense 
oligonucleotides (AONs) (Alton et al., 2016). 
 
Perhaps the largest barrier to successful genetic medicines for CF is the efficacious 
delivery of genetic material to lung tissue. The favoured route of administration for 
specific treatment of lung epithelia is via inhalation of aerosolised vectors (Alton et al., 
2016). In addition to penetrating the cell membrane (and nuclear membrane for gene 
editing and gene therapy strategies), such vectors must be able to penetrate airway 
mucus, mucociliary clearance and the sputum barrier as well as bypassing immune 
responses (Alton et al., 2016). Moreover, the choice of vector must be capable of 
accommodating the large size of the CFTR gene (250 kb). A number of trials have 
been carried out utilising adenovirus or adenoassociated viruses (AAVs), however 
these approaches have suffered from a fall in efficacy over time as a result of immune 
responses following repeated doses (Griesenbach et al., 2015; Alton et al., 2016). For 
this reason, non-viral gene transfer agents (GTAs) may provide a better solution due 
to the reduced risk of induced immune response. Currently, the UK CF Gene Therapy 
Consortium has demonstrated the most promising results using a combination of the 
liposome-based GTA GL67A in conjunction with the pGM169 plasmid containing 
codon optimised CFTR cDNA (Alton et al., 2015). Monthly administration of nebulised 
pGM169/GL67A over a period of 12 months was sufficient to improve FEV1 in patients 
 27 
by 6.4%, showing a benefit without a detectable improvement in quality of life (Alton 
et al., 2015). Whilst the results of this trial were modest compared to trials using small 
molecule CFTR modulators, this is to date the first demonstration of a benefit over an 
extended period of administration for CF gene therapy and provides proof of concept 
that gene therapy is able to alter the progression of CF-related lung disease (Alton et 
al., 2015; Alton et al., 2016). 
 
Gene editing techniques including the use of zinc finger nucleases (ZFNs), 
CRISPR/Cas9, and TAL-Effector Nucleases (TALENs) have all been or are currently 
being investigated for the treatment of CF (Urnov et al., 2005; Li et al., 2011; Lee et 
al., 2012; Schwank et al., 2013). However again, the biggest hurdle faced by these 
approaches is deliverability (Alton et al., 2016). 
 
RNA editing with the use of AONs is another genetic strategy under current 
investigation and has the benefits of both requiring a smaller vector for delivery and 
having a cytosolic activity, thereby removing the requirement to cross the nuclear 
membrane (Zamecnik et al., 2004; Igreja et al., 2016). QR-010 (eluforsen) from ProQR 
Therapeutics is an AON that is designed to bind to F508del-CFTR mRNA in the region 
of the missing F508 codon and facilitate generation of the full CFTR sequence 
(Zamecnik et al., 2004; Beumer et al., 2015). Recent results from a phase 1b study of 
QR-010 were promising (Elborn et al., 2017). 
 
1.6 Evolution and Diversity of CFTR orthologues 
 
Given the similarity in structure with other members of the ABC transporter family, 
such as ABCC4, which utilise the energy released from ATP hydrolysis at the NBDs 
for active transport, is likely that CFTR evolved from an active membrane transporter, 
with loss of an internal gate and inclusion of the RD between NBD1 and TMD2 (Chen 
& Hwang, 2008; Jordan et al., 2008; Sebastian et al., 2013). As shown in the 
cladogram in Figure 1.7, the CFTR gene is present in Gnathostomata (jawed 
vertebrates), but absent from the non-vertebrate chordate subphyla tunicates and 
cephalochordates (Bose et al., 2015). A report of an apparent CFTR gene expressed 
in the cephalochordate amphioxus Branchiostoma floridae (accession no. 
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XP002597646.1) (Pederzoli et al., 2014) actually appears to be an orthologue of 
SLC9A2, a member of the Na+/H+ exchanger family and CFTR does not appear to be 
present within the B. floridae genome (Putnam et al., 2008) (BLAST search of 
XP002597646.1 using Ensembl Genome Browser v.92 confirmed 66% shared amino 
acid identity with SLC9A2 (Zerbino et al., 2018)). Cephalochordates are considered 
an extant equivalent to an early common chordate ancestor (Blair & Hedges, 2005). 
The identification of a CFTR orthologue that does not include the RD in lampreys 
(Sebastian et al., 2013; Cui et al., 2017), suggests that CFTR is likely to have arisen 








Figure 1.7: Cladogram showing the evolutionary diversity of CFTR orthologues. Cladogram was 
constructed by ClustalO alignment of experimentally-derived and predicted sequences using CLC 
sequence viewer software v.7 (Qiagen Bioinformatics).  Percentages shown represent shared amino 
acid identity. Accession numbers for the sequences used are indicated in grey. Figure modified from 
Bose et al. (2015) 
 
CFTR orthologues have been studied in a number of species of teleost fish, including 
Takifugu rubripes (Japanese pufferfish) (Davidson et al., 2000), Fundulus heteroclitus 
(killifish) (Singer et al., 1998), Salmo salar (Atlantic Salmon) (Chen et al., 2001) and 
as mentioned in Section 1.3, Danio rerio (Zebrafish) (Navis & Bagnat, 2015; Zhang & 
Chen, 2016; Zhang et al., 2017). In both S. salar and Anguilla japonica (Japanese eel), 
both euryhaline species that can move between salt and freshwater, two separate 
forms of CFTR are expressed in the gills (Figure 1.7) (Chen et al., 2001; Nilsen et al., 
2007; Wong et al., 2016). Regulation of the relative expression of these CFTR variants 
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alters according to both season and prolonged exposure to freshwater, supporting the 
possibility that CFTR may have evolved for the purpose of osmoregulation (Nilsen et 
al., 2007; Bose et al., 2015). 
 
The RD, encoded by exon 15, is a unique feature of CFTR that is absent from all other 
members of the ABC-transporter family (Sebastian et al., 2013), although Pgp does 
possess a linker region containing regulatory phosphorylation sites (Hardy et al., 
1995). Comparing the CFTR sequence with that of ABCC4, the most closely related 
ABC transporter homologue, Sebastian et al. (2013) hypothesize that the RD 
originates from an originally intronic sequence following the loss of a splice donor site 
in exon 14. Given the absence of the RD from lamprey CFTR, this inclusion is thought 
to have happened between 650 and 550 million years ago (Sebastian et al., 2013). 
Sequence alignments of CFTR orthologues demonstrate that the RD is the least well 
conserved domain, although phosphorylation sites within the RD are highly conserved 
(Figure 1.8 and Appendix 1). Interestingly, sequence evolution within the RD appears 
to have followed a different pattern compared to other regions of CFTR and has not 
followed the same pattern as species evolution, accounting for the differences 
observed between the cladogram in Figure 1.7 and the phylogenetic tree for the same 
species (Sebastian et al., 2013). The RD is the main region involved in this 
evolutionary divergence, suggesting a variation in the selection pressures for evolution 
of this domain, particularly in species such as mouse and rat where the evolution of 
CFTR appears to diverge considerably from the pattern of the phylogenetic tree 









Figure 1.8: Sequence alignment of CFTR RD from diverse species. Sequences for the RD + 10 
residues 5’ and 3’ to the human RD boundaries (F669 – P841) were aligned by ClustalO using CLC 
sequence viewer v.7.5 (Qiagen Bioinformatics). RD residues are indicated by the horizontal grey bar. 
Blue bars indicate percentage conservation. 
 
1.7 Use of functional differences between CFTR orthologues in CF 
research 
 
The large diversity of available species orthologues of CFTR has implications for CF 
research beyond simply gaining an understanding of how CFTR may have evolved. 
Species orthologues provide a repository of functional and structural variations of a 
protein that may demonstrate differences in both function and pharmacology that can 
be studied experimentally (Ostedgaard et al., 2007; Stahl et al., 2012; Bose et al., 
2015). For example, such studies may provide valuable insight into the suitability of 
certain species for use as animal models. These studies may also provide important 
insight into links between structural regions of the protein and function, or indeed 
 32 
pharmacology, where specific differences are observed between orthologues with 
structural differences (Bose et al., 2015). 
 
1.7.1 Current understanding of species differences in CFTR structure, 
function and pharmacology 
1.7.1.1 Species differences in CFTR conductance and gating 
High-resolution, single-channel recording with the patch-clamp technique provides the 
best tool for characterising the gating behaviour and conductance of CFTR 
orthologues (Neher & Sakmann, 1976; Cai et al., 2011). Utilising the excised, inside-
out configuration of this technique, it is possible to activate CFTR by adding ATP and 
PKA to the intracellular side of the channel in the presence of an electrochemical Cl- 
gradient to maximise the driving force for Cl- movement from the intracellular (bath) 
solution to the extracellular (pipette) solution (Cai et al., 2011). This configuration 
facilitates accurate control of the compositions of intra- and extracellular solutions and 
precise manipulation of the conditions affecting CFTR gating (Sheppard et al., 2004). 
By holding the voltage across the cell membrane fixed (i.e. voltage-clamped) it is 
possible to record the change in current that occurs during channel openings, 
producing recordings such as those shown in Figure 1.9B. From these recordings it is 
possible to calculate the proportion of time that the channel occupies the open 
configuration (open probability, Po), single-channel current amplitude (i), single-
channel conductance (γ = i/V), mean burst duration (MBD) and interburst interval (IBI) 
(Figure 1.9) (Cai et al., 2011). Through the generation of dwell-time histograms, it is 
also possible to differentiate between interburst closures and the short-lived, intraburst 
closures which account for the flickery closures that are present within open bursts of 
the channel (Figure 1.9B) (Cai et al., 2011). 
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Figure 1.9: Recording the single-channel activity of CFTR using excised inside-out membrane 
patches. A Schematic diagram showing excised inside-out configuration of the patch-clamp technique. 
After the patch-pipette lightly touches the cell membrane, negative pressure is applied to the pipette to 
form a high resistance seal with the cell membrane (giga seal). The pipette is then withdrawn to excise 
a region of the membrane that contains a single CFTR channel. Following activation of CFTR by ATP 
and PKA added to the intracellular (bath) solution, Cl- ions move into the low Cl- extracellular (pipette) 
solution when a CFTR channel opens. Currents are recorded via a patch-clamp amplifier. B Example 
single-channel recording showing calculation of Po. Downward deflections in the trace from the closed 
level (dotted line) represent channel openings. The open probability (Po) represents the proportion of 
time that the channel spends in the open configuration. 
 
Single-channel data have previously been characterised for CFTR orthologues from 
spiny dogfish (Squalus acanthus), African clawed frog (Xenopus laevis), house mouse 
(Mus musculus), domestic chicken (Gallus gallus domesticus), Australian common 
bushtail possum (Trichosurus vulpecula), European rabbit (Oryctolagus cuniculus), 
domestic sheep (Ovis aries) and domestic pig (Sus scrofa domestica) (Hanrahan et 
al., 1993; Price et al., 1996; Lansdell et al., 1998a; Al-Nakkash & Reinach, 2001; 
Ostedgaard et al., 2007; Demmers et al., 2010; Aleksandrov et al., 2012; Cai et al., 
2015). In these studies, all CFTR orthologues demonstrated cAMP-dependent and 
PKA-regulated Cl- currents (Bose et al., 2015). However, whilst allowing for 
experimental differences between separate studies, all orthologues studied have 
shown species-dependent variations in gating behaviour (Lansdell et al., 1998b), 
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conductance (Cai et al., 2015), ion permeability (Price et al., 1996) and in some cases 
pharmacology (Lansdell et al., 1998a). 
 
One of the first CFTR orthologues to be studied in detail after human was mouse 
CFTR (Lansdell et al., 1998a). Mouse CFTR was of particular interest due to the 
generation of mouse models of CF disease, which were quickly developed following 
the identification of the CFTR gene (Wilke et al., 2011). Mouse WT-CFTR stably 
expressed in Chinese hamster ovary (CHO) cells exhibited a distinct gating behaviour 
that differed considerably from that of human CFTR (Lansdell et al., 1998a; Lansdell 
et al., 1998b). As shown in Figure 1.10A, additional filtering of single-channel 
recordings of mouse CFTR reveal two distinct conductance states, a highly active sub-
conductance state (O1) with a high Po exceeding that of the full open state of human 
CFTR, and a second, fully open state that is very short lived, with brief openings and 
a low Po (Figure 1.10C) (Lansdell et al., 1998a; Lansdell et al., 1998b). Furthermore, 
single-channel conductance for this O2 state is reduced compared to human CFTR, 
resulting in a lower single-channel current when compared to human CFTR at the 
same membrane potential (Figure 1.10B) (Lansdell et al., 1998a). 
 
The reduced activity of mouse CFTR may in part account for some of the phenotypic 
differences between mouse models of CF and the human CF phenotype. Mouse 
models of CF do not exhibit the lung pathology of the human disease (Wilke et al., 
2011). CFTR plays a less prominent role in epithelial fluid secretion in mouse airways, 
with other ion channels such as TMEM16A taking over the role of the main pathway 
for Cl- efflux (Wilke et al., 2011). Whilst the reduced involvement of CFTR in Cl- 
secretion may be the result of lower conductance, it may also be possible that the 
unique gating behaviour of mouse CFTR has evolved subsequent to divergence of the 




Figure 1.10: Single-channel behaviour of diverse CFTR orthologues. A Representative single-
channel recordings of human, sheep (ovine) and mouse (murine) recombinant CFTR expressed in CHO 
cells and studied using excised inside-out membrane patches. Recordings were made in the presence 
of a Cl- gradient (intracellular [Cl-] = 147 mM, extracellular [Cl-] = 10 mM) and following activation of 
CFTR using 0.3 mM ATP and 75 nM PKA. Single-channel traces were filtered at 500 Hz, digitised at 5 
kHz and a 5-fold data reduction has been applied for the purpose of illustration. Expanded traces shown 
on the right were further filtered at 50 Hz. The closed channel state (C), sub-conductance state of 
mouse CFTR (O1) and the full-open state (human and sheep = O, mouse = O2) are indicated by dotted 
lines. B and C Single-channel current amplitude (i) and open probability (Po) of human (h), sheep (o) 
and mouse (m) CFTR. Experimental conditions are the same as for A. Data are means ± SEM (human 
n = 10, sheep n = 24, mouse n = 5), * = P < 0.05 compared to human CFTR. D Relationship between 
body temperature and single-channel conductance (γ) of CFTR orthologues from endothermic 
vertebrates. Values of mean body temperature were accessed from Dawson & Hulbert, (1970), Hudson 
& Scott, (1979) and Aiello & Moses, (2010), values for single-channel conductance have been sourced 
from Hanrahan et al. (1993), Price et al. (1996), Lansdell et al. (1998a), Al-Nakkash & Reinach, (2001), 
Ostedgaard et al. (2007), Demmers et al. (2010), Aleksandrov et al. (2012) and Cai et al. (2015). The 
continuous line represents line of best fit as a result of first-order regression of the data (r2 = 0.51). 




In contrast to the reduced activity of mouse CFTR, other CFTR orthologues have been 
demonstrated to exhibit higher levels of activity compared to human CFTR. Sheep 
CFTR was characterised using single-channel patch-clamp recording by Cai et al. 
(2015), in part to assess the suitability of sheep as a potential animal model for CF. 
Sheep CFTR shares close homology with human CFTR, with 91% shared amino acid 
identity (Figure 1.7) (Cai et al., 2015). Yet despite this high degree of sequence 
conservation, sheep CFTR demonstrated increased activity compared to human 
CFTR, with an increased single-channel current amplitude and higher Po (Cai et al., 
2015) (Figure 1.10, A-C). Like sheep CFTR, chicken CFTR has also been shown to 
have an increased single-channel current amplitude and conductance compared to 
human CFTR, albeit with a lower Po (Aleksandrov et al., 2012). One hypothesis for the 
variation in CFTR conductance between species is a relationship with metabolic rate 
and internal body temperature (Figure 1.10D) (Bose et al., 2015). However, such a 
relationship is highly speculative and differences in experimental conditions used 
across different studies must be taken into account when comparing channel 
conductance recordings. It must also be noted that the linear relationship shown in 
Figure 1.10D (r2 = 0.51) is not maintained when poikilothermic species (e.g. X. laevis 
and S. acanthus) are included in the analysis. 
 
1.7.1.2 Species variation in the effect of CF-related mutations 
The two-stage pattern of CFTR glycosylation that takes place during channel 
maturation facilitates assessment of CFTR biosynthesis via protein assays such as 
Western blot and immunoprecipitation (Ostedgaard et al., 2007). Immature CFTR that 
has undergone ER core-glycosylation and the mature forms that have undergone 
further glycosylation at the Golgi apparatus produce distinct bands following gel 
electrophoresis corresponding to ~150 kDa (band B) and ~170-190 kDa (band C) 
respectively (nascent, unglycosylated protein forms band A) (Ostedgaard et al., 2007). 
Furthermore, the stability of CFTR expressed at the PM may be quantified by 
metabolic 35[S]-methionine pulse-chase (Aleksandrov et al., 2012; Fisher et al., 2012) 
or by monitoring run-down of channel activity during electrophysiological recording 
(Wang et al., 2014a). Studies utilising such techniques have highlighted cross-species 
variation in both WT and mutant CFTR maturation and membrane stability. 
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WT-CFTR homologues from a number of species, including both domestic ferret 
(Mustela putorius furo) (Fisher et al., 2012) and chicken (Aleksandrov et al., 2012) 
demonstrate enhanced maturation efficiency and stability at the PM compared to 
human CFTR. In addition, increased levels of F508del-CFTR maturation have been 
described for murine and porcine F508del-CFTR homologues when compared to 
human (Ostedgaard et al., 2007), and the mutation appears to have a limited impact 
on function and maturation of chicken (Aleksandrov et al., 2012) and ovine CFTR (Cai 
et al., 2015). Increased maturation and functionality of murine and porcine F508del-
CFTR is not specific to the cell line in which homologues are expressed, suggesting 
that structural differences between CFTR homologues are responsible for the 
differences in processing (Ostedgaard et al., 2007). This hypothesis is further 
supported by the observation that substitution of key F508-interacting residues in 
human CFTR by their avian equivalents restores CFTR processing despite the 
presence of the F508del mutation (Aleksandrov et al., 2012). The enhanced 
maturation of mouse F508del-CFTR may also be linked to the inclusion of a threonine 
residue at position 539 in the mouse CFTR sequence (Ostedgaard et al., 2007; Hoelen 
et al., 2010). In the case of human F508del-CFTR, the mutation I539T acts as a 
revertant mutant, reversing the processing defect resulting from F508del, and indeed 
the T539 residue is found in a number of CFTR orthologues that demonstrate 
enhanced maturation and membrane stability (deCarvalho et al., 2002; Aleksandrov 
et al., 2012). 
 
Improving CFTR stability at the PM lies at the heart of therapeutic approaches for 
correction of class VI CF-causing mutations, including F508del. Indeed, the combined 
use of correctors and potentiators for the treatment of F508del is likely to be insufficient 
unless the issue of thermodynamic instability is also addressed (Aleksandrov et al., 
2012; Wang et al., 2014a). In addition to the limited detrimental effects of F508del on 
chicken CFTR gating and maturation, chicken F508del-CFTR also appears to have 
little change in thermostability compared to WT (Aleksandrov et al., 2012). Again, 
understanding how such thermostability is mediated will be a key step towards 
improving the efficacy of treatments for such mutations. 
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1.7.2 Animal models of CF 
The development of animal models that accurately replicate the diverse organ 
pathologies of CF is essential for increasing our understanding of the disease and for 
testing potential new CF therapies. The first mouse model of CF was developed shortly 
after identification of the CFTR gene (Snouwaert et al., 1992). Subsequently, a range 
of CF mouse models were developed by either the introduction of null mutations that 
result in CFTR knock-out, or introduction of CF mutations such as F508del, G551D 
and R117H into the mouse CFTR gene (Wilke et al., 2011; McCarron et al., 2018). 
Unfortunately, whilst these mouse models have proven useful for studying certain 
aspects of the disease, particularly intestinal disease, they do not accurately replicate 
many features of human pathology, including the airway disease phenotype (Wilke et 
al., 2011). Furthermore, the initial mouse models of CF experienced high rates of early 
mortality due to intestinal obstruction (Kent et al., 1996; Wilke et al., 2011). The 
reasons for these differences in phenotype may be varied. For example, in addition to 
the differences in gating behaviour between human and mouse orthologues discussed 
earlier, CFTR plays a less dominant role in Cl- transport in mouse airway epithelia and 
it has been suggested that the calcium-activated chloride channel TMEM16A takes 
over this role in mice (Clarke et al., 1994; Grubb et al., 1994; Grubb & Boucher, 1999; 
Wilke et al., 2011; McCarron et al., 2018). In addition, there are considerable 
differences in the anatomy and physiology of the mouse lung compared to the human 
(Wilke et al., 2011), and as discussed earlier, mutations such as F508del do not have 
the same effect on mouse CFTR processing and function as they do when expressed 
in the human gene (Ostedgaard et al., 2007). 
 
As a result of the differences observed between the mouse and human CF phenotype, 
a number of advances have been made in the generation of mouse CF models. One 
such advance was the development of ‘gut-corrected’ mouse models, where the 
human CFTR gene is expressed in the mouse intestine with local expression 
controlled by linking the gene to the fatty acid-binding protein (FABP) (Zhou et al., 
1994; McCarron et al., 2018). These gut corrected CF mice are less susceptible to 
early mortality caused by intestinal obstruction (Zhou et al., 1994). The development 
of so-called ‘humanised’ mouse models that express human CFTR exclusively may 
also prove to more accurately replicate the human disease (Hodges et al., 2016; 
McCarron et al., 2018). In addition, a mouse model has been developed in which the 
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β-subunit of ENaC is overexpressed in the airways, resulting in a lung phenotype that 
more closely resembles that of human CF patients (Mall et al., 2004; Zhou et al., 
2011). Despite these advances, the requirement for animal models that accurately 
replicate the human airway disease phenotype has led to the development of models 
using species that share closer lung physiology to humans, with models developed in 
rat (Tuggle et al., 2014), rabbit (Xu et al., 2016), ferret (Sun et al., 2010) and pig 
(Rogers et al., 2008b). A sheep CF model has also recently been developed that 
demonstrates many similarities to the human CF phenotype, including pancreatic 
fibrosis, intestinal obstruction and absence of the vas deferens (Fan et al. 2018). As 
was the case with the CF pig (Rogers et al., 2008b) and CF ferret (Sun et.al. 2010) 
models, 100% of the sheep CF animals developed severe meconium ileus leading to 
early mortality (Fan et al. 2018). As such, it is not clear whether sheep CF models 
replicate the lung pathology observed in human patients, however the close 
similarities in lung physiology between sheep and humans provides rationale for the 
use of gut corrected sheep CF models for this purpose. (Harris, 1997; Cai et al., 2015, 
Fan et al. 2018). Whilst not replicating CF airway disease, CF models have also been 
generated in zebrafish for the purpose of studying gastrointestinal and pancreatic 
insufficiency (Navis & Bagnat, 2015), and a model has been developed in Drosophila 
which, although not a species that expresses CFTR, replicates a CF-like phenotype 
as a result of enhanced ENaC activity (Kim et al., 2017). 
 
1.7.3 Use of CFTR orthologues to study CFTR structure and function 
Observed differences in function between diverse CFTR orthologues provide a basis 
for studying structure-function relationships. One technique that has been well 
exploited for such studies is the use of chimeric channels, where structural regions 
from one orthologue are exchanged with sequences from another and used in 
functional studies to determine the role of specific domains in channel function (Price 
et al., 1996; Scott-Ward et al., 2007; Dong et al., 2012). Whilst site-directed 
mutagenesis is an important tool for carrying out structure-function relationships, the 
use of chimeras carries certain advantages. As demonstrated by the large number of 
CF-related mutations identified, a single change in CFTR sequence can have dramatic 
effects on the processing and function of CFTR, and as such small changes in CFTR 
structure can lead to the generation of proteins that are not amenable to study using 
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single-channel patch-clamp recording. Species orthologues however, provide a library 
of structural variations in CFTR that can be expressed using recombinant cDNA and 
should produce functional versions of the protein that can be more easily studied. In 
addition, the CFTR channel has the propensity for multiple potentiator binding sites, 
and the possibility of multiple binding sites for a given potentiator may result in 
potential binding sites being missed by the use of site-directed mutagenesis studies 
(Cui et al., 2016). A study by Stahl et al. (2012) demonstrates the potential value of 
using chimeras over the approach of site-directed mutagenesis. In this study, the effect 
of the CFTR inhibitors CFTRinh-172 (Ma et al., 2002; Caci et al., 2008), glibenclamide 
(Sheppard & Robinson, 1997) and GlyH-101 (Muanprasat et al., 2004) were studied 
on human, killifish, pig and shark CFTR orthologues. Stahl et al. (2012) reported 
species specific responses to CFTR inhibitors despite conservation of residues 
identified in previous studies using site-directed mutagenesis that were thought to 
correspond to the binding sites for these compounds. 
 
As reviewed in Bose et al. (2015), the first example of the use of CFTR chimeras to 
identify structure-function relationships of the channel was the use of human-Xenopus 
chimeras to determine the involvement of ECL1 in CFTR gating (Price et al., 1996). 
Price et al. (1996) generated a human-Xenopus chimera containing the complete 
Xenopus TMD1 sequence (hX1-6) with the remaining protein maintaining the human 
sequence. The hX1-6 chimera demonstrated a gating pattern that was distinct from 
both human and Xenopus WT-CFTR and shared similarities with that of the ECL1 CF 
mutation R117H (Sheppard et al., 1993). Introduction of the ECL1 human sequence 
alone into the hX1-6 chimera was sufficient to restore gating behaviour to a pattern 
resembling that of human WT-CFTR, demonstrating the involvement of specific ECL1 
residues in determining CFTR gating (Price et al., 1996). In a subsequent study by Cui 
et al. (2014), three highly conserved charged residues in ECL1, D110, E116 and R117, 
were found to stabilise the CFTR pore by forming salt bridges with other proximal 
charged residues located within the outer vestibule of the CFTR pore. 
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1.7.4 Use of CFTR orthologues to study the mechanism of action of small 
molecule CFTR modulators 
In addition to functional differences, species orthologues of CFTR have also been 
shown to exhibit notable differences in pharmacology. Lansdell et al. (1998a) studied 
the effects of the non-hydrolysable ATP analogue 5’-adenylyl-imidodiphosphate 
(AMP-PNP) and the inorganic phosphate analogue PPi on mouse CFTR, two 
compounds that were originally used to determine the role of ATP hydrolysis in CFTR 
gating (Anderson et al., 1991; Gunderson & Kopito, 1994; Hwang et al., 1994; Carson 
et al., 1995b). In the presence of ATP, AMP-PNP normally acts on human CFTR by 
prolonging the duration of open bursts (Gunderson & Kopito, 1994; Hwang et al., 1994; 
Carson et al., 1995a). In the case of mouse CFTR, AMP-PNP causes an increase in 
Po but without locking the channel in the open configuration as observed for human 
CFTR. PPi, which causes a robust potentiation of human CFTR and prolongs burst 
duration to a greater extent than AMP-PNP (Gunderson & Kopito, 1994; Carson et al., 
1995a; Carson et al., 1995b), also had no effect on the Po of mouse CFTR (Lansdell 
et al., 1998a). 
 
Further studies (de Jonge et al., 2007) have also reported similar findings for other 
CFTR potentiators, including the Vertex potentiator VRT-532 and the benzamide 
derivative 5-nitro-2-(3-phenylpropylamino) benzoate (NPPB), a dual acting compound 
that potentiates CFTR gating at low concentrations by promoting NBD dimerization, 
whilst also acting as a CFTR pore blocker (Wang et al., 2005; Lin et al., 2016). 
However, there is some discrepancy in the literature regarding the response of mouse 
CFTR to ivacaftor. Reports from both Van Goor et al. (2009) and de Jonge et al. (2007) 
have suggested that mouse CFTR is not potentiated by ivacaftor. Conversely, Cui and 
McCarty have shown that mouse CFTR does respond to ivacaftor (Cui & McCarty, 
2015; Cui et al., 2016). Experimental differences do not seem to wholly account for 
these discrepancies, with all groups studying the effect of ivacaftor on either 
macroscopic membrane patches or intact epithelia at room temperature. However, the 
experiments performed by Cui and McCarty (2015) were carried out using mouse 
CFTR expressed in Xenopus oocytes rather than mammalian cell lines and it is 
therefore possible that the nature of the lipid bilayer in which the channel is expressed 
may have an effect on the behaviour of the channel. Indeed, it is notable that Cui and 
McCarty (2015) did not observe the distinct O1 and O2 sub-conductance and full-open 
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levels of mouse CFTR recorded by other groups, but reported a much higher level of 
sub-conductance and a full-open state of the mouse channel with a higher Po than 
previously reported (Cui & McCarty, 2015). Again, it is possible that these differences 
are related to the environment in which the channel has been expressed, however it 
should be noted that other studies have shown that CFTR orthologues exhibit 
consistent gating behaviour regardless of expression cell type (Lansdell et al., 1998a; 
Ostedgaard et al., 2007). 
 
Building on the observation that PPi has no effect on Po of mouse CFTR, Scott-Ward 
et al. (2007) carried out further studies using CFTR chimeras to investigate the gating 
properties of this orthologue and to determine the binding domain of PPi. Human-
mouse CFTR chimeras were constructed using homologous recombination where the 
RD, NBD1, NBD2 or both NBD1 and 2 in human CFTR were replaced by the 
equivalent regions from mouse CFTR. Cells expressing these chimeras produced 
single-channel recordings that demonstrated a current amplitude that was close to that 
of human CFTR and gating characteristics that were intermediate between mouse and 
human CFTR depending upon the domains included in the chimera (Scott-Ward et al., 
2007). More specifically, it was observed that inclusion of both NBD1 and NBD2 of 
mouse CFTR, but not the RD, was sufficient to endow the human-mouse chimeras 
with the gating pattern associated with the O1 state of mouse CFTR and that inclusion 
of mouse NBD2, but not NBD1 augmented channel activity. These studies highlight 
the involvement of structural differences between human and mouse CFTR that 
determine channel function. By studying the effects of PPi on human-mouse CFTR 
chimeras, Scott-Ward et al. (2007) demonstrated that PPi potentiated channels 
containing human NBD2, but not mouse NBD2. The data suggest that, given that PPi 
potentiates human, but not mouse CFTR (Lansdell et al., 1998a), the mechanism of 
action of PPi involves interaction of the compound with NBD2 and highlight the 






1.8 Current understanding of the mechanism of action of ivacaftor 
 
1.8.1 Potentiation of CFTR by ivacaftor: Comparison with other CFTR 
potentiators 
Potentiators act to increase the Po of CFTR and can do so by prolonging pore openings 
(increased MBD) or by shortening pore closures (decreased IBI).  As discussed in 
Section 1.3.2 and Figure 1.5, opening of the CFTR pore is dependent upon the 
following steps: (1) Phosphorylation of the RD, (2) ATP binding at the NBDs, (3) Tight 
dimerisation of the NBDs, (4) Transmission of movement along the longitudinal axis 
of CFTR from the NBDs to the TMDs. Pore closure is then dependent upon ATP 
hydrolysis (Vergani et al., 2005b). CFTR activators such as UCCF-152 (Pyle et al., 
2011) may enhance RD phosphorylation. CFTR potentiators however act by 
enhancing the favourability of post-phosphorylation events leading to channel opening 
(Yeh et al., 2017), or by inhibiting ATP hydrolysis and thereby prolonging pore opening 
(Eckford et al., 2012). 
 
Hydrolysable ATP analogues such as N6-(2-phenylethyl)-ATP (P-ATP) (Zhou et al., 
2005), 2’- and 3’- deoxy-ATP (dATP) (Aleksandrov et al., 2002; Cai et al., 2006) and 
N6-(2-phenylethyl)-2'-deoxy-ATP (P-dATP) (Miki et al., 2010) act as potentiators for 
CFTR by both binding more efficiently at the ATP-binding sites, and by enhancing 
NBD dimerisation (Yeh et al., 2017). Ivacaftor however appears to potentiate CFTR 
independently of ATP as well as in the presence of ATP, as shown both by potentiation 
of the channel in the absence of Mg-ATP when purified recombinant CFTR is 
expressed in planar lipid bilayers (Eckford et al., 2012), and after washout of ATP in 
excised inside-out membrane patches (Jih & Hwang, 2013). This may in part explain 
the efficacy of ivacaftor for patients carrying the G551D mutation, which affects the 
hydrolytic site formed by the WA and WB motifs on NBD2, and demonstrates only 
ATP-independent gating, failing to respond to dATP or AMP-PNP (Li et al., 1996; 
Bompadre et al., 2007). One proposed mechanism for ivacaftor-mediated potentiation 
of CFTR is therefore that the compound enhances ATP-independent gating (Eckford 
et al., 2012). 
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CFTR activators promote phosphorylation of the RD. The isoxazole UCCF-152 for 
example has been shown to act as a CFTR activator, inducing PKA-dependent 
phosphorylation of the RD (Pyle et al., 2011). In the same study however, it was shown 
that neither VRT-532 nor ivacaftor enhanced phosphorylation of the RD (Pyle et al., 
2011). Furthermore, it has been demonstrated that ivacaftor potentiates CFTR 
channels that lack the RD (ΔR-CFTR) (Csanády et al., 2000; Bompadre et al., 2005; 
Jih & Hwang, 2013). 
 
The CFTR permeant anion NO3- has similarly been shown to increase the Po of ΔR- 
CFTR (Yeh et al., 2015). However, in addition to testing NO3- on ΔR-CFTR, Yeh et al. 
(2015) tested both NO3- and ivacaftor using CFTR that had been truncated to remove 
NBD2 (ΔNBD2-CFTR). Both NO3- and ivacaftor increased the Po of ΔNBD2-CFTR, 
indicating that the mechanism by which potentiation was being facilitated was 
independent of NBD dimerisation and ATP hydrolysis at the hydrolytic site (Yeh et al., 
2015). This finding is further supported by the observation that ivacaftor is effective for 
the potentiation of the CF mutation W1282X, which results in a truncated CFTR protein 
missing the C-terminal half of NBD2 (Haggie et al., 2017). Interestingly, the effect of 
NO3- and ivacaftor when used in conjunction was additive, indicating independent 
mechanisms for potentiation (Yeh et al., 2015). 
 
Given these observations, it is therefore likely that ivacaftor favours CFTR pore 
opening by affecting the movement of the TMDs and acting independently of ATP 
binding and RD phosphorylation. According to the schematic gating model shown in 
Figure 1.11, we can therefore infer that ivacaftor is likely to affect the transition rates 
μ+1 κ+1 and θ+1. Furthermore, Jih and Hwang (2013) have proposed a ‘re-entry’ 
mechanism in which there is a short window of opportunity for ATP to re-occupy the 
hydrolytic binding site that is vacated post-hydrolysis, shifting CFTR from the unstable 
O2ATP open state back to the more stable O12ATP open state (a shift from left to right 
in the dashed box as indicated by the red arrow in Figure 1.11) (Jih & Hwang, 2013). 
Jih and Hwang (2013) used multiple assays to demonstrate this idea. Firstly, using 
macroscopic currents recorded from inside-out membrane patches, CFTR was 
activated in the presence of 2.75 mM ATP which was then switched to the non-
hydrolysable ATP analogue PPi for 1 second before washout (Jih & Hwang, 2013). In 
the absence of ivacaftor, a current ~50 % of that in the presence of ATP was observed 
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following the switch to PPi, which decayed exponentially as channels closed. This 
current, which was enhanced in the presence of ivacaftor, likely represents the current 
flowing through channels that have been locked in the O2 open state. In addition, Jih 
and Hwang (2013) tested the effect of ivacaftor on R352C-CFTR, a mutated channel 
that shows two distinct open levels of single-channel current thought to correspond to 
O1 and O2, respectively. In this case, ivacaftor was observed to result in a greater 
increase in the time the channel spent in the O2 state rather than the O1 state, 
suggesting that ivacaftor is prolonging the O2 state and increasing the time available 
for ATP re-entry at the hydrolytic binding site (Jih & Hwang, 2013). 
 
Figure 1.11: Ivacaftor modifies the gating cycle of CFTR. Potential stages in the gating cycle of 
CFTR that may be affected by ivacaftor are indicated by the red shading. Other details as in Figure 1.5. 
Adapted from Jih and Hwang (2013). 
These studies indicate that ivacaftor may potentiate CFTR via two routes, increasing 
the likelihood of ATP-independent gating and by promoting the re-entry of ATP at the 
hydrolytic binding site (Eckford et al., 2012; Jih & Hwang, 2013). 
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1.8.2 Potential binding sites for ivacaftor 
Identifying the binding site for ivacaftor would represent a major step forward in 
determining mechanism of action and would greatly assist the design and 
development of novel CFTR potentiators. Ivacaftor is a highly hydrophobic compound 
and is therefore likely to occupy the lipid bilayer when applied to cells (Jih & Hwang, 
2013). Indeed, ivacaftor has been shown to accumulate within the inner leaflet of the 
plasma membrane (Baroni et al., 2014) and a recent study has also demonstrated that 
the destabilising effect of ivacaftor on CFTR membrane stability is likely to be the result 
of increased membrane fluidity and disruption of lipid rafts (Chin et al., 2018). The 
accumulation of ivacaftor in the plasma membrane, coupled with the data discussed 
in Section 1.8.1, suggest that the binding site of ivacaftor is most likely to be located 
on the TMDs where they interact with the lipid bilayer, or at the interface between the 
TMDs and NBDs, reducing the energy barrier for pore opening independent of ATP 
binding at the NBDs (Jih & Hwang, 2013; Sorum et al., 2015). Furthermore, this idea 
is supported by the observation that in excised membrane patches, ivacaftor 
demonstrates similar efficacy when applied either from the intra- or extracellular side 
of the membrane (Jih & Hwang, 2013). This result would not be expected if ivacaftor 





Figure 1.12: Potential binding sites of ivacaftor based upon HDX exchange. Regions where HDX 
exchange was reduced by -10% of that of the apo CFTR profile following addition of ivacaftor are 
highlighted. Regions where HDX reduction were greatest are highlighted in red. The F508 residue is 
highlighted in green. Based on data published by Byrnes et al. (2018). 
 
A recent study by Byrnes et al. (2018) utilised hydrogen/deuterium exchange (HDX) 
mass spectrometry to identify potential binding sites for ivacaftor. In HDX, hydrogen 
atoms covalently bonded to amides in the backbone residues of a protein are 
exchanged for deuterium, with the rate of deuterium uptake indicating the solvent 
accessibility of these residues. Byrnes et al. (2018) compared deuterium uptake for 
both the unbound (apo) and ivacaftor bound CFTR protein to identify regions in the N-
terminus, ICLs, TMD1 and NBD2 that showed protection to deuterium uptake after 
addition of ivacaftor (Figure 1.12) (Byrnes et al., 2018). The regions that showed the 
highest level of protection to HDX were located within the vicinity of F508, 
corresponding to the interfaces between TMD2 and both NBD1 and NBD2 (Figure 
1.12) (Byrnes et al., 2018). These data strongly support the hypothesis that ivacaftor 
binds to the TMDs, facilitating movement of the protein along the longitudinal axis and 
subsequent opening of the channel pore. However, as average uptake of deuterium 
by the apo CFTR protein is only 60%, with low coverage at the TMDs due to decreased 
solvent accessibility in this region, it is not possible to rule out the potential for 
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alternative or more preferential binding sites in the regions not covered by HDX 
(Byrnes et al., 2018). The use of functional studies, including for example the use of 
CFTR chimeras, could therefore yield more powerful support to these hypotheses. 
 
1.9 Hypothesis and aims of the present study 
 
Based on the data collected to date for the mechanism of CFTR potentiation by 
ivacaftor, this study aims to address the following hypothesis: 
 
“The mechanism of action of ivacaftor involves interactions with the 
transmembrane helices of CFTR.” 
 
In order to test this hypothesis, we will employ the use of CFTR chimeras in a similar 
manner to Scott-Ward et al. (2007), and will be addressing the following aims: 
 
1) Characterise species differences in the function of diverse CFTR 
orthologues - We will investigate the gating properties and single-channel 
behaviour of a diverse range of CFTR orthologues covering a wide spectrum of 
the phylogenetic tree. In order to do this, recombinant CFTR cDNAs will be 
expressed in mammalian cell lines and studied using high-resolution single-
channel recordings. 
 
2) Characterise the effect of CF-causing mutations on diverse CFTR 
orthologues - The impact of CF-causing mutations will be assessed on diverse 
CFTR orthologues. Focus will be placed on determining the effect of mutations 
on the gating behaviour and membrane thermal stability of CFTR. 
 
3) Assess pharmacological differences between different CFTR orthologues 
- CFTR orthologues will be tested for their response to small molecule 




4) Identify structural regions of the CFTR protein that are involved in the 
mechanism of action of ivacaftor using CFTR chimeras - Where species-
specific variation in the response of CFTR orthologues are identified, we will 
generate CFTR chimeras and identify structural regions involved in the 
mechanism of action of ivacaftor by studying the effect of ivacaftor on these 
chimeras. These experiments will be carried out in conjunction with our 
industrial partner (Novartis Institutes for Biomedical Research) where the use 
of high-throughput, automated electrophysiology will enable testing of a large 






















2. Materials and methods 
 
2.1 Single-channel patch-clamp recordings 
 
2.1.1 Cell Culture 
2.1.1.1 Cell lines stably expressing CFTR constructs 
For single-channel patch-clamp studies of human CFTR, we used baby hamster 
kidney (BHK-21), Chinese hamster ovary (CHO), or NIH 3T3 cells stably transfected 
with WT or F508del-CFTR homologues. Cell line choice depended upon the 
experiment being carried out as indicated in the Results chapters and mean data 
represents a single choice of stable cell line throughout. BHK cells were cultured in a 
1:1 mixture of Dulbecco’s modified Eagle’s Medium (DMEM) and Ham’s F-12 nutrient 
medium (DMEM/F-12) that had been supplemented with 5% foetal bovine serum 
(FBS), 100 U·ml-1 penicillin, 100 µg·ml-1 streptomycin (all purchased from Invitrogen 
Ltd., Paisley, UK) and 200 µg·ml-1 methotrexate (Merck Chemicals Ltd., Nottingham, 
UK  or AAH Pharmaceuticals Ltd., Coventry, UK). CHO cells were cultured in Ham’s 
F-12 nutrient mixture that had been supplemented with 10% FBS, 100 U·ml-1 penicillin 
and 100 µg·ml-1 streptomycin (Invitrogen Ltd.) and 0.6 mg∙ml-1 neomycin (Merck, 
previously Sigma-Aldrich Company Ltd., Gillingham, UK). NIH 3T3 cells were cultured 
in DMEM supplemented with 1% GlutaMAX supplement (Invitrogen Ltd.), 10% FBS, 
100 U·ml-1 penicillin, 100 µg·ml-1 streptomycin and 0.25 mg·ml-1 G-418. All cells were 
maintained in 25 ml rectangular canted neck cell culture flasks (Corning, New York, 
USA) at 37 °C in a humidified atmosphere containing 5% CO2 except where otherwise 
stated. Media was changed every 24-48 hours and cells were passaged when > 95% 
confluence was achieved by first washing with Versene solution before dissociation 
with 0.05% Trypsin (both from Invitrogen Ltd.). For storage, cryovials containing > 5 
million cells suspended in a freezing media containing 10% dimethyl sulfoxide (DMSO) 
and 90% FBS were preserved in liquid nitrogen. Following defrosting, cells were used 
for a maximum of 10 weeks. 
  
CHO cells stably expressing mouse WT- and F508del-CFTR were also cultured using 
Ham’s F-12 nutrient mixture supplemented with 10% FBS, 100 U·ml-1 penicillin and 
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100 µg·ml-1 streptomycin with either 0.2 mg∙ml-1 neomycin (mouse WT-CFTR) or 200 
µg·ml-1 methotrexate (mouse F508del-CFTR). 
 
For patch-clamp experiments, cells expressing WT-CFTR orthologues were seeded 
at low density and grown on glass coverslips in 35 x 10 mm Petri dishes (Corning) with 
2.5 ml DMEM/F-12 media, incubated at 37 °C in a humidified atmosphere containing 
5% CO2 for 24-48 hours prior to each experiment. Cells expressing F508del-CFTR 
homologues were seeded following the same protocol as WT homologues but 
incubated at 27 °C in a humidified atmosphere with 5% CO2 for at least 24 hours prior 
to experiments. This protocol was followed to correct the processing defect caused by 
the F508del mutation and restore CFTR expression at the cell membrane (Denning et 
al., 1992). Coverslips were cut into smaller sections and media was renewed up to 24 
hours prior to experiments. 
 
2.1.1.2 Cell lines transiently expressing CFTR constructs 
For generation of transiently transfected cell lines, CHO-K1 cells that did not express 
endogenous CFTR were used. Cells were cultured in Ham’s F-12 nutrient medium 
supplemented with 10% FBS, 100 U·ml-1 penicillin and 100 µg·ml-1 streptomycin (all 
purchased from Invitrogen Ltd.). All cells were maintained in 25 ml rectangular canted 
neck cell culture flasks (Corning) at 37 °C in a humidified atmosphere with 5% CO2 
except where otherwise stated. Media was changed every 24-48 hours and cells were 
passaged as described above when > 95% confluence was achieved. 
 
For patch-clamp experiments, cells were seeded at low density and grown on glass 
coverslips in 35 x 10 mm Petri dishes (Corning) with 2.5 ml Ham’s F-12 media, 
incubated at 37 °C in a humidified atmosphere comprising 5% CO2 for 24 - 48 hours 
prior to transfection. Cells were co-transfected with plasmids containing the desired 
CFTR orthologue together with the enhanced green fluorescent protein N1 plasmid 
(pEGFP-N1) transfection marker at least 24 hours before experiments using the 
Lipofectamine transfection system (Invitrogen Ltd.). Cells expressing F508del-CFTR 
orthologues were seeded following the same protocol as WT homologues, but 
incubated at 27 °C in a humidified atmosphere with 5% CO2 for at least 24 - 48 hours 
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prior to experiments. Coverslips were cut into smaller sections and media was 
renewed up to 24 hours prior to experiments. 
 
2.1.2 Plasmid design 
Table 2.1 lists the human CFTR chimeras that were used in this study. Human-mouse 
CFTR chimeras were designed by Dr. Christopher Boyd (University of Edinburgh, UK), 
with the exception of constructs 5, and 16 (Table 2.1), which were generated by the 
laboratory of Prof. Michael J. Welsh (University of Iowa, USA). Whole-domain 
chimeras (constructs 3, 4 and 15) were generated via homologous recombination. 
Constructs 6-14 were generated following the insertion of restriction sites placed at 
regular intervals within the modified backbone of human WT-CFTR. Regions to be 
inserted were constructed by GeneArt® Gene Synthesis (ThermoFisher Scientific, 
Regensberg, Germany). The protocol for generation of chimeras as outlined in Scott-
Ward et al. (2007) and Dong et al. (2012) was as follows: 
i) Target domains from mouse-CFTR cDNA expressed in pFLM-CFTR 
plasmids were amplified via polymerase chain reaction (PCR) using primers 
containing human-CFTR sequences corresponding to the 5’ ends. 
ii) pCMV/pcDNA.3.1-CFTR plasmids expressing the human-CFTR sequence 
were linearised in the domain of interest. 
iii) Products of step i) and ii) were co-electroporated into the recombinogenic 
E. coli strain DH10B-U/pSpRecGam. 
iv) Intact chimeric plasmids were recovered where intermolecular 
recombination had been successful between homologous sequences of 
linear pCMV/pcDNA3.1-CFTR and PCR products. 
v) Sequences were confirmed by sequencing. 
vi) For automated electrophysiology, constructs were amplified to a 








Construct Residue boundaries Plasmid Source 
1 human WT N/A pCMV Edinburgh 
2 mouse WT N/A pCMV  Edinburgh 
3 hmNBD1/2 432-611:1226-1419 pCMV Edinburgh 
4 hmNBD1 432-611 pCMV Edinburgh 
5 hmNBD2 1178-1480 pcDNA3.1 Iowa 
6 hmTM1-12 79-355:858-1152 pCMV Edinburgh 
7 hmTM1-6 79-355 pCMV Edinburgh 
8 hmTM7-12 858-1152 pCMV Edinburgh 
9 hmTM5+6 307-355 pCMV Edinburgh 
10 hmTM5+6:TM1+2 307-355:78-153 pCMV Edinburgh 
11 hmTM5+6:TM3+4 307-355:154-306 pCMV Edinburgh 
12 hmTM5+6:TM7+8 307-355:858-935 pCMV Edinburgh 
13 hmTM5+6:TM9+10 307-355:987-1034 pCMV Edinburgh 
14 hmTM5+6:TM11+12 307-355:1095-1152 pCMV Edinburgh 
15 hmRD 653-837 pCMV Edinburgh 
16 hmRI 404-436 pcDNA3.1 Iowa 
 
Table 2.1: Human and mouse WT and chimeric cDNA constructs created by the Boyd 
(Edinburgh) and Welsh (Iowa) labs and used in this study. Construct names indicate the regions of 
the protein that have been exchanged from the human to the mouse sequence, for example hmNBD1 
indicates a human CFTR background with a mouse sequence for NBD1, whilst hmTM5+6 indicates a 
human sequence for CFTR with mouse sequence for TM5 and TM6. Residue boundaries refer to the 
mouse residues that are present in the chimera. 
 
2.1.3 Reagents 
Protein kinase A (PKA) purified from bovine heart was obtained from Calbiochem 
(Merck Chemicals Ltd., Nottingham, UK). Unless otherwise stated, all other chemicals 
were supplied by the Sigma-Aldrich Company Ltd. (now Merck). The low-Cl- pipette 
(extracellular) solution contained 140 mM N-methyl-D-glucamine (NMDG), 140 mM 
aspartic acid, 5 mM CaCl2, 2 mM MgSO4 and 10 mM N-tris[hydroxymethyl]methyl-2-
aminoethanesulphonic acid (TES). Pipette solution pH was adjusted to 7.3 using Tris 
([Cl-] = 10 mM, mean osmolarity = 281 ± 0.5 mosM, n = 3). Bath (intracellular) solution 
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contained 140 mM NMDG, 3 mM MgCl2, 1 mM CsEGTA and 10 mM TES. Bath 
solution pH was adjusted to 7.3 using HCl ([Cl-] = 147 mM, [Ca2+]free = <10-8 M, mean 
osmolarity = 279 ± 0.5 mosM, n = 3). Fresh 0.2 M ATP stock solutions were made on 
each day of experiments and stored in ice before use. Ivacaftor and lumacaftor were 
sourced from Selleckchem (Munich, Germany) and added to DMSO to create a 10 mM 
stock. Genistein was purchased from LC laboratories (Woburn, MA, USA) and added 
to DMSO to give a 50 mM stock. CFTRinh-172 was sourced from Sigma and added to 
DMSO to create a 30 mM stock. Stock solutions of all drugs were stored at -20°C in 
aliquots of 20 μl and used immediately after defrosting. 
 
2.1.4 Electrophysiological recordings 
Three patch-clamp setups were used for single-channel patch-clamp recordings. 
However, the configuration of equipment used for data acquisition and analysis of 
recordings remained the same regardless of the setup used. After cutting to size, 
coverslips with transfected cells were transferred to the 0.5 ml experimental chamber 
of a temperature-controlled microscope stage (Brook Industries, Lake Villa, IL, USA) 
mounted to an inverted microscope (patch-clamp setup 1: Nikon Diaphot 200 inverted 
microscope, Nikon, Tokyo, Japan; patch-clamp setups 2 and 3: Leica DMiRB or DMi8, 
Leica Microsystems, Wetzlar, Germany). All experiments were carried out at 37  C 
unless otherwise stated. 
 
Single-channel patch-clamp experiments to measure CFTR activity were carried out 
using excised inside-out membrane patches. Glass patch pipettes were pulled from 
filamented thin-walled borosilicate glass capillary tubing (for higher resistance 
pipettes, length = 75.0 mm, outer diameter = 1.50 mm, inner diameter = 1.17 mm; for 
lower resistance pipettes, length = 75.0 mm, outer diameter = 1.50 mm, inner diameter 
= 0.86 mm, Harvard Apparatus UK, Biochrom Ltd., Cambridge, UK) using either a two 
stage vertical pipette puller (David Kopf Instruments, model 750; Clark Electromedical 
Instruments, Reading, UK) or a P-97 Flaming/Brown Micropipette Puller (Sutter 
Instruments, Novato, CA, USA) programmed for a two stage pull. Fresh pipettes were 
fabricated for each day of experiments and stored in a closed container to prevent 
dust contamination. Pipette resistance for pipettes pulled using the Sutter P-97 puller 
were within the range 10-90 MΩ when filled with low Cl- pipette solution with resistance 
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tailored to the expression level of CFTR. Pipette capacitance was controlled by coating 
pipettes with Sylgard to within 1 mm of the pipette tip (Merck Ltd., Lutterworth, UK). 
Pipette resistances for pipettes pulled using the Kopf 750 puller were higher to adjust 
for the high expression of CFTR in BHK cells, in the range 80-150 MΩ. 
 
Voltage-clamp and current amplification were achieved using an Axopatch 200A 
(setup 1) or 200B (setups 2 and 3) patch-clamp amplifier (Axon Instruments Inc., now 
Molecular Devices Corp., San Jose, CA, USA) and data acquired using pCLAMP 
software (v 6.02, 9.2 or 10.3; Molecular Devices Corp.). Where traces from single-
channel patch-clamp experiments are shown, the conventional standard has been 
used throughout; where positive current represents movement of positive charge 
passing from intra- to extracellular solutions. For most single-channel recordings, 
holding voltage (VH) was clamped at either -50 mV or -80 mV. For generation of single-
channel current/voltage (i/V) relationships, voltage was stepped at 20 mV intervals 
from -100 mV to +20 mV for periods of at least 30 s at each voltage. 
 
For initial experiments, data obtained from single-channel recordings were filtered at 
a bandwidth of 10 kHz using the amplifiers built-in 80 dB/decade Bessel filter and 
recorded to digital audio tape (DAT) at a sampling rate of 48 kHz using a digital tape 
recorder (Biologic Scientific Instruments, model DTR-1204; Intracel Ltd., Royston, 
UK). For analysis, records were filtered using an eight-pole Bessel Filter (Frequency 
Devices, model 902LPF2; supplied by SCENSYS Ltd., Aylesbury, UK) on playback at 
a corner frequency of 500 Hz and digitised using a DigiData 1200 or 1320A AD-
converter interface and pCLAMP software (v 6.02 or 9.2, Axon Instruments Inc.) at a 
sampling rate of 5 kHz. Due to the difficulty of sourcing DAT recording tapes, data 
acquisition and storage was switched to external hard drives for the latter stages of 
the project. For subsequent recordings, data were filtered at a bandwidth of 10 kHz 
using the amplifiers built-in Bessel filter and recorded to external hard drive (Toshiba) 
using pCLAMP software v 9.2 (setup 2) or v 10.3 (setup 3) at a sampling frequency of 
50 kHz. For analysis, data were filtered as previously described at a corner frequency 
of 500 Hz using an eight-pole Bessel Filter (Frequency Devices, model 902LPF2) and 
a sampling frequency of 5 kHz. For the purpose of illustration, example patch-clamp 
recordings used in figures have undergone an additional 5-fold data reduction. 
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Patch-clamp experiments were performed as follows: Cover-slips seeded with cells 
were added to the experimental chamber. The tips of filamented glass patch pipettes 
were dipped in extracellular solution with positive pressure applied to the rear of 
pipettes as contact was made at the air-liquid interface to prevent accumulation of 
debris. Negative pressure was then applied to the rear of the pipette to aid filling of the 
narrow tip section. Pipettes were back-filled with extracellular solution to around 10 
mm from the end of the pipette using MicroFil micropipette (MF28G67-5, World 
Precision Instruments, Sarasota, FL, USA) and checked to ensure that solution was 
continuous with the tip section of the patch pipette. Patch pipettes were attached to 
the headstage of the patch-clamp amplifier with current recorded to the patch-clamp 
amplifier via an AgCl coated silver wire and the ground input of the amplifier headstage 
was connected to the experimental chamber via an agar bridge comprising 10 cm 
polythene tubing filled with 5% agar and 1M KCl. A fresh agar bridge was used for 
each day of experiments and agar bridges were stored in 1 M KCl at 5 °C before use. 
Positive pressure was applied to the rear of the pipette to reduce the risk of tip 
blockage with debris before the pipette was lowered into the experimental chamber 
which contained 0.5 ml intracellular solution. Short voltage pulses were applied across 
the tip of the pipette to measure the electrical resistance of the pipette at the junction 
between the intracellular and extracellular solutions. The pipette offset resulting from 
this liquid junction was corrected to zero immediately after pipettes had been lowered 
into the intracellular solution, and immediately before contact was made with the cell 
membrane. Cells were selected for experiments by visual inspection based on 
morphology of the cells and intensity of fluorescence if using transiently transfected 
cells expressing pEGFP. After identification of target cells, the pipette was lowered 
until contact was made with the cell membrane, as confirmed visually and by a change 
in the resistance recorded across the pipette tip. Negative pressure was then applied 
to the rear of the pipette to aid formation of a giga ohm seal (> 10 MΩ). The resulting 
membrane patch was excised by lifting the pipette to form an inside-out membrane 
patch. To reduce the risk of electrical noise in recordings, pipettes containing excised 
patches were raised to the level of the surface film of the intracellular solution. 
 
CFTR was activated by adding ATP and PKA to the bath (internal) solution at a final 
bath concentration of 1 mM ATP and 75 nM PKA. Maintenance of pH at 7.3 was 
obtained by adding NaOH in conjunction with the ATP. For experiments where 0.3 mM 
 57 
ATP was used, CFTR was first activated with 1 mM ATP before complete exchange 
of bath solution via perfusion with 10 ml bath solution containing 0.3 mM ATP. PKA 
was added to all internal solutions and maintained throughout experiments to avoid 
channel rundown. All experiments were initially voltage clamped at -50 mV. Because 
of the difficulty of washing ivacaftor from the experimental chamber, ivacaftor had to 
be added cumulatively to the experimental chamber for dose response experiments 
via direct addition. Prior to experiments, ivacaftor was stored in aliquots of 10 mM 
stock maintained at -20 °C. Before use, aliquots were defrosted and diluted to 0.5 mM 
in DMSO, before serial dilution to 0.05 mM and 0.005 mM stocks in bath solution 
before addition to the experimental chamber at the desired final concentration. All 
stock solutions added were pre-mixed in 30 μl bath solution prior to addition to the 
chamber to ensure sufficient dispersal. After experiments, chambers were washed in 
40% DMSO for 24 hours to prevent ivacaftor contamination of subsequent 
experiments. For dose response experiments, control recordings were made for a 
minimum of 5 minutes following stable activation of CFTR channels. Subsequent 
recordings were made for a minimum of 5 minutes at each concentration of the test 
compound. For experiments using genistein, after obtaining control data, 10 ml 
intracellular solution containing 50 μM genistein and 1 mM ATP was continuously 
perfused through the experimental chamber at a rate of 160 μl·s-1 to ensure complete 
exchange of solution. 75 nM PKA was added to the experimental chamber via direct 
addition before recordings were made in the presence of the drug. 
 
2.1.5 Analysis and statistics 
2.1.5.1 Analysis of single-channel recordings 
Recordings were analysed using pClamp software v9.2 or v10.3 (Molecular Devices 
Corp.). Single-channel current amplitude (i) was measured by fitting Gaussian 
distributions to current amplitude histograms as shown in Figure 2.1, and calculated 
from the difference between the closed (mu-1) and open (mu-2) levels (Cai et al., 
2004; Sheppard et al., 2004). Current amplitude histograms were generated from 
recordings containing £ 5 simultaneous channel openings and fitted using a 2-
component Gaussian equation. The total number of channels present in a membrane 
patch (N) was determined from the maximum number of simultaneous channel 
openings present within a recording of a minimum duration of 5 minutes for active 
 58 
channels, or 10 minutes for inactive channels (e.g. mouse WT-CFTR or human 
F508del-CFTR). To facilitate correct determination of N, experimental conditions were 
designed to strongly enhance CFTR activity by using 1.0 mM ATP or by using a CFTR 
potentiator (ivacaftor). However, it is possible that for inactive channels, the value 
calculated for N is an underestimate despite these criteria. 
 
 
Figure 2.1: Current amplitude histogram generated from 30 s single-channel recording of human 
WT-CFTR at -50 mV. Histograms were fitted using a 2-component Gaussian fit (continuous black line) 
and single-channel current amplitude (i) was calculated as the differences between Mu-1 (closed) and 
Mu-2 (open) levels. 
 
The open probability (Po) for single-channel recordings containing £ 5 channels was 
calculated from event lists generated from open- and closed-times using a half-
amplitude crossing criterion for event detection. Events were determined where a 
change in current was detected that was > 50% that of the current recorded for the 
previous event (Cai et al., 2004). Events of a duration < 1 ms were excluded from 
analysis, corresponding to the rise time predicted by the corner frequency (fc) of the 
eight-pole Bessel filter used for recordings (fc at 500 Hz = ~ 0.73 ms).  Po was 











Where N indicates the maximum number of simultaneous channel openings recorded, 
TN = the duration of time spent at a given level for the number of channels N, and Ttot 
= the total time period for the analysed recording. 
 
Where only one channel was observed for the duration of an experiment, mean burst 
duration (MBD) and interburst interval (IBI) were calculated by burst analysis using 
pCLAMP software v6.0. Dwell time histograms were generated from event lists for 
open- and closed-events using logarithmic x-axes and 10 bins·decade-1 (Figure 2.2). 
Histograms were fitted using one or more component exponential functions using the 





Figure 2.2: Example dwell-time histograms for open- and closed-time events generated from 
single-channel recordings of human WT-CFTR. Histograms have been fitted with one- (open) or 
two-component (closed) exponential functions (continuous black line). Logarithmic x-axes are used for 
both open and closed time histograms plotted with 10 bins·decade-1. Dashed lines indicate mean open 
(τo) and mean closed (τc1 and τc2) durations. Individual components for the τc1 and τc2 of the closed-
time histogram are indicated by red and grey dotted lines, respectively. 
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To further investigate the duration of channel openings, the burst delimiter tc, 
representing the time that differentiates intraburst closures from interburst closures, 
was calculated after fitting closed-time dwell-time histograms using the maximum 
likelihood method (Carson et al., 1995a). Events lists generated from recordings were 
used to calculate MBD and the open probability within bursts using pClamp software 







where Tb = MBD x the open probability within a burst. 
 
Where i/V relationships were plotted using data collected from single-channel 
recordings, the reversal potentials were compared to equilibrium potentials calculated 










In this equation, R = the universal gas constant (8.314472 J·K-1·mol-1), T = 
temperature (310 K), z = valency (i.e. -1 for Cl-), F = Faraday constant (9.648533 x104 
C· mol-1), [Cl-]o = concentration of extracellular Cl- (147 mM) and [Cl-]i = concentration 
of intracellular Cl- (10 mM). 
 
2.1.5.2 Statistics 
Unless indicated otherwise, results have been expressed as means ± standard error 
of the mean (SEM) of n observations. Where n = 2, results have been expressed as 
means ± standard deviation (SD). Differences were considered statistically significant 
when P < 0.05 and power analysis was performed for all statistics with significance 
requiring a power of 0.8 where α = 0.05. All tests were performed using SigmaStat™ 
(SigmaPlot™ version 13.0, Systat Software Inc., San Jose, CA, USA). 
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To test for differences between two groups of data a two-tailed Student’s t-test was 
used and where two sets of data were obtained from the same cell or membrane 
patch, a paired, two-tailed Student’s t-test was used. 
 
Where multiple concentrations of a drug compound were used in the same 
experiment, data were analysed using one-way repeated measures ANOVA and 
where a statistically significant difference was observed interventions were compared 
with control using Dunnett’s multiple comparison test. 
 
Dose response curves for drugs were fitted using a 3-parameter sigmoidal equation: 
 
Eq. 4: 
f (x) = 
ymax




Where KD is the apparent dissociation constant and ymax = the maximum predicted 
value for y. 
 
2.2 Automated whole-cell patch-clamp recordings 
 
2.2.1 Cell culture and transfection 
Untransfected CHO-K1 cells were cultured in F-12K medium (Kaighn’s Modification of 
Ham’s F-12 Medium, American Type Culture Collection, Manassas, USA) 
supplemented with 10% FBS, 1% L-glutamine, 100 U·ml-1 penicillin and 100 µg·ml-1 
streptomycin. All cells were maintained in either 150 cm2 rectangular canted neck cell 
culture flasks (Corning) or in HYPERflasks (Corning) at 37 °C in a humidified 
atmosphere with 5% CO2 except where otherwise stated. Media was changed every 
24-48 hours and cells were passaged when > 95% confluent by washing with 
Dulbecco’s phosphate buffered saline (DPBS) before dissociating using Detachin™ 
(Genlantis, San Diego, USA). 
 
Transient cell lines were generated by electroporation of cells with CFTR cDNA 
plasmids. To ensure maximum transfection efficiency for automated patch-clamp 
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recording, CHO-K1 cells were transfected using a MaxCyte STX Scalable 
Transfection System (MaxCyte Inc., Gaithersburg, USA). Initial optimisation protocols 
were run for cDNA plasmids as follows: 
• CHO-K1 cells were cultured as described above and harvested for optimisation 
by first washing with 14 ml DPBS followed by 4 ml Detachin™ (Genlantis). Cells 
were centrifuged at 1500 rpm for 5 minutes and rinsed with MaxCyte 
electroporation buffer, before being centrifuged again at 1500 rpm for 5 minutes 
and re-suspended in electroporation buffer at high density (2 x108 cells∙ml-1). 
 
• Re-suspended cells were mixed with cDNA plasmids at concentrations of 100, 
200 and 300 μg∙ml-1 and transferred to MaxCyte OC-100 processing 
assemblies and transfected using the recommended MaxCyte electroporation 
protocol for CHO cells. 
 
• Following transfection, cells were transferred to a multiwell dish and allowed to 
recover for 20 minutes at 37 ˚C before being transferred to 75 ml cell culture 
flasks (Corning) with F-12K culture medium. 
 
• Cells were incubated at 37 °C in a humidified atmosphere with 5% CO2 for 24 
hours before being transferred to 27 °C to prevent further cell growth. 
 
• Expression levels were tested at 24, 48 and 72 hour time points by comparing 
the success rate for observing CFTRinh-172-sensitive forskolin-induced whole-
cell currents when cells were tested using either QPatch HTX (Sophion 
Bioscience A/S, Ballerup, Denmark) or a SyncroPatch 384PE (Nanion 
Technologies GmbH, Munich, Germany), automated patch-clamp systems as 
described below. (MaxCyte optimisation protocols carried out using the 
SyncroPatch 384PE platform were kindly performed by Kelly McKiernan 
(NIBR)). 
 
• Optimum protocols were selected for plasmids based on cell viability, 
percentage of cells exhibiting CFTR-mediated current, and the maximum 
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current amplitude generated. The optimum protocol for all plasmids was 
transfection at 300 μg∙ml-1 and incubation for 72 hours prior to cryopreservation. 
Following optimisation of the transfection protocol, cell lines were generated and 
scaled up for cryopreservation using MaxCyte electroporation for each of the 
constructs listed in Table 2.1. Prior to transfection, CHO-K1 cells were cultured as 
described above in 150 cm2 rectangular canted neck cell culture flasks (Corning) 
before being transferred to HYPERflask M cell culture flasks (Corning) which enabled 
generation of up to 1.72 x108 cells per flask. For each cell line, cells were harvested 
from HYPERflasks by washing with 100 ml DPBS and adding 50 ml Detachin™. Cells 
were incubated at 37 °C with Detachin for 10 minutes and once all cells were fully 
dissociated, 50 ml culture medium was added to deactivate the Detachin™. Cell 
viability and density were measured using a Vi-CELL XR cell counter (Beckman-
Coulter Life Sciences, Indiana, USA), resuspended in MaxCyte electroporation buffer 
at a concentration of 2.0 x108 cells ml-1 and added to plasmid cDNA to give a final 
cDNA concentration of 300 μg·ml-1. 400 µl of each cDNA-cell suspension was then 
added to a MaxCyte OC-400 processing assembly and transfection was carried out 
via electroporation using the appropriate transfection protocol designated for CHO-K1 
cells. Following transfection, cell suspensions were transferred from the OC-400 
processing assemblies to multi-well plates and incubated for 20 minutes at 37 °C to 
allow recovery from the electroporation process. Cells were transferred to 
HYPERflasks in 500 ml culture medium and incubated at 37 °C for 24 hours, before 
being transferred to 27 °C and incubated for a further 48 hours before 
cryopreservation. Cells were harvested as described above, divided into aliquots of 5 
x106 cells and frozen at -80 °C in freezing media (90% FBS, 10% DMSO) using 
CoolCell freezing containers (Corning). For long term use, aliquots were transferred 
to liquid nitrogen after initial freezing at -80 °C for a minimum of 24 hours. For 
experiments, cells were rapidly thawed, re-suspended in serum-free suspension 
media (CHO-S-SFM II, Invitrogen) at a minimum cell density of 2 x106 cells∙ml-1 and 
transferred to the QPatch cell storage tank. Cells were used for experiments within 4 





All chemicals were supplied by Sigma-Aldrich (now Merck) unless stated otherwise. 
For QPatch assays, extracellular solution contained 160 mM NaCl, 4.5 mM KCl, 2 mM 
CaCl2, 1 mM MgCl2, 5 mM Glucose, 10 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES, Invitrogen) and 2 mM Mg-ATP ([Cl-] = 171 mM, 
osmolarity = 295 mOsm). Extracellular solution pH was adjusted to 7.3 with NaOH. 
Intracellular solution contained 145 mM KCl, 10 mM NaCl, 2 mM MgCl2, 10 mM 
ethylene glycol-bis(β-aminoethyl ether)-N,N,N’,N’-tetraacetic acid (EGTA), 10 mM 
HEPES and 5 mM Na-ATP ([Cl-] = 159 mM, osmolarity = 290 mOsm). Intracellular 
solution pH was adjusted to pH 7.2 with CsOH. Responses to the vehicle control were 
tested using DMSO diluted to 3% in extracellular solution. CFTR was activated using 
10 μM forskolin (FSK) and CFTR-specific responses were recorded by inhibiting 
activity with 30 μM CFTRinh-172 at the end of each protocol. All reagents were diluted 
to the required concentration in extracellular solution, stored in QPatch MTP-96 plates 
at room temperature and added to the extracellular side of each QPlate well for 
experiments. 10 mM forskolin stock was stored in aliquots at -20 °C when not in use. 
Ivacaftor was sourced in powdered from Selleckchem. and added to DMSO to create 
a 10 mM stock that was stored at -20 °C. CFTRinh-172 was purchased from Sigma in 
powdered form and stored in 30 mM solution (DMSO) at -20 °C until required. 
 
2.1.4 QPatch automated electrophysiological recordings 
For experiments using the QPatch HTX screening station, harvested cells were 
counted, centrifuged, and resuspended in suspension media at a concentration of 2.5 
x106 cells·ml-1. Cells were allowed to rest for at least 1 hour at room temperature and 
maintained in solution by stirring before being added to individual wells of a 48 well 
QPlate. Figure 2.3 shows a schematic diagram of an individual well from a QPlate 
used for experiments on the QPatch HTX screening station. Before experiments, 
QPatch pipettes were washed using 50 ml H2O. The experimental process for running 
experiments on the QPatch HTX screening station ran as follows (details adapted from 
protocol as described in the Sophion QPatch HTX Screening Station Handbook, 
©2004-2012 Sophion Bioscience A/S): 




II. The intracellular well was primed by application of pressurised air for duration 
of 3 minutes to press liquid into the channel of the QPlate. 
 
III. The protective manifold was moved into position to cover the QPlate and 
provide electrical isolation of the experiment. 
 
IV. Extracellular solution was added to the cell and compound well and a vacuum 
applied to the waste reservoir in order to ensure sufficient uptake of liquid to 
the extracellular chamber. 
 
V. Integrated Ag/AgCl electrodes were allowed to stabilise for a period of 120 s. 
 
VI. Resistance and offset potential were measured between the working and 
reference electrodes and offset potential was compensated for by the QPatch 
built in amplifier. 
 
VII. Cells that had been washed and resuspended in extracellular solution were 
added to the cell and compound wells of the QPlate. 
 
VIII. Negative pressure applied to the intracellular solution wells of the QPlate to 
position cells onto the patch-clamp orifice (Figure 2.3). 
 
IX. Following successful positioning of cells, gigaohm seals were obtained using 
the parameters set in the whole-cell protocol of the QPatch Assay software 
(see below). 
 
X. System capacitance (C-Fast) was recorded throughout the process of gigaseal 
establishment and values for C-Fast used to compensate for the capacitive 
component of measured current. 
 
XI. Following gigaseal formation, whole-cell configuration was obtained using the 
sequence defined in the whole-cell protocol and whole-cell configuration was 
detected by an increase in cell capacitance (C-Slow). 
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XII. C-Slow (typically between 4 and 15 pF), series resistance (R-Series) and 
membrane resistance (R-Membrane) were monitored and recorded throughout 
the duration of experiments. 
 
XIII. Experiments proceeded according to the sequence specified in the application 
protocol specified in the QPatch Assay software. 
 
Figure 2.3: Experimental well from the QPlates used for QPatch experiments. Qplates are primed 
with intra- and extracellular solutions prior to cell addition. After cells are applied to the QPlate wells, 
suction at the intracellular side of the plate aids positioning of cells at the patch-clamp orifice and 
gigaohm seals and whole-cell patch-clamp configuration were obtained using the whole-cell protocol. 
Compounds were tested by addition to the extracellular solution. 
 
Assays for use with the QPatch HTX screening station were designed using QPatch 
Assay v5.6 (Sophion). All experiments were carried out at room temperature (21 °C) 
Assays consisted of a whole-cell protocol for establishing the whole-cell patch-clamp 
configuration, an application protocol for applying test compounds and a voltage 
protocol. For testing the response of cells expressing either WT-CFTR constructs or 
CFTR chimeras to CFTR potentiators, these protocols were set up as follows: 
• Whole-cell protocol: For positioning of cells, a wait time of 5 s was set and a 
positioning pressure of -100 mbar. The resistance increase for success was set 
to 750% with a positioning timeout of 30 s. For formation of gigaseals, minimum 
seal resistance was set to 0.1 GΩ, holding potential -30 mV and holding 
pressure -20 mbar. Time set for improving gigaseal resistance was 180 s. For 
whole-cell configuration minimum seal resistance was set to 0.05 GΩ (typical 
seal resistance = ~ 1GΩ), holding potential -30 mV and holding pressure -20 
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mbar. For gigaseal formation, start pressure was set to -70 mbar, wait time 
before holding voltage change was 8 s. QPatch software abandoned 
experiments where the criteria for gigaseal was no longer met. 
 
• Application protocol: For testing CFTR potentiatiors, solutions were added 
using the following application protocol; break in > saline (extracellular 
solution), 5 min > DMSO (3%), 5 min > forskolin (10 µM), 15 min > ivacaftor (10 
µM), 5 min > CFTRinh-172 (30 µM), 5 min. For each liquid period, complete 
exchange of solution was achieved via perfusion. 10 µM Forskolin was present 
in solutions throughout the ivacaftor and CFTRinh-172 phases. During each 
experiment, compounds were stored at room temperature for use in an MTP-
96 plate. 
 
• Voltage protocol: Figure 2.4 shows the voltage protocol used for each sweep 
during QPatch experiments. Sweeps were repeated every 10 seconds for the 
duration of each experiment. Whole-cell patches were maintained at a holding 
potential (VH) of -30 mV. Voltage was stepped to -80 mV for 50 ms after the 
start of each sweep and maintained for 20 ms before being ramped from -80 
mV to +80 mV over a period of 200 ms before returning to VH. Leak current was 
calculated from the current observed at -30 mV. 
Figure 2.4: Voltage protocol used for whole-cell patch-clamp experiments using QPatch 
screening station. Holding voltage (VH) was -30 mV. After 50 ms, voltage was stepped to -80 mV for 
20 ms before being ramped to 80 mV over a period of 200 ms. 
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2.1.5 Analysis of QPatch recordings 
Analysis of data obtained from the QPatch screening station was performed using 
QPatch Assay v5.6 software. Figure 2.5 shows an example recording of human WT-
CFTR from a QPatch experiment detailing the protocol used. QPatch software 
discounted experiments where the criteria for the whole-cell configuration were no 
longer met (i.e. minimum seal resistance was lost due to unstable patch). Data were 
then manually inspected for CFTR expression as indicated by a response to 10 µM 
forskolin following washout of the 3% DMSO vehicle control period. Whole-cell 
recordings were not analysed where no response to forskolin and subsequent 
inhibition by CFTRinh-172 was observed. For each experiment, mean values were 
taken for the maximum outward (+80 mV) and inward (-80 mV) current for each 
intervention from the final 10 voltage sweeps in each liquid handling phase (indicated 
by the green areas of shading in Figure 2.5). The lower traces shown in example 
figures from QPatch recordings represent the current recorded at -30 mV for each 
sweep (Figure 2.5). This value was subtracted from the current recorded at +80 mV 
for each sweep. 
 
Figure 2.5: Example QPatch recording of human WT-CFTR activity in response to 10 µM 
forskolin followed by 10 µM ivacaftor and 30 µM CFTRinh-172. 
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All data were normalised for cell size by dividing by the values recorded for C-Slow in 
each liquid handling phase. Specific CFTR responses to forskolin and ivacaftor were 




For testing the response of constructs to 10 μM ivacaftor, the response current of 
individual cells to ivacaftor was compared to that of forskolin from the same cell using 
paired, two-way Students t-test (P < 0.05 = significant). As all cell stock for each 
construct was sourced from a single MaxCyte transfection protocol, experiments 
performed on individual cells were considered as individual repeats (i.e. n = 5 




















3. Species differences in WT and F508del-CFTR function as 




CFTR orthologues from a number of species have been studied at the single-channel 
level, including spiny dogfish (Hanrahan et al., 1993), Xenopus (Price et al., 1996), 
mouse (Lansdell et al., 1998a), domestic chicken (Aleksandrov et al., 2012), 
Australian common bushtail possum (Demmers et al., 2010), European rabbit (Al-
Nakkash & Reinach, 2001), sheep (Cai et al., 2015), and pig (Ostedgaard et al., 2007). 
The gating behaviour of these diverse orthologues shows variance that does not 
appear to follow the pattern of homology (see Figure 1.7). For example, mouse CFTR 
has been shown to possess a unique gating behaviour characterised by a highly active 
sub-conductance state and brief openings to a fully open state, despite sharing 79% 
amino acid (a.a.) sequence identity with human CFTR (Figure 1.10) (Lansdell et al., 
1998b). In contrast, Xenopus CFTR demonstrates gating behaviour that more closely 
resembles human CFTR, despite sharing only 76% a.a. identity with human CFTR 
(Price et al., 1996). Closely related orthologues such as sheep (91% a.a. identity) and 
pig (92% a.a. identity) still show differences in gating and conductance compared to 
human CFTR (Ostedgaard et al., 2007; Cai et al., 2015). Before investigating the 
pharmacology of CFTR orthologues from diverse species, we therefore considered it 
important to determine the single-channel gating behaviour and conductance 
properties of CFTR orthologues from diverse species. In addition, previous studies 
have highlighted differences in the effects of CF-causing mutations when expressed 
in different CFTR orthologues (Ostedgaard et al., 2007; Aleksandrov et al., 2012; Cai 
et al., 2015). We therefore aimed to investigate the effect of the F508del mutation on 
divergent orthologues. 
 
Given the wide range of CFTR orthologues available to study, it was decided to focus 
on six different CFTR orthologues (including human CFTR) that would represent a 
broad range of species from across the evolutionary tree. In deciding upon which 
species to investigate, we also opted for species that are currently being developed, 
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or being considered for the development of CF animal models, i.e. sheep, pig, ferret, 
mouse, rat, rabbit and zebrafish (McCarron et al., 2018). It was considered that an 
understanding of the gating behaviour of these species as well as their pharmacology, 
was essential for assessing the suitability of these models as investigational tools for 
CF research. The chosen species encompassed a broad spectra of mammalian 
species as well as an example of teleost fish (zebrafish). CFTR orthologues from other 
phyla, including birds, amphibians and marsupials but not reptiles have been 
previously characterised (Price et al., 1996; Demmers et al., 2010; Aleksandrov et al., 
2012). Figure 3.1 shows the cladogram of the species we chose to study based upon 
ClustalO alignment of the full CFTR sequences (Appendix 1), whilst Table 3.1 shows 




Figure 3.1: Cladogram of CFTR orthologues studied. Cladogram illustrates the degree to which the 
investigated CFTR orthologues are likely to be related based on amino acid sequence identity. 












Common Name Latin name GenBank 
Accession No. 
Shared amino acid identity with 
human CFTR (%) 
Human Homo sapiens NM_000492.3 100 
Pig Sus scrofa AY585334.1 92 






House Mouse Mus musculus NM_021050.2 79 
Zebrafish Danio rerio NM_001044883.1 54 
 
Table 3.1: Sequence homologies of CFTR orthologues used in this study. Shared amino acid 
identity was calculated following ClustalO sequence alignment using CLC Sequence Viewer software 
(v7.5). GenBank accession numbers for the sequences used are shown. 
 
3.2 Comparison of WT-CFTR gating behaviour between diverse 
species 
 
3.2.1 Single-channel gating behaviour of diverse CFTR orthologues 
Figure 3.2 shows representative examples of single-channel recordings from all six of 
the species that were used for this study. The recordings highlight the diversity 
exhibited in the gating behaviour of these different species. Figure 3.3 summarises 
the quantification of single-channel recordings from these CFTR orthologues. Due to 
the low conductance that was observed for ferret, mouse and zebrafish CFTR, traces 
from these species have been displayed at -80 mV (ferret and mouse) and -100 mV 
(zebrafish) respectively in Figure 3.2. Specific details for each species are discussed 
in the following sections: 
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Figure 3.2: The single-channel activity of CFTR from diverse species. Representative single-
channel recordings of WT-CFTR orthologues from diverse species recorded using excised inside-out 
membrane patches. ATP (1 mM) and PKA (75 nM) were continuously present in the intracellular 
solution. For the purpose of illustration, recordings have been filtered at 500 Hz and digitised at 5 kHz 
before file size was compressed by 5-fold data reduction. Dotted grey lines represent the closed level 
for each channel. For human, sheep and pig, holding potential was -50 mV. Due to the low conductance 
of ferret, mouse and zebrafish CFTR, example traces for ferret and mouse were made at -80 mV, whilst 
the trace for zebrafish CFTR was recorded at -100 mV. For all recordings, temperature was maintained 
at 37 °C in the presence of a Cl- concentration gradient across the membrane patch ([Cl-]internal = 147 
mM; [Cl-]external = 10 mM). 
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Figure 3.3: Single-channel properties of CFTR orthologues. A Comparison of the Po recorded for 
CFTR orthologues. Po for all species was recorded from single-channel patch-clamp recordings 
following activation of CFTR by 1 mM ATP and 75 nM PKA in the presence of a Cl- concentration 
gradient. For mouse CFTR, data are for the full open (O2) state. Holding potential (VH) was -50 mV for 
all species except zebrafish. For zebrafish, measurement of Po was only possible at -100 mV. B 
Comparison of i values for CFTR orthologues at VH of -50 or -100 mV. Experimental conditions were 
the same as described for A. C i/V relationships for CFTR orthologues. VH was stepped from -100 to 0 
mV for periods of at least 30 s. Continuous lines indicate best fit by linear regression. D slope 
conductance measurements calculated from the i/V relationships reported in C. For all graphs, error 
bars represent SEM or SD when n = 2 and individual data points are indicated by the circles adjacent 
to bars (human, n = 5-10; pig, n = 2-3; sheep n = 6; ferret n = 6; mouse, n = 4; zebrafish n = 1). 
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3.2.1.1 Human CFTR 
As shown in Figure 3.2, following activation by PKA-dependent phosphorylation 
human CFTR stably expressed in BHK cells produced single-channel currents in the 
presence of an asymmetric Cl- gradient ([Cl-]internal = 147 mM; [Cl-]external = 10 mM) with 
the same characteristics at -50 mV as previously reported for human CFTR single-
channel recordings (Sheppard & Welsh, 1999). Human CFTR produced single-
channel activity characterised by open channel bursts as represented by downward 
deflections in the example trace with a Po of 0.33 ± 0.01 and single-channel current of 
-0.68 ± 0.01 pA at -50 mV (n = 7) (Figure 3.2 and Figure 3.3A and B). In order to 
quantify the slope conductance for human CFTR, i/V relationships were constructed 
by measuring single-channel current following step changes in voltage from -100 mV 
to 0 mV with each voltage clamped for a minimum of 30 seconds (Figure 3.3C). Under 
asymmetric Cl- concentrations, CFTR demonstrates inward rectification with minimal 
current at positive voltages (Sheppard et al., 1993). However, at negative voltages 
Human WT-CFTR produced a linear i/V relationship with a slope conductance (γ) of 
7.18 ± 0.22 pS (n = 10) (Figure 3.3D). 
 
3.2.1.3 Pig CFTR 
Unfortunately, only limited data were collected for pig CFTR with only two successful 
single-channel patches obtained from transiently expressed pig CFTR in CHO cells. 
However, currents were observed following channel activation by PKA-dependent 
phosphorylation and where single-channel currents were observed gating behaviour 
appeared to be similar to that of human WT-CFTR. A number of macroscopic currents 
were observed suggesting that there was not a processing deficit present for pig 
CFTR. However due to the large variance in single-channel current between the 
patches that were obtained for this orthologue it is not possible to infer details 
regarding the single-channel current and conductance of this channel without further 
experiments. From the data that were obtained, single-channel current was calculated 
as -0.72 ± 0.26 pA at -50 mV, whereas Po was 0.47 ± 0.05 (n = 2) (Figure 3.3A and 
B). The data for Po does correlate with data that have been published for pig CFTR 
which showed activity to be similar to human (Ostedgaard et al., 2007). However, this 
previously study reported a decreased conductance of pig CFTR compared to human 
CFTR, in contrast to the increase observed from our data (8.10 ± 0.4 pS, n = 3, Figure 
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3.3C and D). It is likely that this variance results from the low power of our recordings 
and more data would be required to confirm the conductance of pig WT-CFTR. 
 
3.2.1.2 Sheep CFTR 
Sheep CFTR, transiently expressed in CHO cells produced Cl- currents after activation 
by PKA-dependent phosphorylation at -50 mV with a similar gating behaviour to that 
of human CFTR (Figure 3.2). However, sheep WT-CFTR had a higher Po (0.45 ± 0.05) 
and single-channel current (-0.85 ± 0.06 pA) (n = 6) at -50 mV, indicating increased 
activity when compared to human CFTR (Figure 3.3A and B). Slope conductance 
calculated from the i/V curve from -80 mV to 0 mV was 8.79 ± 0.25 pS, confirming an 
increased conductance compared to human CFTR (Figure 3.3C and D). These data 
for sheep CFTR are consistent with previous recordings for sheep CFTR that have 
been published by our group (Cai et al., 2015), and confirm that sheep CFTR is more 
active than human CFTR at the single-channel level. 
 
3.2.1.4 Ferret CFTR 
Ferret CFTR transiently expressed in CHO cells produced a Cl- current after activation 
by PKA-dependent phosphorylation that demonstrated similar gating properties to 
those observed for human, sheep and pig CFTR, albeit with a decreased single-
channel current, which was -0.24 ± 0.02 pA at -50 mV (n = 6, Figures 3.2 and 3.3B). 
Po for ferret CFTR was recorded as 0.44 ± 0.07 (n = 6, Figure 3.3A). Despite the low 
single-channel current observed for ferret CFTR, slope conductance calculated from 
the i/V slope from -100 mV to -40 mV was high (8.48 ± 0.52 pS, Figure 3.3C and D). 
Due to the low signal to noise ratio and small single-channel current at voltages more 
positive to -40 mV, it was not possible to calculate the single-channel current at more 
positive voltages. According to the Nernst equation (Equation 3, section 2.1.5), the 
equilibrium potential for Cl- (ECl) under the experimental conditions used was 
calculated as 71.8 mV. Linear extrapolation of the i/V relationships for the majority of 
CFTR orthologues tested, as shown in Figure 3.3C, suggests a reversal potential of 
around +20 mV to +30 mV, although CFTR does demonstrate inward rectification at 
positive voltages in the presence of a Cl- concentration gradient (Sheppard & Welsh, 
1999). It is therefore possible that the high slope conductance calculated for ferret 
CFTR at voltages below -40 mV is indicative of rectification at voltages more positive 
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to -40 mV. Indeed, previous studies have identified inward rectification for some CFTR 
orthologues (e.g. mouse) (Cai et al. 2003; Cui & McCarty, 2015). Further testing, either 
using macroscopic Cl- currents or alternatively under symmetrical Cl- conditions, would 
be required to confirm this rectification property for ferret CFTR. 
 
3.2.1.5 Mouse CFTR 
As shown by the example traces in both Figure 3.2 and Figure 3.7, mouse CFTR 
demonstrates a unique gating behaviour following activation by PKA-dependent 
phosphorylation compared to the other CFTR orthologues tested. As reported by 
Lansdell et al. (1998b), mouse CFTR expressed in CHO cells demonstrated two levels 
of opening, with a highly active sub-conductance state (O1) that was visible when 
traces underwent additional filtering at 50 Hz, and brief openings to a fully open state 
(O2) with a reduced single-channel current of -0.21 ± 0.02 pA (n = 5) at -50 mV, 
representing 37% of human CFTR (Figure 3.3B). The Po of the O2 state of mouse WT-
CFTR was 0.05 ± 0.01 (n = 5), representing an 88% reduction compared to human 
WT-CFTR. In addition, mouse CFTR demonstrated a low slope conductance 
calculated from the i/V relationship from -100 mV to 0 mV, with γ = 3.32 ± 0.80 pS (n 
= 5). 
 
3.2.1.6 Zebrafish CFTR 
Only one single-channel patch was obtained for zebrafish CFTR and caution must 
therefore be used in the interpretation of these data. However, the data showed that 
transient expression of zebrafish CFTR in CHO cells resulted in the activation of 
single-channels by 1 mM ATP and 75 nM PKA at negative voltages. From visual 
comparison of the recording obtained for zebrafish CFTR with other CFTR orthologues 
(Figure 3.2), zebrafish CFTR appeared to demonstrate a gating behaviour 
intermediate between that of mouse CFTR and human CFTR. Zebrafish CFTR 
demonstrated brief openings that were more active than those of mouse CFTR, but 
not as active as human CFTR, with a Po of 0.16 and a single-channel current of -0.20 
pA at -50 mV (n = 1). It was not possible to generate an i/V relationship from these 
data as analysis was only possible at a holding potential of -100 mV due to the small 
amplitude of single-channel current and low signal to noise ratio of this recording. The 
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small single-channel current amplitude at -100 mV suggests that conductance of 
zebrafish CFTR is lower than that of the other orthologues tested at negative 
membrane potentials. 
 
3.3 Different effects of the F508del mutation in diverse CFTR 
orthologues 
 
Previous studies have highlighted that CFTR orthologues from different species are 
affected differently by CF-related mutations (Ostedgaard et al., 2007; Aleksandrov et 
al., 2012; Cai et al., 2015). We therefore chose to investigate the effect of the common 
CF mutation F508del on sheep and mouse CFTR to determine if the effects of this 
mutation were different for these orthologues when compared to human F508del-
CFTR. 
3.3.1 The impact of F508del on human CFTR 
Figure 3.4 shows the effects of the F508del mutation on the gating behaviour of human 
CFTR as observed following activation by PKA-dependent phosphorylation. 1 s 
sections of traces in Figure 3.4 A and B (indicated by black bars) have been expanded 
for comparison. For these experiments, both human F508del- and WT-CFTR were 
stably expressed in NIH 3T3 cells. Cells expressing F508del-CFTR were incubated at 
27 °C for at least 24 hours prior to experiments to correct for the processing defect 
caused by the F508del mutation. For cells expressing human F508del-CFTR, addition 
of 1 mM ATP and 75 nM PKA resulted in the observation of single-channel currents at 
a holding potential of -50 mV with a Po of 0.08 ± 0.03 and single-channel current of -
0.61 ± 0.05 pA (n = 7). These data demonstrate that F508del results in a severe gating 
defect of human CFTR with an 81% reduction in Po (P < 0.05) compared to WT and 
no change in single-channel current amplitude (Figure 3.4B, C and D). 
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Figure 3.4: Comparison of i and Po for human WT- and F508del-CFTR. A Representative trace 
recorded following activation of human WT-CFTR by 1 mM ATP and 75 nM PKA at -50 mV and 37 °C. 
For the purpose of illustration, recordings have been filtered at 500 Hz and digitised at 5 kHz before file 
size was compressed by 5-fold data reduction. Dotted grey lines represent the closed level for each 
channel. Lower trace shows expanded 1 s region as indicated by black horizontal bar. B Representative 
trace recorded following activation of human F508del-CFTR. Conditions were the same as described 
for A. C and D i and Po for human WT- and F508del-CFTR. Error bars represent SEM and individual 
data points are indicated by circles adjacent to each bar (human WT-CFTR, n = 5; human F508del-
CFTR, n = 7; * = P < 0.05, unpaired, two-way Student’s t-test). 
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From visual inspection of the traces shown in Figure 3.4A and B, the gating defect of 
F508del appears to result in an increase in IBI and potentially a decrease in MBD. 
Only one excised-membrane patch was obtained for cells expressing human F508del-
CFTR where only one level of opening was observed for the duration of the 
experiment. From this recording, dwell-time histograms were generated using pClamp 
software (v6.02) and used to measure mean open- (τo) and closed- (τc) times (Figure 
3.5 and Table 3.2). As shown in Figure 3.5B and Table 3.2, human F508del-CFTR 
demonstrated two populations of open-times (τo1 and τo2) representing brief openings 
(τo1) and longer openings (τo2) with a reduced frequency compared to the single 
population of human WT-CFTR openings (τo1) as indicated by the area under the curve 
(Table 3.2). Both human WT-CFTR and F508del-CFTR showed two populations of 
closed-times representing intraburst (τc1) and interburst (τc2) closures respectively. 
These data show that the reduced Po of human F508del-CFTR compared WT-CFTR 




Figure 3.5: Representative dwell-time histograms for open- and closed-time events of human 
WT- (A) and F508del-CFTR (B). Histograms have been fitted with one- or two-component exponential 
functions (solid black lines). Logarithmic x-axes are used for both open and closed time histograms 
plotted with 10 bins·decade-1. Dashed lines indicate mean open (τo1 and τo2) and mean closed (τc1 and 
τc2) durations. Individual components for the τc1 and τc2 of the closed-time histogram are indicated by 









 Human WT-CFTR Human F508del-CFTR 
τO1 (ms) - 1.74 
τO2 (ms) 32.4 ± 10.9 35.1 
τC1 (ms) 4.16 ± 2.15 6.21 
τC2 (ms) 117 ± 14.1 995 
Area under curve τO1 - 0.67 
Area under curve τO2 1 0.33 
Area under curve τC1 0.69 ± 0.03 0.66 
Area under curve τC2 0.31 ± 0.03 0.34 
n 3 1 
 
Table 3.2: Open- and closed-time constants of human WT- and F508del-CFTR. Open- (τo1 and 
τo2) and closed-time (τc1 and τc2) constants were derived from dwell time histograms as shown in 
Figure 3.5. Areas under curve indicate the proportion of the total area under the fitted exponential 
curve. 
3.3.2 The impact of F508del on sheep CFTR 
Figure 3.6 shows the impact of the F508del mutation on sheep CFTR when 
recombinant cDNA was transiently expressed in CHO cells. Figure 3.6A shows a 
representative recording demonstrating the gating behaviour of sheep WT-CFTR. As 
mentioned earlier, sheep WT-CFTR shows increased activity compared to human WT-
CFTR with a 7% increase in Po and a 35% increase in single-channel current (Figure 
3.3). Compared to sheep WT-CFTR, sheep F508del-CFTR demonstrated a Po of 0.19 
± 0.08 and single-channel current of -0.81 ± 0.07 pA (n = 5) at -50 mV, representing a 
58% reduction in Po (P < 0.05) and no change in single-channel current (Figure 3.6C 
and D). These results suggest that the F508del mutation results in a gating defect in 
sheep-CFTR that is less severe than that caused by F508del when present in human 
CFTR. Unfortunately, insufficient data were collected from cells expressing sheep 
F508del-CFTR to enable the generation of dwell-time histograms and calculation of τo 
and τc for this orthologue. 
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Figure 3.6: Comparison of i and Po for sheep WT- and F508del-CFTR A Representative trace 
recorded following activation of sheep WT-CFTR by 1 mM ATP and 75 nM PKA at -50 mV and 37 °C. 
For the purpose of illustration, recordings have been filtered at 500 Hz and digitised at 5 kHz before file 
size was compressed by 5-fold data reduction. Dotted grey lines represent the closed level for each 
channel. Lower trace shows expanded 1 s region as indicated by black horizontal bar. B Representative 
trace recorded following activation of sheep F508del-CFTR. Conditions were the same as described 
for A. C and D i and Po for sheep WT- and F508del-CFTR. Data for sheep WT-CFTR are the same as 
that shown in Figure 3.3. Error bars represent SEM and individual data points are indicated by circles 
adjacent to each bar (sheep WT-CFTR, n = 6; sheep F508del-CFTR, n = 5; * = P < 0.05, unpaired, two-
way Student’s t-test). 
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3.3.3 The impact of F508del on mouse CFTR 
Figure 3.7 shows the effect of the F508del mutation on mouse CFTR cDNA transiently 
expressed in CHO cells. Following addition of 1 mM ATP and 75 nM PKA, at -50 mV, 
mouse WT-CFTR produced single-channel currents as indicated by downward 
deflections in the recorded trace (Figure 3.7A). Following introduction of the F508del 
mutation in mouse CFTR, single-channel currents were observed that showed close 
resemblance to those of mouse WT-CFTR (Figure 3.7B). The gating behaviour of 
mouse WT-CFTR was characterised by brief openings to the fully open (O2) state and 
a highly active sub-conductance (O1) state as discussed earlier in Section 3.2. Due to 
the small amplitude of the sub-conductance state (O1) and low signal to noise ratio of 
recordings, it was not possible to quantify this level. However, quantification of the 
second, fully open level (O2) is shown in Figures 3.7C and D. Data from human WT- 
and F508del-CFTR expressed in NIH 3T3 cells are also shown in Figures 3.7C and D 
for the purpose of comparison (human data are the same as that shown in Figure 3.4). 
Po of mouse F508del-CFTR was 0.06 ± 0.02, whereas single-channel current was -
0.35 ±0.04 pA at -50 mV (n = 3) suggesting that the F508del mutation did not have an 
effect on the activity of the O2 state of mouse F508del-CFTR when compared to 
mouse WT-CFTR. 
 
Figure 3.8 and Table 3.3 show dwell-time histograms and values for τo and τc 
generated from single-channel recordings for mouse WT- and F508del- CFTR. Only 
one membrane patch showing a single level of channel-opening was obtained for 
either mouse WT- or F508del-CFTR and caution must therefore be used in the 
interpretation of these data. However, as shown in Figure 3.8, both mouse WT- and 
F508del- showed three populations of closed-times as reported previously (Lansdell 




Figure 3.7: Comparison of i and Po for mouse WT- and F508del-CFTR A Representative trace 
recorded following activation of mouse WT-CFTR by 1 mM ATP and 75 nM PKA at -50 mV and 37 °C. 
For the purpose of illustration, recordings have been filtered at 500 Hz and digitised at 5 kHz before file 
size was compressed by 5-fold data reduction. Dotted grey lines represent the closed level for each 
channel. Lower trace shows expanded 1 s region as indicated by black horizontal bar. Sub-conductance 
and full open levels of mouse CFTR are indicated by O1 and O2, respectively. B Representative trace 
recorded following activation of mouse F508del-CFTR. Conditions were the same as described for A. 
C and D i and Po for human and mouse WT- and F508del-CFTR. Data for human WT-CFTR and human 
F508del-CFTR are from Figure 3.3. Data are means ± SEM, individual data points are indicated by 
circles adjacent to each bar (mouse WT-CFTR, n = 5; mouse F508del-CFTR, n = 3; * = P < 0.05, two-
way unpaired Student’s t-test). 
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Figure 3.8: Representative dwell-time histograms for open- and closed-time events of mouse 
WT- (A) and F508del-CFTR (B). Histograms have been fitted with one- or three-component 
exponential functions (solid black lines). Logarithmic x-axes are used for both open and closed time 
histograms plotted with 10 bins·decade-1. Dashed lines indicate mean open (τo1) and mean closed (τc1, 
τc2 and τc3) durations. Individual components for the τc1, τc2 and τc3 of the closed-time histogram are 
indicated by red, grey and blue dotted lines respectively. Measurements were made using the 








 Mouse WT-CFTR Mouse F508del-CFTR 
τO1 (ms) 4.88 2.88 
τC1 (ms) 6.5 5.84 
τC2 (ms) 98.4 82.4 
τC3 (ms) 342 501 
Area under curve τO1 1 1 
Area under curve τC1 0.47 0.3 
Area under curve τC2 0.44 0.61 
Area under curve τC3 0.09 0.09 
n 1 1 
 
Table 3.3: Open- and closed-time constants of mouse WT- and F508del-CFTR. Open- (τo1) and 
closed-time (τc1, τc2 and τc3) constants were derived from dwell time histograms as shown in Figure 
3.8. Areas under curve indicate the proportion of the total area under the fitted exponential curve. 
 
3.3.4 Thermal stability of F508del-CFTR orthologues at 37 °C 
In addition to effects on gating behaviour, the F508del mutation also results in a 
reduction in the thermal stability of human CFTR at the PM (Lukacs et al., 1993; 
Schultz et al., 1999; Wang et al., 2014a). Using single-channel patch-clamp 
experiments, this thermal instability can be observed as a rundown in CFTR activity 
from patches maintained at 37 °C (Schultz et al., 1999; Wang et al., 2014a). As our 
results shown in Figure 3.9 demonstrate that the F508del mutation does not affect the 
gating behaviour of mouse CFTR, we aimed to determine if the resistance of the 
mouse CFTR orthologue to the effects of F508del extended to the thermal instability 
(Class V) defect of this mutation (Wang et al., 2011b). In order to test this idea, mouse 
F508del-CFTR stably expressed in CHO cells was first activated at 27 °C using 1 mM 
ATP and 75 nM PKA. Following full activation of the channels, the temperature of the 
experimental chamber was then rapidly increased to 37 °C (temperature increased 
from 27 °C to 37 °C in less than 2 minutes). The activity of single-channels was then 
recorded for an extended period (10 to 30 minutes) and Po was quantified for 30 s 
intervals for the first 10 minutes. The example trace shown in Figure 3.9A shows the 
continuous recording made from a membrane patch containing two mouse F508del-
CFTR channels for a period of 10 minutes. As shown by the expanded regions in 
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Figure 3.9B, taken from early, mid-point and late sections of the trace, the activity of 
mouse F508del-CFTR was sustained for the 10-minute duration of this recording. The 
Po recorded for 30 s intervals from multiple patches was quantified and shown in 
Figure 3.9C (green bars). For the first 10 minutes after temperature had been 
increased to 37 °C, the Po of the O2 state of mouse F508del-CFTR was maintained 
between 0.05 ± 0.01 and 0.07 ± 0.01 indicating that Po remained steady for the 
duration of the experiment. The grey line plotted in Figure 3.9C shows the results from 
the same experimental protocol using human F508del-CFTR. These data were 
collected by our group prior to this project and have been used here with permission 
from the original authors (Wang et al., 2014a). These data demonstrate a rapid 
reduction in the Po of human F508del-CFTR during the first 5 minutes after 
temperature was increased to 37 °C, with complete loss of channel activity after ~7 
mins (Figure 3.9C). The data collected for mouse-CFTR therefore demonstrates that 
mouse F508del-CFTR shows increased thermal stability at the PM at 37 °C compared 
to human F508del-CFTR under the same experimental conditions. 
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Figure 3.9: Thermal stability of mouse F508del-CFTR A Representative 10-minute recording from 
an excised inside-out membrane patch from a CHO cell expressing mouse F508del-CFTR at -50 mV. 
CFTR was activated at 27 °C with 1 mM ATP and 75 nM PKA. Following full activation of CFTR, 
temperature was rapidly increased (< 2 minutes) to 37 °C. B 2-s long recordings labelled sections 1-3 
taken from beginning, middle and end of the recording shown in A as indicated by the dashed lines. 
For the purpose of illustration, recordings in A and B have been filtered at 500 Hz and digitised at 5 
kHz before file size was reduced by 5-fold data reduction. Dotted lines in A and B represent the closed 
state of channels. C Po time-course of mouse F508del-CFTR for the initial 10 minutes following increase 
in temperature to 37 °C. Data are means ± SEM (n = 3). Values for Po were calculated for each 30-s 
time interval as shown by vertical green bars. Grey line represents data for human F508del-CFTR as 








3.4.1 Variations in the gating behaviour of CFTR orthologues 
Figures 3.2 and 3.3 highlight the diversity observed in the gating behaviour of CFTR 
orthologues from different species. The first three species studied, human, pig and 
sheep, are more closely related as indicated by the cladogram in Figure 3.1 and have 
shared amino acid identities of > 90%. It may therefore be expected that these CFTR 
orthologues would demonstrate similarities in gating. Despite this, within this group 
variations were observed indicating that relatively minor changes in sequence can 
lead to changes in gating behaviour. For example, sheep CFTR shares 91% shared 
a.a. identity with human CFTR, with most of the sequence variation occurring in the 
RD (Appendix 1). However, sheep CFTR showed a 7% increase in Po and a 35% 
increase in single-channel current amplitude compared to human CFTR. Comparison 
of the architecture of the channel pore of human and sheep CFTR has shown that the 
structure of these regions is similar between the different orthologues, suggesting that 
sequence variations in other, non-regulatory regions of the channel may have an 
influence on gating properties (Cai et al., 2015). Our data are at variance with data 
published by Aleksandrov et al. (2012) where sheep CFTR was expressed in planar 
lipid bilayers. However as discussed in Cai et al. (2015) these variations may result 
from differences in the orthologues used, for example the CFTR construct used in our 
study includes the F229L polymorphism and lacks the C-terminus attached green 
fluorescent protein tag used by Aleksandrov et al. (2012). Of the orthologues tested, 
pig CFTR is the most closely related to human, with 92% shared a.a. identity. 
Unfortunately, only two successful single-channel patches were obtained for this 
orthologue and as such caution must be used in interpreting these data. However, 
keeping this in mind, pig and sheep CFTR do appear to share more similarities in 
gating behaviour with human CFTR than the other CFTR orthologues that were tested. 
These similarities provide support for the use of both pig and sheep animal models of 
CF although further clarification of the gating behaviour of pig CFTR is required. 
 
Although only one excised inside-out membrane patch was successfully obtained for 
zebrafish CFTR, the data that were obtained for zebrafish CFTR does suggest that 
this orthologue shows a very different gating pattern to human CFTR and may be more 
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closely related to mouse CFTR. Zebrafish CFTR demonstrated a reduced single-
channel current amplitude and Po compared to human CFTR. The activity of zebrafish 
CFTR was higher than that of mouse CFTR. However, visual comparison of the mouse 
and zebrafish traces in Figure 3.2 show similarities, principally the presence of brief 
channel openings. It may also be possible that zebrafish CFTR demonstrates mouse-
like sub-conductance, although it was not possible to accurately determine this 
possibility from the data collected. Zebrafish shares 54% a.a. identity with human 
CFTR and is one of the most divergent CFTR orthologues to have been studied at the 
single-channel level. Despite this variance, comparison of the high resolution cryo-EM 
structures of human CFTR and zebrafish CFTR showed that these two orthologues 
share remarkably similar structure despite this difference (Zhang & Chen, 2016; Liu et 
al., 2017). This observation suggests that the percentage of shared amino acid identity 
is not a good predictor of structural similarity. 
 
The cladogram shown in Figure 3.1 suggests two evolutionary clades of the 
orthologues that were tested in this investigation based on sequence alignments. The 
first clade includes human, pig and sheep CFTR, whilst the second includes mouse 
and zebrafish. Of the sequences tested however, ferret CFTR occupies a clade of its 
own. Indeed, whilst ferret CFTR demonstrated a pattern of channel gating that was 
closer to human, pig and sheep CFTR, the single-channel current amplitude of ferret 
CFTR was notably smaller than these species, but higher than mouse and zebrafish. 
It therefore appears that there may be correlation between the evolutionary divergence 
of CFTR sequence as highlighted in the construction of the cladogram in Figure 3.1 
and channel function as shown in Figures 3.2 and 3.3. CFTR function has most likely 
evolved in a way that is optimised for its role in different species (Bose et al., 2015). 
The cladogram shown in Figure 1.7 in Section 1.6 suggests that ferret CFTR shares 
a similar structure with that of dog and cat CFTR. It would therefore be interesting to 
compare the gating behaviour of these species to determine if they are more closely 
related to ferret in terms of CFTR function than to human. Indeed, both dog and cat 
models of CF may be considered in addition to the existing ferret models. However, 
the differences in function between human and ferret CFTR identified in this study may 
have relevance for the use of existing ferret CF models. 
 
In an early study of the mouse CFTR orthologue, Lansdell et al. (1998b) showed that 
 92 
heavy filtering of single-channel current traces recorded from cells expressing mouse 
CFTR revealed a sub-conductance state (O1) with a small amplitude corresponding to 
around 10% of the amplitude of the full conductance state (O2). This sub-conductance 
state has subsequently been observed in other studies both at 37 °C (Scott-Ward et 
al., 2007) and at 25 °C (Ostedgaard et al., 2007). Due to the small amplitude of this 
sub-conductance state at a holding potential of -50 mV and the signal to noise ratio 
present in recordings, it has not been possible to provide a detailed analysis of this 
sub-conductance state beyond observing that the Po of O1 appears to be considerably 
higher than that of O2 (Figure 3.7). Interestingly, a second sub-conductance state with 
a current amplitude lying between those of O1 and O2 has been observed by Cui & 
McCarty (2015) in excised inside-out membrane patches studied at room temperature 
and with a holding potential of -100 mV. However, this sub-conductance state has not 
been observed either in our experiments or in previous studies by other groups 
(Lansdell et al., 1998a; Lansdell et al., 1998b; Ostedgaard et al., 2007; Scott-Ward et 
al., 2007). 
 
3.4.2 Variation in the impact of the F508del mutation on CFTR 
orthologues 
A number of previous studies have examined the impact of F508del in different CFTR 
orthologues and have shown that this mutation may have species-specific effects on 
channel processing and gating activity (Ostedgaard et al., 2007; Fisher et al., 2011; 
Aleksandrov et al., 2012; Cai et al., 2015). For example, whereas human F508del-
CFTR is characterised by a severe processing defect that results in targeting by the 
endoplasmic-reticulum-associated degradation (ERAD) pathway (Lukacs et al., 1994; 
Ward et al., 1995), both mouse and pig F508del-CFTR have been shown to retain 
levels of expression at the plasma membrane (Ostedgaard et al., 2007). Aleksandrov 
et al. (2012) have also demonstrated variation in the maturation of F508del-CFTR in 
a wide range of both mammalian and non-mammalian species. Understanding the 
impact of mutations on different species is important, for example in determining the 
suitability of CF animal models based on gene mutations rather than knock-out and it 
should be kept in mind that mutations will not affect all orthologues for a given gene in 
the same way. Additionally, understanding the structural variations between diverse 
CFTR orthologues that relate to differences in the susceptibilities of these orthologues 
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to CF-related mutations may provide insights for the development of potential 
therapeutic strategies for CF. 
 
Human F508del-CFTR shows severely reduced activity compared to WT-CFTR when 
the processing defect of this mutation is corrected, characterised by a reduction in the 
duration of channel openings and a prolongation of channel closures (Figures 3.4 and 
3.5) (Dalemans et al., 1991). In contrast, our data showed that in the case of both 
mouse and sheep CFTR, the F508del mutation does not cause a severe reduction in 
activity (Figures 3.6 and 3.7). In the case of sheep F508del-CFTR, our data showed 
that Po was reduced compared to WT, however this corresponded to a 58% reduction 
compared to the 81% reduction observed for human F508del-CFTR (Figure 3.4). 
 
Whilst previous studies have demonstrated that the F508del mutation has a minimal 
impact on the processing of mouse CFTR (Ostedgaard et al., 2007), our data suggest 
that the disruption to channel gating normally associated with F508del is absent in the 
case of mouse CFTR (Figure 3.7). In previous studies of the F508del mutation in 
human, pig, mouse and sheep the reduction in Po caused by F508del has been shown 
to result mainly from an increase in the inter-burst interval (IBI) corresponding to 
channel closures, rather than a severe reduction in the mean burst duration (MBD) 
(Ostedgaard et al., 2007; Cai et al., 2015). As discussed in Section 1.3.2, channel 
opening is dependent upon tight dimerization of NBD1 and NBD2 on binding of ATP 
(Vergani et al., 2005b; Hwang & Sheppard, 2009). The increase in IBI observed in the 
case of F508del therefore likely results from an increase in the energy barrier for 
channel opening, suggesting that the gating defect caused by F508del may be linked 
to disruption of the formation of the NBD1-NBD2 dimer (Cai et al., 2015). Jih et al. 
(2011) have further examined the effect of F508del on CFTR gating using PPi, which 
locks the channel in the fully bound NBD1-NBD2 dimer configuration, and by testing 
the ligand exchange time for ATP/P-dATP, a measure of the stability of the dimer 
following ATP hydrolysis at site 2. This study demonstrated that the F508del mutation 
destabilises both the full and partial NBD dimer configurations during the CFTR gating 
cycle (Jih et al., 2011). These data are further supported by evidence from studies 
using nuclear magnetic resonance that also appear to show that the F508del mutation 
results in impaired NBD dimerization (Chong et al., 2015). 
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Taking these points into consideration, our data appear to show that the disruption 
observed in NBD dimer formation by the F508del mutation does not appear to affect 
the gating properties of mouse CFTR. It is therefore possible that in the case of mouse 
CFTR, structural differences compared to the human CFTR channel may provide 
stabilisation to this dimer interface. In addition, many structural models of CFTR 
suggest a close interaction between ICL4 and the region of NBD1 that includes F508, 
which includes the helical regions H3 and H4, known as the H loop (Callebaut et al., 
2004; Mornon et al., 2008; Serohijos et al., 2008; Mornon et al., 2014; Liu et al., 2017). 
Despite the relatively low sequence homology between human and mouse CFTR, 
focussing on sequence differences within the NBD1 and ICL4 highlights certain 
residues that warrant further study into their involvement in providing resistance to the 
F508del gating defect. The first of these changes is I539T, which is of particular 
interest as when included in human CFTR this sequence alteration acts as a revertant 
mutant of F508del (deCarvalho et al., 2002; Ostedgaard et al., 2007; Hoelen et al., 
2010). In mice, it is therefore possible that T539 helps to stabilise NBD1-NBD2 dimer. 
Another sequence alteration that is of interest is G1069R located in ICL4. According 
to the cryo-EM structure of human CFTR produced by Liu et al. (2017), G1069 is likely 
to be located in the vicinity of the coupling helix of ICL4, the region most likely to 
interact with NBD1 and F508. Indeed, further support for this idea is provided by the 
observation that the sequence change R1070W is known to correct the folding defect 
of F508del-CFTR (Thibodeau et al., 2010; Molinski et al., 2012; Phuan et al., 2014). It 
is therefore possible that the addition of the large, positively charged side-chain of this 
additional arginine residue in mouse CFTR helps to stabilise the interaction of ICL4 
and NBD1 in the absence of F508del. 
 
3.4.3 Thermal stability of mouse F508del-CFTR 
Human F508del-CFTR exhibits a marked thermal instability and rapidly deactivates at 
37 °C (Wang et al., 2011b; Liu et al., 2012; Wang et al., 2014a). Previous work by our 
group has shown that sheep F508del-CFTR also demonstrates thermal instability, 
albeit to a lesser degree than that of human F508del-CFTR (Cai et al., 2015). In 
contrast, Aleksandrov et al. (2012) have demonstrated that chicken F508del-CFTR 
demonstrates thermal stability at the plasma membrane, and there is also evidence 
from pulse-chase experiments that suggests ferret F508del-CFTR may be more stable 
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than human F508del-CFTR (Fisher et al., 2012). Our data show that in contrast to the 
thermal instability previously shown for human and sheep CFTR, mouse F508del-
CFTR retains a high level of activity at 37 °C that was sustained beyond 10 minutes 
(Figure 3.9). In this respect, mouse F508del-CFTR appears to share the characteristic 
of thermal stability that has been previously documented for chicken F508del-CFTR 
(Aleksandrov et al., 2012). 
 
By comparing the sequences of chicken and human CFTR, Aleksandrov et al. (2012) 
identified the presence of four additional proline residues that are present in chicken 
CFTR, but not human CFTR, corresponding to sequence alterations S422P, S434P, 
S492P and A534P, as well as the F508del revertant mutation I539T discussed earlier 
(deCarvalho et al., 2002). When introduced into human F508del-CFTR via site-
directed mutagenesis, these sequence alterations restored channel processing, 
membrane stability and functionality (Aleksandrov et al., 2012). Given that the human 
CFTR residues S422, S492 and A534 are conserved in mouse CFTR these proline 
substitutions do not account for the similarities observed between mouse and chicken 
CFTR. However as previously mentioned, mouse CFTR does include T539 and it is 
possible that this residue may be involved in stabilising the co-translational folding of 
mouse F508del-CFTR NBD1 as has been reported for human F508del-CFTR (Hoelen 
et al., 2010). However, Dong et al. (2012) have demonstrated that whilst I539T 
improves processing of human F508del-CFTR, this sequence alteration has a 
negative impact on channel gating and does not improve the processing of human-
mouse chimeras expressing the mouse sequence for residues 433-632 in NBD1. 
Mouse CFTR also contains a number of other sequence alterations in this region, 
which is adjacent to the interface between TMD1 and NBD1, including S434C. It is 
therefore possible that sequence alterations in this region may contribute to some of 
the differences observed between mouse and human F508del-CFTR orthologues. 
Further knowledge of the involvement of this region in protein function and the 
involvement of specific amino acids in providing resistance to the deleterious effects 
of F508del may therefore be gained by studying human-mouse chimeric proteins that 
contain this region of mouse CFTR. 
 
In conclusion, our data have demonstrated variations in the gating behaviour of CFTR 
orthologues that may occur despite high levels of homology. Furthermore, our data 
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suggest that structural variation between CFTR orthologues may reduce the impact of 





























4. The effects of small molecule CFTR modulators on the 





CFTR orthologues have previously been shown to demonstrate cross species 
differences in response to small molecule CFTR modulators. For example, Stahl et al. 
(2012) showed that pig CFTR does not respond to the CFTR inhibitor glibenclamide, 
whereas shark CFTR does not respond to CFTRinh-172. Furthermore, differential 
responses of CFTR orthologues to CFTR potentiators have previously been used to 
determine the binding domains for these compounds. The observation that mouse 
CFTR does not respond to the inorganic phosphate analogue PPi (Lansdell et al., 
1998a), provided rationale for use of human-mouse CFTR chimeras to determine the 
binding site for this compound (Scott-Ward et al., 2007). Scott-Ward et al. (2007) 
demonstrated that substitution of the human NBD2 sequence for the equivalent mouse 
domain was sufficient to prevent the response of human CFTR to PPi, thereby 
demonstrating the role of NBD2 in binding the compound (Scott-Ward et al., 2007). 
 
Given the potential for cross-species chimeras to determine regions of the CFTR 
protein that may be involved in the mechanism of action of CFTR potentiators, we 
aimed to determine how the CFTR orthologues we chose to study in Chapter 3 
respond to such potentiators. In particular, we chose to focus on the CFTR potentiator 
ivacaftor (VX-770; Kalydeco®, Vertex Pharmaceuticals). Ivacaftor was the first small 
molecule CFTR modulator to be licensed for the treatment of CF (Van Goor et al., 
2009; Ramsey et al., 2011). Yet despite over a decade of research, very little is known 
about the mechanism of action of this compound and few studies have investigated 
the efficacy of ivacaftor for potentiation of non-human CFTR orthologues (Bose et al., 
2015; Cui & McCarty, 2015; Cui et al., 2016). Identification of variations in the 
response of diverse CFTR orthologues to ivacaftor may therefore provide insight into 
structural regions of CFTR involved in the mechanism of action of this compound. 
Such differences may also have implications for the use these species in the 
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development of novel CF therapies that share the same or similar mechanism of action 
as ivacaftor. 
 
As discussed in Chapter 1, ivacaftor is effective for a range of class III CF-causing 
mutations such as G551D and S549N that affect channel gating behaviour and result 
in a decrease in CFTR activity (Sheppard et al., 2017). Ivacaftor enhances ATP-
independent gating (Eckford et al., 2012), and increases the potential for re-entry of 
ATP at the hydrolytic binding site by stabilising the post-hydrolytic open state of the 
CFTR channel (Jih & Hwang, 2013). At the single-channel level, ivacaftor enhances 
both human WT- and mutant CFTR activity, primarily via an increase in MBD and the 
frequency of channel openings (Van Goor et al., 2009; Wang et al., 2018). We 
therefore aimed to investigate the response of CFTR orthologues to ivacaftor using 
the single-channel patch-clamp technique to determine whether ivacaftor potentiates 
these orthologues and to learn how the compound may affect CFTR gating in different 
species. 
 
4.2 Effects of ivacaftor on the activity of CFTR orthologues 
 
4.2.1 Potentiation of WT-CFTR from diverse species by ivacaftor 
4.1.1.1 Human CFTR 
Figure 4.1 shows the effect of cumulative addition of ivacaftor at concentrations 
between 10 nM and 10 μM to the intracellular solution bathing excised inside-out 
membrane patches taken from NIH 3T3 cells stably expressing human WT-CFTR in 
the continuous presence of 1 mM ATP and 75 nM PKA at 37 °C. Washout of ivacaftor 
between test concentrations was not possible as the high viscosity of this compound 
resulted in carry-over of the drug between successive interventions. Experimental 
chambers therefore required submersion in 40% DMSO for a minimum of 4 hours 
between treatments to ensure removal of the compound. 
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Figure 4.1: Effect of ivacaftor on human WT-CFTR in the presence of 1 mM ATP and 75 nM PKA. 
A Representative single-channel recordings from an inside-out membrane patch excised from an NIH 
3T3 cell showing the response of human WT-CFTR to ivacaftor at concentrations from 0.01 μM to 10 
μM in the presence of a Cl- concentration gradient ([Cl-]int = 147 mM; [Cl-]ext = 10 mM). Holding potential 
was clamped at -50 mV throughout and recordings were made in the continuous presence of 1 mM 
ATP and 75 nM PKA. Temperature was maintained at 37 °C. Dotted lines represent the closed level for 
the channel. 5-fold data reduction was applied to traces in A for the purpose of illustration. B and C 
Single-channel current amplitude (i) and Po of human WT-CFTR at ivacaftor concentrations from 10 nM 
to 10 μM. Graphs in B and C were fitted with 3-parameter sigmoidal curves using SigmaPlot software 
v13.0 (n = 3, * = P < 0.05, one-way repeated measures ANOVA and Dunnett’s multiple comparisons). 
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Figure 4.1A, shows representative single-channel recordings for control, 0.1 μM, 1.0 
μM and 10 μM ivacaftor, respectively, at a holding potential of -50 mV. Addition of 
ivacaftor did not affect single-channel current amplitude (Figure 4.1B), but resulted in 
an increase in the Po of human WT-CFTR from 0.41 ± 0.06 under control conditions 
to 0.56 ± 0.13 at 10 μM, with a peak of 0.62 ± 0.09 at 0.1 μM (n = 3, P < 0.05 compared 
to control) (Figure 4.1C). Data collected for the response of human WT-CFTR to 
ivacaftor was fitted with a 3-parameter sigmoidal curve (Equation 4), however due to 
the high level of potentiation observed at ivacaftor concentrations as low as 0.01 μM 
(Po = 0.62 ± 0.07, n = 3) it was not possible to calculate KD from this analysis. 
 
Due to the high activity of human WT-CFTR at 1 mM ATP, the effect of ivacaftor was 
also tested in the presence of 0.3 mM ATP (Figure 4.2). For these experiments, human 
WT-CFTR stably expressed in BHK cells was activated by direct addition of ATP to 
the experimental chamber at a concentration of 1 mM in conjunction with 75 nM PKA. 
The ATP concentration was then reduced to 0.3 mM by perfusing the experimental 
chamber with 10 ml bath solution containing 0.3 mM ATP and subsequent addition of 
75 nM PKA. Again, ivacaftor did not affect the single-channel current amplitude of 
human CFTR (Figure 4.2B), but resulted in an increase in Po at all concentrations 
tested, with a Po of 0.19 ± 0.03 before addition of ivacaftor, increasing to 0.30 ± 0.04 
at both 1.0 μM and 10 μM ivacaftor (Figure 4.2C) (n = 4, P < 0.05 compared to control), 




Figure 4.2: Effect of ivacaftor on human WT-CFTR in the presence of 0.3 mM ATP. A 
Representative single-channel recordings from an excised inside-out membrane patch from a BHK cell 
showing the response of human WT-CFTR to ivacaftor at concentrations of 1.0 μM and 10 μM. Holding 
potential was clamped at -50 mV throughout and recordings were made in the continuous presence of 
0.3 mM ATP and 75 nM PKA. Dotted lines represent the closed channel level. A 5-fold data reduction 
was applied to traces in A for the purpose of illustration. B and C Single-channel current amplitude (i) 
and Po of human WT-CFTR at ivacaftor concentrations of 1.0 μM and 10 μM (n = 4, * = P < 0.05, one-
way repeated measures ANOVA and Dunnett’s multiple comparisons). 
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4.1.1.2 Sheep CFTR 
Due to the high activity of sheep WT-CFTR, the effect of ivacaftor on this orthologue 
was tested at 0.3 mM ATP rather than at 1 mM ATP. Figure 4.3A shows representative 
single-channel recordings of sheep WT-CFTR in the absence and presence of 
ivacaftor using excised inside-out membrane patches taken from CHO cells transiently 
expressing sheep WT-CFTR at a holding potential of -50 mV following PKA-dependent 
phosphorylation. Figure 4.3A, demonstrates the increased activity of sheep WT-CFTR 
in response to ivacaftor at concentrations between 1.0 μM and 10 μM. Visual 
inspection of the traces in Figure 4.3A suggests that ivacaftor increased the length of 
sheep WT-CFTR channel openings whilst decreasing interburst intervals. 
Quantification of single-channel current amplitude and Po are shown in Figures 4.3B 
and C, respectively. As with human WT-CFTR, ivacaftor had little or no effect on 
single-channel current amplitude, although a small, but statistically significant 
decrease was observed at 0.3 μM and 1.0 μM ivacaftor (control = -0.81 ± 0.05 pA; 0.3 
μM ivacaftor = -0.71 ± 0.03 pA; 1.0 μM ivacaftor = -0.71 ± 0.04 pA; n = 3, P < 0.05). 
Ivacaftor increased Po significantly at concentrations between 0.1 μM and 10 μM 
(Figure 4.3C) with an increase from 0.31 ± 0.04 (control) to 0.52 ± 0.09 at 10 μM (n = 
3, P < 0.05). This represented an increase of 68%, indicating an increase in the 
response of sheep CFTR to ivacaftor when compared to the increase of 58% that was 
observed for human CFTR at 0.3 mM ATP. However, the rightward shift in the ivacaftor 
dose response curve generated for sheep WT-CFTR with a KD of 0.19 μM as 
calculated from sigmoidal fitting of the dose response curve suggests a decrease in 




Figure 4.3: Effect of ivacaftor on sheep WT-CFTR in the presence of 0.3 mM ATP. A 
Representative single-channel recordings from an excised inside-out membrane patch from a CHO cell 
showing the response of sheep WT-CFTR to ivacaftor at concentrations from 0.1 μM to 10 μM. Holding 
potential was clamped at -50 mV throughout and recordings were made in the continuous presence of 
0.3 mM ATP and 75 nM PKA. Dotted lines represent the closed level for the channel. A 5-fold data 
reduction was applied to traces in A for the purpose of illustration. B and C Single-channel current 
amplitude (i) and Po of sheep WT-CFTR at ivacaftor concentrations from 10 nM to 10 μM. Graphs in B 
and C were fitted with 3-parameter sigmoidal curves using SigmaPlot software v13.0 (n = 3, * = P < 
0.05, one-way repeated measures ANOVA and Dunnett’s multiple comparisons). 
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4.1.1.3 Pig CFTR 
Very limited data were collected for pig WT-CFTR with only two successful patches 
obtained, and these data are summarised in Figure 4.4. Although the power of these 
data are insufficient to demonstrate an effect of ivacaftor on pig CFTR statistically, the 
representative traces shown in Figure 4.4A indicate an increase in the Po of pig WT-
CFTR in response to increasing concentrations of ivacaftor, resulting from an increase 
in the duration of channel openings. For these experiments, pig WT-CFTR was 
transiently expressed in CHO cells and recordings were made from excised inside-out 
membrane patches at a holding potential of -50 mV and temperature of 37 °C after the 
addition of 1 mM ATP and 75 nM PKA. Although there was a large spread in the data 
obtained, no change in single-channel current was observed following addition of 
ivacaftor to the intracellular solution (Figure 4.4B). However, an increase in Po was 
observed from 0.47 ± 0.07 (SD) under control conditions to a maximum of 0.70 ± 0.1 
(SD) at 1.0 μM ivacaftor, representing a 49% increase in activity. This response to 
ivacaftor peaked at 1.0 μM and decreased slightly at higher concentrations, similar to 
the decrease in activity that was observed for human WT-CFTR at 10 μM ivacaftor 
compared to 1.0 μM ivacaftor. This decrease was not found to be significant following 
statistical testing in either case, although statistical interpretation of these results 
requires caution due to the low power of the data. 
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Figure 4.4: Effect of ivacaftor on pig WT-CFTR in the presence of 1 mM ATP. A Representative 
single-channel recordings from an excised inside-out membrane patch from a of CHO cells showing 
the response of pig WT-CFTR to ivacaftor at concentrations from 0.1 μM to 10 μM. Holding potential 
was clamped at -50 mV throughout and recordings were made in the continuous presence of 1 mM 
ATP and 75 nM PKA. Dotted lines represent the closed level for the channel. A 5-fold data reduction 
was applied to traces in A for the purpose of illustration. B and C Single-channel current amplitude (i) 
and Po of pig WT-CFTR at ivacaftor concentrations from 10 nM to 10 μM. Graphs in B and C were fitted 
with 3-parameter sigmoidal curves using SigmaPlot software v13.0 (n = 2, error bars = SD, P = ns, one-
way repeated measures ANOVA). 
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4.1.1.4 Ferret CFTR 
Representative single-channel patch-clamp recordings from CHO cells transiently 
expressing ferret WT-CFTR and quantification of single-channel current amplitude and 
Po are shown in Figure 4.5. Recordings were made in the presence of 1 mM ATP and 
75 nM PKA at a holding potential of -50 mV and temperature of 37 °C. Visual 
inspection of the traces shown in Figure 4.4A suggests that ivacaftor increased the 
duration of ferret WT-CFTR channel openings whilst decreasing the duration of 
channel closures. Ivacaftor did not result in any change in single-channel current 
amplitude compared to control (Figure 4.5B) but did increase activity at all 
concentrations tested (Figure 4.5C). Under control conditions, single-channel current 
amplitude was -0.50 ± 0.04 pA and Po was 0.44 ± 0.07 (n = 6) (Figure 4.5B and C). 
Cumulative addition of ivacaftor to the experimental chamber increased channel 
activity with Po at 10 μM being 0.66 ± 0.04 (n = 4, P < 0.05 compared to control), 
representing a 50% increase in activity (Figure 4.5C). 
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Figure 4.5: Effect of ivacaftor on ferret WT-CFTR in the presence of 1 mM ATP. A Representative 
single-channel recordings from an excised inside-out membrane patch from a CHO cell showing the 
response of ferret WT-CFTR to ivacaftor at concentrations from 0.1 μM to 10 μM. Holding potential was 
clamped at -50 mV throughout and recordings were made in the continuous presence of 1 mM ATP 
and 75 nM PKA. Dotted lines represent the closed level for the channel. A 5-fold data reduction was 
applied to traces in A for the purpose of illustration. B and C Single-channel current amplitude (i) and 
Po of ferret WT-CFTR at ivacaftor concentrations from 10 nM to 10 μM. Graphs in B and C were fitted 
with 3-parameter sigmoidal curves using SigmaPlot software v13.0 (n = 3 - 6, * = P < 0.05, one-way 
repeated measures ANOVA and Dunnett’s multiple comparisons). 
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4.1.1.5 Mouse CFTR 
Figure 4.6A, shows representative single-channel recordings from an inside-out 
membrane patch excised from a CHO cell stably expressing mouse WT-CFTR 
following activation by 1 mM ATP and 75 nM PKA at a holding potential of -50 mV and 
temperature of 37 °C. The patch-clamp recording shown in Figure 4.6A was from a 
membrane patch containing two mouse WT-CFTR channels and shows the unique 
gating behaviour of mouse CFTR as discussed in Section 3. Visual inspection of traces 
in Figure 4.6A suggests that addition of ivacaftor did not result in a change in the gating 
behaviour of mouse WT-CFTR. Quantification of the effects of increasing 
concentrations of ivacaftor from 10 nM to 10 μM are shown in Figure 4.6B and C. The 
single-channel current amplitude for the full open state (O2) of mouse WT-CFTR 
before addition of ivacaftor was -0.23 ± 0.02 pA (n = 4) and no change was observed 
following addition of ivacaftor at concentrations between 10 nM and 10 μM. As 
reported in Section 3, the Po of the O2 state of mouse WT-CFTR was low at 1 mM ATP 
(0.049 ± 0.01, n = 4). Successive additions of ivacaftor up to a concentration of 10 μM 
however did not result in any increase in the Po of the O2 state of mouse WT-CFTR 
(Figure 4.6C). Due to the small amplitude of the sub-conductance state (O1) of mouse 
CFTR, and the ratio of signal to noise of recordings, it was not possible to quantify the 




Figure 4.6: Effect of ivacaftor on mouse WT-CFTR in the presence of 1 mM ATP. A Representative 
single-channel recordings from an excised inside-out membrane patch from a CHO cell showing the 
response of mouse WT-CFTR to ivacaftor at concentrations from 0.1 μM to 10 μM. Holding potential 
was clamped at -50 mV throughout and recordings were made in the continuous presence of 1 mM 
ATP and 75 nM PKA. Dotted lines represent the closed level for the channels. A 5-fold data reduction 
was applied to traces in A for the purpose of illustration. B and C Single-channel current amplitude (i) 
and Po of mouse WT-CFTR at ivacaftor concentrations from 10 nM to 10 μM. Graphs in B and C were 
fitted with 3-parameter sigmoidal curves using SigmaPlot software v13.0 (n = 4, P = ns, one-way 
repeated measures ANOVA). 
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4.1.1.6 Zebrafish CFTR 
Figure 4.7A shows example single-channel recordings from an excised inside-out 
membrane patch from a CHO cell transiently expressing zebrafish WT-CFTR under 
control conditions (1 mM ATP and 75 nM PKA), and following addition of 0.1, 1.0 and 
10 μM ivacaftor in the continuous presence of ATP and PKA. Quantification of single-
channel current and Po are shown for all concentrations tested between 0 and 10 μM 
in Figure 4.7B and C. As mentioned in Chapter 3, Cl- currents were only observed in 
one experiment using cells expressing zebrafish WT-CFTR and therefore due to the 
lack of power care must be taken in the interpretation of these data. It must also be 
noted that due to the low activity of zebrafish CFTR and the small current amplitude, 
there may be an underestimate in the correct number of channels present within this 
membrane patch. However, taking these considerations into account, channel activity 
was observed following activation by PKA-dependent phosphorylation, characterised 
by brief channel openings that resembled those of mouse WT-CFTR. No significant 
increase in activity or change in single-channel current amplitude was observed in 
response to ivacaftor. The single-channel current amplitude of zebrafish CFTR under 
control conditions at -50 mV and 1 mM ATP was -0.20 pA (n = 1) and this level 
remained unchanged (within the range ± 3.0 x10-3) at increasing ivacaftor 
concentrations up to 10 μM (Figure 4.7B). Po before addition of ivacaftor was 0.16 (n 
= 1). At 10 nM ivacaftor, Po was observed to increase slightly to 0.24 after which Po 
steadily decreased as the concentration of ivacaftor was increased to 10 μM (n = 1 
throughout). Further experiments are required however before interpretation of the 
significance of these data is possible. 
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Figure 4.7: Effect of ivacaftor on zebrafish WT-CFTR in the presence of 1 mM ATP. A 
Representative single-channel recordings from an excised inside-out membrane patch of a CHO cell 
showing the response of zebrafish WT-CFTR to ivacaftor at concentrations from 0.1 μM to 10 μM. 
Holding potential was clamped at -50 mV throughout and recordings were made in the continuous 
presence of 1 mM ATP and 75 nM PKA. Dotted lines represent the closed channel level. A 5-fold data 
reduction was applied to traces in A for the purpose of illustration. B and C Single-channel current (i) 
and Po of zebrafish WT-CFTR at ivacaftor concentrations from 10 nM to 10 μM. Graphs in B and C 
were fitted with 3-parameter sigmoidal curves using SigmaPlot software v13.0 (n = 1). 
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4.2.2 Effect of ivacaftor on the single-channel behaviour of F508del-
CFTR from diverse species 
 
4.2.2.1 Effect of ivacaftor on Human and Mouse F508del 
CFTR following low temperature correction 
To test the effect of ivacaftor on F508del-CFTR, the processing defect of the mutation 
must first be corrected. Incubation of cells expressing F508del-CFTR at 27 °C has 
previously been shown to deliver F508del-CFTR to the plasma membrane (Denning 
et al., 1992). We therefore used low temperature correction to test the effects of 
ivacaftor on both human and mouse F508del-CFTR gating behaviour. Cells were 
incubated at 27 °C for a minimum of 24 hours before experiments. Glass coverslips 
on which cells had been seeded were transferred to the experimental chamber at room 
temperature (23 °C) and CFTR was then activated at 27 °C following membrane patch 
excision by adding 1 mM ATP and 75 nM PKA to the intracellular solution. Once CFTR 
channels were observed and had been fully activated, the temperature of the 
experimental chamber was increased to 37 °C within 2 minutes using a heated 
microscope stage (Brook Industries) as described in the Section 2. Experiments were 





Figure 4.8: Effect of ivacaftor on human and mouse F508del-CFTR following low temperature 
correction. A Representative single-channel recordings from a membrane patch excised from a CHO 
cell showing the response of mouse F508del-CFTR to ivacaftor at concentrations of 1.0 and 10 μM. 
Holding potential was clamped at -50 mV throughout and recordings were made at 37 °C in the 
continuous presence of 1 mM ATP and 75 nM PKA. The processing defect caused by F508del was 
corrected by incubating cells at 27 °C for at least 24 hours before experiments. Dotted lines represent 
the closed level for the channels. A 5-fold data reduction was applied to traces in A for the purpose of 
illustration. B and C Single-channel current amplitude (i) and Po of human (grey circles) and mouse 
(green circles) F508del-CFTR at ivacaftor concentrations from 0 to 10 μM (mouse F508del-CFTR was 
not tested at 10 nM). Graphs in B and C were fitted with 3-parameter sigmoidal curves using SigmaPlot 
software v13.0 (human n = 2 – 5; mouse, n = 3; * = P < 0.05 vs control, one-way repeated measures 
ANOVA and Dunnett’s multiple comparisons). 
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Excised inside-out membrane patches from cells expressing human F508del-CFTR 
(Figure 4.8) produced CFTR-mediated Cl- currents with reduced activity compared to 
WT-CFTR (Figure 4.1) (for human F508del-CFTR: i = -0.60 ± 0.06; Po = 0.10 ± 0.01; 
n = 5). Addition of ivacaftor at increasing concentrations up to a maximum of 10 μM 
resulted in a 160% increase in Po to 0.26 ± 0.06 at 10 μM ivacaftor (P < 0.05 compared 
to control) with no change in single-channel current amplitude (Figures 4.8B and C). 
As shown by the example traces in Figure 4.8A and the quantification of data in 
Figures 4.8B and C, increasing concentrations of ivacaftor did not result in any 
significant change in either single-channel current amplitude or Po of the full open state 
(O2) of mouse F508del-CFTR above the level of control (Control: i = -0.37 ± 0.02 pA; 
Po = 0.07 ± 0.01, n = 3). 
 
4.2.2.2 Effect of ivacaftor on Human and Mouse F508del-CFTR  following 
correction by lumacaftor 
Use of CFTR potentiators in conjunction with CFTR correctors has proven a feasible 
approach for the treatment of CF patients carrying the F508del mutation (Okiyoneda 
et al., 2013). The first such ‘combination therapy’ to be approved by the FDA was 
Orkambi (Vertex Pharmaceuticals), which utilises ivacaftor with lumacaftor (VX-809, 
Vertex Pharmaceuticals) (Van Goor et al., 2011; Wainwright et al., 2015). For this 
reason, we aimed to determine if correction of human or mouse F508del-CFTR using 
lumacaftor rather than low temperature altered the observed response of these CFTR 
orthologues to potentiation by ivacaftor. Cells expressing human or mouse F508del-
CFTR were incubated at 37 °C with 3 μM lumacaftor for 24 hours prior to experiments. 
F508del-CFTR was activated at 37 °C following patch excision using 1 mM ATP and 




Figure 4.9: Effect of ivacaftor on human and mouse F508del-CFTR following correction with 3 
μM lumacaftor. A Representative single-channel recordings from a membrane patch excised from a 
CHO cell showing the response of mouse F508del-CFTR to ivacaftor at 10 μM. Holding potential was 
clamped at -50 mV throughout and recordings were made in the continuous presence of 1 mM ATP 
and 75 nM PKA. The processing defect caused by F508del was corrected by incubating cells with 3 μM 
lumacaftor at 37 °C for at least 24 hours before experiments. Dotted lines represent the closed level for 
the channels. A 5-fold data reduction was applied to traces in A for the purpose of illustration. B and C 
Single-channel current amplitude (i) and Po of human and mouse F508del-CFTR at 0 and 10 μM 
ivacaftor (human n = 3 – 4; mouse, n = 2; * = P < 0.05 vs control, paired two-way Student’s t-test). 
 
As with low temperature correction, 10 μM ivacaftor increased the Po of human 
F508del-CFTR, but to a greater extent, with an increase of 350% from 0.08 ± 0.04 (n 
= 4) to 0.36 ± 0.05 (n = 3) (Figure 4.9C) following correction by 3 μM lumacaftor without 
a change in single-channel current amplitude (Figure 4.9B). As shown by the 
representative traces in Figure 4.9A, channel gating of lumacaftor-corrected mouse 
F508del-CFTR remained unchanged following addition of 10 μM ivacaftor. At -50 mV, 
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under control conditions, the single-channel current amplitude of mouse F508del-
CFTR was -0.33 ± 0.05 pA whilst Po was 0.03 ± 0.005 pA (n = 2) and addition of 10 
μM ivacaftor did not result in any change in either Po or single channel current. 
 
4.3.3 Effect of genistein on the single-channel behaviour of CFTR 
orthologues 
Genistein, an isoflavonoid sourced from soy beans, is a CFTR potentiator (Illek et al., 
1995), that demonstrates potentiation of CFTR at low concentrations and inhibition at 
higher concentrations (Wang et al., 1998). This dual effect of genistein is thought to 
arise from binding of the drug at different sites between the two NBDs (Huang et al., 
2009). Given this potential difference in mechanism of action between genistein and 
ivacaftor, we were keen to test if mouse CFTR showed potentiation in response to 
genistein. We tested the effect of 50 μM genistein on both human and mouse F508del-
CFTR (Figure 4.10). 50 μM genistein potentiated human F508del-CFTR, increasing 
Po by 54% from 0.13 ± 0.02 to 0.20 ± 0.03 (n = 4) without affecting single-channel 
current amplitude (Figure 4.10B and C). 50 μM genistein did not affect the Po of mouse 
F508del-CFTR (Control = 0.04 ± 0.01; 50 μM genistein = 0.05 ± 0.01, n = 2). However, 
a small decrease in single-channel current was observed from -0.29 ± 8.9 x10-3 pA to 




Figure 4.10: Effect of 50 μM genistein on human and mouse F508del-CFTR following low 
temperature correction. A Representative single-channel recordings from a membrane patch excised 
from a CHO cell showing the response of mouse F508del-CFTR to 50 μM genistein added to the 
intracellular solution. Holding potential was clamped at -50 mV throughout and recordings were made 
in the continuous presence of 1 mM ATP and 75 nM PKA. The processing defect caused by F508del 
was corrected by incubating cells at 27 °C for at least 24 hours before experiments. Dotted lines 
represent the closed level for the channels. A 5-fold data reduction was applied to traces in A for the 
purpose of illustration. B and C Single-channel current amplitude (i) and Po of human and mouse 
F508del-CFTR in the absence and presence of 50 μM genistein (human n = 4; mouse, n = 2; * = P < 




Our data indicate species specific responses to the CFTR potentiator ivacaftor. As 
highlighted by the summary of our data for Po in Figure 4.11, human, pig, sheep and 
ferret WT-CFTR orthologues all demonstrated potentiation in response to ivacaftor, 
however no potentiation was observed in the case of either mouse or zebrafish, 
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although the lack of power in the data collected for zebrafish (n = 1) warrants caution 
for the interpretation of these data. 
 
Figure 4.11: Summary of the response of CFTR orthologues from diverse species to ivacaftor 
as studied using single-channel patch-clamp. Recording responses of WT-CFTR orthologues from 
human (A), pig (B), sheep (C), ferret (D), mouse (E) and zebrafish (F) to ivacaftor at concentrations 
between 0.01 and 10 μM. All species orthologues were transiently expressed in CHO cells with the 
exception of human CFTR, which was stably expressed in NIH 3T3 cells. Recordings were made from 
excised inside-out membrane patches in the continuous presence of 1 mM ATP and 75 nM PKA at 37 
°C (human; n = 3, pig; n = 2, sheep; n = 3, ferret; n = 4 – 6, mouse; n = 5 – 6, zebrafish; n = 1, * = P < 
0.05, one-way repeated measures ANOVA and Dunnett’s multiple comparisons). 
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Comparison of the bar graphs shown in Figures 4.11A and C for human and sheep 
WT-CFTR, as well as Figures 4.1C and 4.3C, suggests that ivacaftor has a decreased 
efficacy for sheep compared to human CFTR, although it was not possible to quantify 
KD for ivacaftor’s effect on human CFTR due to the high levels of potentiation of this 
orthologue at low concentrations. This difference in efficacy may result from a lower 
affinity of ivacaftor binding to sheep CFTR or from structural differences that affect the 
mechanism by which ivacaftor potentiates CFTR gating. 
 
In a previous study by our group, Cai et al. (2015) investigated the effect of the 
fluorescein derivative phloxine B on sheep WT-CFTR. In the case of human CFTR, 
phloxine B acts as a potentiator at concentrations up to 3 μM, and an inhibitor at higher 
concentrations (Cai & Sheppard, 2002). Phloxine B does not potentiate sheep CFTR 
at low concentrations, however it does inhibit sheep CFTR at concentrations over 3 
μM (Cai et al., 2015). Cai et al. (2015) speculated that phloxine B, like PPi, potentiates 
human CFTR through by interacting with the NBDs. Our observation that ivacaftor 
potentiates sheep CFTR leads us to speculate that the mechanism of action of 
ivacaftor differs from that of both PPi and phloxine B, potentially resulting from a 
different binding location on the TMDs. 
 
Our data demonstrates that when expressed in CHO cells, the fully open state (O2) of 
mouse WT- and F508del-CFTR orthologues do not show increased activity in 
response to ivacaftor at concentrations between 10 nM and 10 μM when studied using 
the excised inside-out patch-clamp technique (Figures 4.6, 4.8 and 4.9). Our data 
contradict previous studies that have shown potentiation of mouse CFTR in response 
to ivacaftor when expressed in Xenopus oocytes at room temperature (Cui & McCarty, 
2015). Interestingly, the gating behaviour reported by Cui and McCarty (2015) for 
mouse CFTR channels expressed in Xenopus oocytes appears to differ from that 
reported by other studies where mouse CFTR was expressed in mammalian cells 
(Lansdell et al., 1998a; Lansdell et al., 1998b; Ostedgaard et al., 2007; Scott-Ward et 
al., 2007; Dong et al., 2012), with a higher Po evident for the O2 fully open state of the 
channel and an absence of the distinctive gating behaviour replicated in previous 
studies as well as our current study (e.g. Figure 4.6A). As we have been unable to 
quantify the O1 state in our present study due to the small amplitude of this sub-
conductance state, one potential explanation of the observed difference in response 
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to ivacaftor is that ivacaftor acts on mouse CFTR by potentiating this sub-conductance 
state. However, our observation that mouse CFTR is not potentiated by ivacaftor has 
also been supported by data obtained using iodide efflux utilising cells expressing 
mouse CFTR (de Jonge et al., 2007). As we would expect O1 state potentiation to 
result in an increase in overall CFTR activity as measured using iodide efflux the 
explanation that potentiation of mouse CFTR by ivacaftor involves potentiation of the 
O1 state of mouse CFTR does not seem likely. Furthermore, the observations obtained 
using iodide efflux that show ivacaftor does not potentiate mouse-CFTR at the whole-
cell level is supported by previous studies showing that ivacaftor does not affect CFTR-
regulated smooth muscle contraction in mouse lung slices, although it is possible that 
this is a tissue-specific effect (Cook et al., 2016). The reported Kd of ivacaftor for 
mouse CFTR was 7.32 nM (Cui & McCarty, 2015), however in this study we tested a 
range of concentrations from 10 nM to 10 µM and did not see an increase in Po at any 
concentration (Figure 4.6). This leads us to conclude that ivacaftor does not affect 
mouse CFTR within this concentration range under the experimental conditions used 
here. 
 
A further difference between the data that we have collected, and previous studies is 
the experimental temperature that we have used. In our single-channel studies, all 
experiments were carried out at 37 °C to more accurately replicate physiological 
conditions. However, data collected by our group replicating the experiments in this 
section using mouse WT-CFTR, but repeated at low temperature (Figures 4.12, data 
reproduced with permission of Dr Yiting Wang) indicate that mouse CFTR still does 
not demonstrate potentiation at lower temperatures. This therefore raises the 
possibility that mouse-CFTR gating behaviour may be in part determined by the 
expression system used, suggesting that membrane interactions may have a role in 
determining both gating behaviour and pharmacology of this CFTR orthologue 




Figure 4.12: Temperature-dependence of mouse F508del-CFTR treated with ivacaftor. A 
Representative recordings of mouse F508del-CFTR Cl- channels in an excised inside-out membrane 
patch from a CHO cell. The recordings were acquired at the indicated temperatures in the presence of 
ATP (1 mM) and PKA (75 nM) in the intracellular solution. Dotted lines indicate where channels are 
closed (C) and the first open level (O1) and downward deflections correspond to the second open level 
(O2). Black bars indicated 2 s sections where traces have been additionally filtered at 50 Hz and shown 
separately to the right in panel A. B and C summary data show change in single-channel current 
amplitude (i) and Po between 23 °C and 37 °C for mouse F508del in the presence and absence of 
ivacaftor (VX-770). Data are means ± SEM (control, n = 9-12; ivacaftor, n = 5). (Data from experiments 
carried out by Dr Yiting Wang and reproduced with permission). 
 
The observation that mouse CFTR does not respond to the potentiator PPi has been 
used previously to determine the binding location of PPi to CFTR using human-mouse 
CFTR chimeras (Scott-Ward et al., 2007). Our observation of similar differences in the 
response of human and mouse WT and F508del-CFTR to ivacaftor therefore provides 
strong rationale for the use of human-mouse CFTR chimeras to study the mechanism 
of action of ivacaftor. Furthermore, the observation that genistein also shows species 
specific potentiation of CFTR orthologues demonstrates that this approach may be 
used to determine information about the mechanism of action of multiple CFTR 
potentiators. Using docking simulations, Huang et al. (2009) previously speculated 
 122 
that genistein is likely to bind at multiple locations at the interface between the NBDs. 
Given that human, but not mouse CFTR shows potentiation in response to genistein, 
these data suggest that the use of human-mouse chimeras may provide insight into 

































5.1.1 Overview of the use of chimeras to determine drug-binding sites 
Chimeras constructed by combining sequences from different CFTR orthologues have 
previously been used to investigate structure-function relationships as well as the 
pharmacology of CFTR. For example, Price et al. (1996) developed human-Xenopus 
chimeras by replacing the sequences of either TMD1 or TMD2 in human CFTR with 
the equivalent regions of the Xenopus sequence. By investigating the single-channel 
gating properties of these chimeras, Price et al. (1996) identified that incorporation of 
Xenopus TMD1 domain into human CFTR (hX1-6) resulted in gating behaviour 
characterised by brief openings with increased intraburst closures that closely 
resembled that which we have observed for mouse and zebrafish CFTR. However, 
incorporation of Xenopus TMD2 into human CFTR (hX7-12) produced gating 
behaviour that more closely resembled that of the human WT channel (Price et al., 
1996). Subsequent mutation of the Xenopus ECL1 residues Arg111-Asp-Asn-Glu-
His115 back to the human equivalent Pro111-Asp-Asn-Lys-Glu115 resulted in a chimera 
(hx1-6+REH/PKE), which demonstrated gating behaviour more closely resembling 
that of human CFTR, thereby demonstrating the role of this region in determining the 
gating behaviour of CFTR (Price et al., 1996). 
 
Our observation that mouse CFTR is not potentiated by ivacaftor supports the 
possibility that human-mouse CFTR chimeras may be used to identify structural 
regions of the CFTR protein that are involved in ivacaftor-mediated potentiation. This 
approach has been utilised by our group in the past to determine the binding domain 
of PPi (Scott-Ward et al., 2007). In that study, Scott-Ward et al. (2007) designed a 
panel of human-mouse whole-domain chimeras where the NBDs and RD of human 
CFTR were replaced by the mouse sequences of the corresponding domains. PPi is 
a compound known to bind at the NBDs and acts as a CFTR potentiator at 
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concentrations below 3 mM but an allosteric inhibitor of CFTR at higher concentrations 
(Carson et al., 1995b; Scott-Ward et al., 2007; Li & Sheppard, 2009). However, PPi 
had been shown to only inhibit mouse WT-CFTR (Lansdell et al., 1998a; Scott-Ward 
et al., 2007). Using human-mouse CFTR chimeras, Scott-Ward et al. (2007) 
demonstrated that this pattern of potentiation and inhibition was still present when 
either NBD1 or the RD were substituted by the mouse CFTR sequence for these 
domains. However, introduction of the mouse sequence for NBD2, either alone or in 
conjunction with NBD1, resulted in a PPi response that matched that of mouse WT-
CFTR, demonstrating only inhibition at higher concentrations without showing 
potentiation at concentrations under 3 mM (Scott-Ward et al., 2007). This study 
therefore demonstrated that binding of PPi occurred at NBD2 rather than NBD1. Thus 
the Scott-Ward et al. (2007) study provides proof of concept for the use of chimeras 
to determine regions of the CFTR protein involved in the mechanism of action of CFTR 
potentiators. Furthermore, this functional approach has advantages over the use of 
site-directed mutagenesis, for example by reducing the chances of multiple binding 
sites leading to a false-negative result, and by reducing the risk of developing a non-
functional protein that cannot be studied using electrophysiological techniques. 
 
5.1.2 Selection and design of chimeras 
We worked in collaboration with Dr Christopher Boyd and Ann Doherty at the 
University of Edinburgh to design a panel of 13 CFTR chimeras that would encompass 
both whole domain sequence changes as well as chimeras for specific TM helices. 
Two additional human-mouse CFTR chimeras (hmNBD2 and hmRI) were also kindly 
provided by Professor Lynda Ostedgaard at the University of Iowa. The chimeras that 
were used are shown in Table 5.1. As detailed in Section 2, whole-domain chimeras 
were generated via homologous recombination, while transmembrane helix chimeras 
were constructed by inserting unique restriction sites at regular intervals into the 
modified backbone of human WT-CFTR. An alignment of the full sequences for each 







Construct Residue boundaries Plasmid Source 
1 human WT N/A pCMV Edinburgh 
2 Mouse WT N/A pCMV  Edinburgh 
3 hmNBD1/2 432-611:1226-1419 pCMV Edinburgh 
4 hmNBD1 432-611 pCMV Edinburgh 
5 hmNBD2 1178-1480 pcDNA3.1 Iowa 
6 hmTM1-12 79-355:858-1152 pCMV Edinburgh 
7 hmTM1-6 79-355 pCMV Edinburgh 
8 hmTM7-12 858-1152 pCMV Edinburgh 
9 hmTM5+6 307-355 pCMV Edinburgh 
10 hmTM5+6:TM1+2 307-355:78-153 pCMV Edinburgh 
11 hmTM5+6:TM3+4 307-355:154-306 pCMV Edinburgh 
12 hmTM5+6:TM7+8 307-355:858-935 pCMV Edinburgh 
13 hmTM5+6:TM9+10 307-355:987-1034 pCMV Edinburgh 
14 hmTM5+6:TM11+12 307-355:1095-1152 pCMV Edinburgh 
15 hmRD 653-837 pCMV Edinburgh 
16 hmRI 404-436 pcDNA3.1 Iowa 
Table 5.1: Human and mouse WT and chimeric cDNA constructs used in this study, created by 
the laboratories of Dr Christopher Boyd (Edinburgh) and Professor Michael Welsh (Iowa). 
 
Models of 12 of the constructs tested based upon the high-resolution cryo-EM 
structure of human CFTR generated by Liu et al. (2017) are shown in Figure 5.1. In 
this figure, human residues in each construct are shown in blue, whilst mouse residues 
are indicated in yellow. 
 
5.1.3. Experimental approach for studying the effect of ivacaftor on 
human-mouse CFTR chimeras 
Due to the large number of CFTR chimeric constructs to be tested (16 in total including 
human and mouse WT-CFTR), the use of the low-throughput single-channel patch-
clamp technique was determined to be impractical. For this reason, the high-
throughput automated patch-clamp technique (Billet et al., 2017) was used to 




Figure 5.1. Structural models of human-mouse CFTR chimeras. For each of these constructs, 
human residues are shown in blue and mouse residues are shown in yellow. Models are based upon 
the human CFTR structure PDB: 5UAK (Liu et al., 2017) (The chimeras for hmRD and hmRI are not 
shown in this figure due to the lack of inclusion of these domains in the PDB: 5UAK structure). 
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5.2 Response of human and mouse WT-CFTR to ivacaftor using the 
automated whole-cell patch-clamp technique 
 
5.2.1 Response of Human WT-CFTR to ivacaftor 
Before testing chimeras using the automated patch-clamp technique, it was important 
to characterise the response of human and mouse WT-CFTR channels to ivacaftor at 
the whole-cell level. Figure 5.2 shows an example experimental trace recorded using 
the QPatch HTX platform from a CHO cell expressing human WT-CFTR (hCFTR). All 
whole-cell patch clamp experiments were recorded at room temperature (21 °C) with 
[Cl-]int = 159 mM, [Cl-]ext = 171 mM. Voltage ramp protocols were applied every 10 s 
from -80 mV to +80 mV as described in Section 2. In Figure 5.2, only the maximal 
outward current at 80 mV for each voltage sweep is shown (circles). The current at  
-30 mV for each voltage sweep is indicated by squares and this was subtracted from 
the maximal outward current for analysis. Following application of the saline solution 
(extracellular solution), extracellular solution containing 3% DMSO was applied to 
each experimental cell for 5 minutes as a vehicle control. This solution was then 




Figure 5.2: Representative QPatch whole-cell recording showing the response of human WT-
CFTR to ivacaftor. Whole-cell currents were recorded from a CHO cell transiently expressing hCFTR 
at room temperature. Circles represent the outward current for each voltage sweep at 80 mV. Squares 
represent the current recorded at the holding potential of -30 mV. Arrows indicate cumulative addition 
of specified agents to the extracellular solution. Green shaded areas represent the final 10 sweeps from 
each liquid application period that were used to calculate average current. Example recording is the 
same as Figure 2.5 in Section 2. 
 
Following activation of CFTR by FSK, an increase in the maximal outward current was 
observed (Figure 5.2). After 15 minutes, 10 μM ivacaftor was added to the extracellular 
solution, resulting in a further increase in maximal outward current. Following 
application of ivacaftor for 5 minutes, CFTR was inhibited using 30 μM CFTRinh-172. 
10 μM FSK was present throughout both the ivacaftor and CFTRinh-172 liquid 
application periods. For analysis, the mean maximal current for the final 10 sweeps 
for each liquid application period was used as indicated by the green bar shading in 
Figure 5.2. Current recordings were normalised for cell size by dividing by the recorded 
cell capacitance (C-slow) for each sweep. To ensure the recorded current was specific 
to CFTR, the change in current (ΔI) was calculated by subtracting the remaining 
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current following application of CFTRinh-172 and the response of CFTR to FSK alone 
compared to that following addition of ivacaftor as shown in Figure 5.3. 
 
Figure 5.3: Response of human WT-CFTR to ivacaftor as recorded using automated whole-cell 
patch-clamp technique. Data points represent the mean maximal outward current at the end of liquid 
application protocols for control (10 μM FSK) and 10 μM ivacaftor in the presence of 10 μM FSK 
following subtraction of current recorded at -30 mV and normalisation for cell capacitance. Symbols 
connected by lines represent individual experiments (n = 13, * = P < 0.05, two-way Student’s paired t-
test). 
As shown in Figure 5.3, for human WT-CFTR addition of 10 μM ivacaftor resulted in 
an increase in the mean outward current from 37.7 ± 6.61 pA/pF to 50.4 ± 8.00 pA/pF 
(P < 0.05, n = 13). 
 
5.2.2 Response of mouse WT-CFTR to ivacaftor 
Figure 5.4 shows a representative QPatch recording from a CHO cell expressing 
mouse WT-CFTR during activation by 10 μM FSK and subsequent addition of 10 μM 
ivacaftor and 30 μM CFTRinh-172. As is evident from this example the pattern of 
activation of mouse WT-CFTR was different from that of human WT-CFTR. 
Interestingly, addition of 10 μM FSK resulted in an initial increase in activity, followed 
by a slower rise in outward current during the 15-minute liquid application period for 
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FSK (Figure 5.4). However, addition of ivacaftor following FSK activation resulted in a 
decrease in activity, suggesting inhibition of the channel by ivacaftor at this 
concentration (Figure 5.4). Indeed, the rate of current decay following addition of 
CFTRinh-172 after 5 minutes appears to be the same as that observed in the presence 
of ivacaftor (Figure 5.4). 
 
Figure 5.4: Representative QPatch whole-cell recording showing the response of mouse WT-
CFTR to ivacaftor. Whole-cell currents recorded from a CHO cell transiently expressing mCFTR at 
room temperature. Circles represent the outward current for each voltage sweep at 80 mV. Squares 
represent the current recorded at the holding potential of -30 mV, open circles represent data points 
that were excluded from analysis. Green shaded areas represent the final 10 sweeps from each liquid 
application period that were used to calculate average current. 
 
As would be expected given the distinct gating behaviour exhibited by mouse WT-
CFTR shown by our previous single-channel currents, the whole-cell currents 
recorded from cells expressing mouse WT-CFTR following activation by 10 μM FSK 
were small, in part accounting for the apparent greater current variation observed in 
Figure 5.5. The mean outward current of mouse WT-CFTR in response to FSK was 
15.9 ± 3.19 pA/pF (n = 11) (Figure 5.5). The outward current 5 minutes following the 
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addition of 10 μM ivacaftor was reduced compared to the FSK-activated current, with 
a mean current of 5.92 ± 1.64 pA/pF (P < 0.05, n = 11). 
 
Figure 5.5: Response of mouse WT-CFTR to ivacaftor as recorded using automated whole-cell 
patch-clamp technique. Data points represent the mean maximal outward current at the end of liquid 
application protocols for control (10 μM FSK) and 10 μM ivacaftor in the presence of 10 μM FSK 
following subtraction the current recorded at -30 mV and normalisation for cell capacitance. Symbols 
connected by lines represent individual experiments (n = 11, * = P < 0.05, two-way Student’s paired t-
test). 
 
5.3 Determining compound-interacting domains using automated 
whole-cell patch-clamp technique to study human-mouse CFTR 
chimeras 
 
5.3.1 Effect of ivacaftor on whole-domain CFTR chimeras 
Given the differences observed in the response to ivacaftor for human and mouse WT-
CFTR at both single-channel and whole-cell levels, 10 μM ivacaftor was tested for its 
effects when applied to whole-domain human-mouse CFTR chimeras. The same 
experimental procedure was used to study these chimeras using the QPatch 
automated whole-cell patch-clamp system as had been used for both human and 
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mouse WT-CFTR. Representative recordings from CHO cells transiently expressing 
whole-domain chimeras of the NBDs and TMDs are shown in Figure 5.6, whilst 
quantification of the response to 10 μM FSK followed by addition of 10 μM ivacaftor in 
the presence of 10 μM FSK for all experiments is shown in Figure 5.7 (Summary data 
for QPatch whole-cell currents recorded from all human-mouse CFTR chimeras is 
shown in Figure 5.18). 
As shown in Figures 5.6 and 5.7A, for hmNBD1/2 10 μM ivacaftor resulted in a further 
increase in whole-cell outward current following initial activation of the chimera by 10 
μM FSK. Mean whole-cell current following activation by FSK was 19.3 ± 3.58 pA/pF. 
Ivacaftor potentiated the NBD1/2 CFTR chimera, increasing the mean outward current 
to 43.5 ± 7.21 pA/pF (P < 0.05, n = 7) (Figure 5.7A). Having established that ivacaftor 
potentiates CFTR chimeras that express sequences from both mouse NBDs, we next 
tested chimeras where either the NBD1 or NBD2 sequence was individually 
exchanged for their mouse equivalent. As shown in the example recordings in Figure 
5.6 and Figures 5.7B and C, potentiation by ivacaftor occurred when just one mouse 
NBD was expressed on a human CFTR background. In the case of NBD1 (hmNBD1), 
the maximal outward current increased from 15.0 ± 7.30 pA/pF following activation by 
FSK, to 33.6 ± 10.7 pA/pF after the addition of 10 μM ivacaftor (P < 0.05, n = 4). When 
mouse NBD2 was expressed (hmNBD2), maximal outward current increased from 
14.7 ± 3.01 pA/pF to 25.3 ± 4.67 pA/pF (P < 0.05, n = 15). These results, combined 
with those for hmNBD1/2, suggest that the differences in the effect of 10 μM ivacaftor 
on human and mouse WT-CFTR channels is not related to sequence differences 




Figure 5.6: Representative QPatch whole-cell recordings showing the response of human-
mouse CFTR whole-domain chimeras to ivacaftor. Whole-cell currents recorded from CHO cells 
transiently expressing the indicated whole-domain human-mouse CFTR chimeras at room temperature 




Figure 5.7: Effects of ivacaftor on human-mouse CFTR whole-domain chimeras. Data points 
represent the mean maximal outward current at the end of liquid application protocols for control (10 
μM FSK) and 10 μM ivacaftor in the presence of 10 μM FSK following subtraction of the current recorded 
at -30 mV and normalisation for cell capacitance. Symbols connected by lines represent individual 
experiments. A hmNBD1/2; n = 7. B hmNBD1; n = 4. C hmNBD2; n = 15. D hmTM1-12; n = 5. E 
hmTM1-6; n = 7. F hmTM7-12; n = 6 (* = P < 0.05, two-way Student’s paired t-test). 
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To investigate the effect of sequence changes in the TMDs, we tested the hmTMD1-
12 chimera, in which the mouse sequence for both TMDs was expressed on a human 
CFTR background (Figure 5.6 and 5.7D). In the case of hmTM1-12, the mean outward 
current was reduced following addition of 10 μM ivacaftor from 23.5 ± 6.48 pA/pF in 
the presence of 10 μM FSK alone to 9.52 ± 3.34 pA/pF (P < 0.05, n = 6). As illustrated 
by the example QPatch trace shown in Figure 5.6, outward currents were inhibited by 
both ivacaftor and CFTRinh-172. Following addition of 10 μM ivacaftor, an exponential 
decay was observed in the outward current, which reached a stable level within the 5-
minute period of this liquid application (Figure 5.6). Addition of CFTRinh-172 resulted 
in a further exponential decay in outward current (Figure 5.6). 
 
To determine whether the sequence alterations between human WT-CFTR and the 
hmTM1-12 chimera responsible for the difference in the effect of ivacaftor on these 
two constructs were limited to a single TMD, we next tested chimeras in which 
complete sequences for either TMD1 or TMD2 were exchanged for the murine 
equivalent (constructs hmTM1-6 and hmTM7-12, Figure 5.6 and 5.7E and F). In the 
case of hmTM1-6, potentiation was observed, with an increase in the mean outward 
current from 28.1 ± 9.37 pA/pF following activation by FSK, to 65.5 ± 22.0 pA/pF (P < 
0.05, n = 8). With the exception of one cell, cells expressing hmTM1-6 showed 
relatively small increases in outward current when treated with ivacaftor. This likely 
accounts for the large variance observed in the data. In the case of hmTM7-12 (Figure 
5.7F), little or no change in outward current was observed following addition of 
ivacaftor with a mean outward current following addition of 10 μM FSK of 31.0 ± 7.14 
pA/pF and a current of 36.3 ± 8.58 pA/pF after application of ivacaftor (P = ns, n = 6). 
Interestingly, the inhibition of outward currents by ivacaftor observed for the construct 
hmTM1-12 and mouse WT-CFTR was not replicated by either the hmTM1-6 or the 
hmTM7-12 chimeras. 
 
5.3.2 Effect of ivacaftor on TM-helix CFTR chimeras 
The results from testing human-mouse CFTR chimeras with whole domains 
exchanged suggested that sequence alterations within the TMDs rather than the 
NBDs were responsible for the differences observed in the action of ivacaftor on 
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human and mouse WT-CFTR. We therefore tested human-mouse CFTR chimeric 
constructs where pairs of TM helices in the human CFTR sequence and their linking 
ICLs and ECLs were exchanged with sequences from mouse CFTR. The first of these 
TM helix chimeras to be tested was the hmTM5+6 construct, in which the sequences 
for TM5 and TM6 were exchanged for their mouse equivalents. As shown in the first 
panel of Figure 5.8 and 5.9A, no change in the FSK-activated outward current was 
observed following addition of 10 μM ivacaftor in the presence of FSK. Following 
addition of 10 μM FSK alone, the mean CFTR-mediated outward current was 21.9 ± 
3.66 pA/pF and this did not change significantly, remaining at 22.0 ± 7.02 pA/pF 
following application of 10 μM ivacaftor (P = ns, n = 8). These results suggest that 
exchange of the human sequences for TM5 and TM6 alone for their mouse 
equivalents is sufficient to prevent potentiation by ivacaftor. 
 
In Section 5.4.1, we demonstrated that when the human sequences in TMD1 were 
exchanged for the equivalent mouse sequences the resulting hmTM1-6 chimera still 
showed potentiation by ivacaftor (Figures 5.6 and 5.7E). Conversely, potentiation was 
not observed in the case of the construct hmTM7-12 (Figures 5.6 and 5.7F). One 
potential reason for the discrepancy between these findings and the observation that 
exchange of TM5+6 results in a construct that was not potentiated by ivacaftor is that 
interactions between TM5 and TM6 and other transmembrane helices in either TMD1 
or TMD2 may restore the capacity for potentiation by ivacaftor. We therefore tested 
chimeras where mouse sequences for alternative transmembrane helices were 
exchanged in conjunction with TM5 and TM6. The first of these chimeras to be tested 
was hmTM5+6:1+2. As can be seen from the recording shown in Figure 5.8 and the 
summary graph in Figure 5.9B, no potentiation was observed in response to 10 μM 
ivacaftor in the case of the hmTM5+6:1+2 chimera, with a mean outward current at 80 
mV of 19.3 ± 2.41 pA/pF following activation by 10 μM FSK, and 17.8 ± 5.84 pA/pF 
following application of 10 μM ivacaftor in the presence of 10 μM FSK (P = ns, n = 7). 
Inclusion of mouse sequences for TM3 and TM4 in conjunction with mouse TM5 and 
TM6 did however produce a chimera (hmTM5+6:3+4) that demonstrated potentiation 
by ivacaftor (Figures 5.8 and 5.9C). The FSK-induced mean outward current 
generated by the hmTM5+6:3+4 construct at 80 mV increased from 23.5 ± 3.84 pA/pF 





Figure 5.8: Representative QPatch whole-cell recordings showing the response of human-
mouse CFTR TM-helix chimeras to ivacaftor. Whole-cell currents recorded from CHO cells 
transiently expressing the indicated transmembrane helix human-mouse CFTR chimeras at room 
temperature are shown. INH-172 = CFTRinh-172. Other details same as Figure 5.2. 
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Figure 5.9: Effects of ivacaftor on human-mouse CFTR TM-helix chimeras. Data points represent 
the mean maximal outward current at the end of liquid application protocols for control (10 μM FSK) 
and 10 μM ivacaftor in the presence of 10 μM FSK following subtraction of the current recorded at -30 
mV and normalisation for cell capacitance. Symbols connected by lines represent individual 
experiments. A hmTM5+6; n = 8. B hmTM5+6:1+2; n = 7. C hmTM5+6:3+4; n = 9. D hmTM5+6:7+8; n 
= 6. E hmTM5+6:9+10; n = 8. F hmTM5+6:11+12; n = 4 (* = P < 0.05, two-way Student’s paired t-test). 
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To investigate potential interactions between TM5 and TM6 in TMD1 with 
transmembrane helices from TMD2, we next tested chimeras where mouse 
sequences in TMD2 were expressed in conjunction with mouse TM5+6 and the 
remaining sequences in the CFTR construct matched the human sequence. The first 
of these constructs to be tested was hmTM5+6:7+8. The FSK-induced maximal 
outward current for hmTM5+6:7+8 at 80 mV was 28.8 ± 7.20 pA/pF before, and 41.4 
± 5.71 pA/pF after addition of 10 μM ivacaftor (P = ns, n = 6) (Figure 5.8 and Figure 
5.9D). However, when mouse sequences TM9 and TM10 in TMD2 were expressed in 
conjunction with mouse TM5 and TM6 in TMD1, mean outward current at 80 mV 
increased from 18.9 ± 5.78 pA/pF following activation by FSK to 55.0 ± 15.0 pA/pF 
following addition of ivacaftor (P < 0.05, n = 8) (Figures 5.8 and 5.9E). Potentiation by 
ivacaftor was not observed for the hmTM5+6:11+12 chimera although there was 
variation within the data for this chimera (Figures 5.8 and 5.9D). The mean maximal 
outward current at 80 mV recorded for hmTM5+6:11+12 before application of ivacaftor 
was 15.6 ± 6.80 pA/pF and this increased to 35.7 ± 23.4 pA/pF following addition of 
10 μM ivacaftor (P = ns, n = 4). However as indicated by the large error for this 
recording, only one of the four successful experiments using this construct indicated 
potentiation (Figure 5.8 and Figure 5.9D) and the observed overall increase was not 
found to be significant. Caution must therefore be used in interpreting this result due 
to the low number of successful experiments achieved and lack of statistical power. 
 
Having investigated the involvement of specific transmembrane helices in the 
differences observed in the response of human and mouse WT-CFTR to ivacaftor, we 
next aimed to investigate the involvement of regulatory regions of the CFTR protein. 
Two further chimeras were studied where either the RD or the regulatory insertion (RI), 
a flexible region between residues 404-436 that contains serine residues that can be 
targeted for PKA-mediated phosphorylation (Lewis et al., 2004), were exchanged for 
their mouse equivalents. Although an ivacaftor-mediated response was observed in 
some experiments completed using the hmRD chimera (example trace in Figure 5.10), 
no overall potentiation was observed for this construct. Mean outward current at 80 
mV following addition of FSK was recorded at 28.5 ± 3.52 pA/pF and 31.8 ± 4.92 pA/pF 
following addition of 10 μM ivacaftor (P = ns, n = 14) (Figure 5.11A). In the case of the 
hmRI chimera, mean outward current at 80 mV was 30.5 ± 4.84 pA/pF following 
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addition of FSK alone, and 29.1 ± 6.78 pA/pF after addition of 10 μM ivacaftor (P = ns, 
n = 11) (Figures 5.10 and 5.11B).  
 
 
Figure 5.10: Representative QPatch whole-cell recordings showing the effects of 10 μM ivacaftor 
on human-mouse CFTR RD and RI chimeras. Whole-cell currents recorded from CHO cells 
transiently expressing the indicated human-mouse CFTR chimeras for the RD and RI at room 
temperature are shown. INH-172 = CFTRinh-172. Other details same as Figure 5.2. 
 
 
Figure 5.11: Effects of ivacaftor on the human-mouse CFTR chimeras hmRD and hmRI. Data 
points represent the mean maximal outward current at the end of liquid application protocols for control 
(10 μM FSK) and 10 μM ivacaftor in the presence of 10 μM FSK following subtraction of the current 
recorded at -30 mV and normalisation for cell capacitance. Symbols connected by lines represent 
individual experiments. A hmRD; n = 14. B hmRI; n = 11 (P > 0.05, two-way Student’s t-test). 
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5.4 The gating behaviour of human-mouse CFTR chimeras as 
determined using single-channel patch-clamp recordings 
 
The technique of automated whole-cell patch-clamp recording enabled rapid testing 
of multiple human-mouse CFTR chimeras for their response to ivacaftor when 
transiently expressed in CHO cells. The purpose of these experiments was to 
determine whether or not different CFTR constructs were potentiated by ivacaftor. 
However, these data provide limited information about the response of human-mouse 
CFTR chimeric constructs to ivacaftor at the molecular level. In particular, the lack of 
control over the level of expression of CFTR constructs and potential variation in 
expression between cells expressing the same construct using the transfection system 
prevented detailed quantitative analysis of the observed response of these cells to 
ivacaftor. As such, we selected four of the studied human-mouse CFTR chimeric 
constructs for further study using the single-channel patch-clamp technique utilised in 
Chapters 3 and 4. 
 
Figure 5.12A shows representative single-channel recordings at -80 mV from excised 
inside-out membrane patches taken from CHO cells transiently expressing the 
hmNBD1/2, hmTM1-6, hmTM5+6 and hmTM5+6:9+10 chimeric CFTR constructs. As 
can be seen from these representative traces, each of the four constructs produced 
currents when exposed to a Cl- gradient and following activation by 1 mM ATP and 75 
nM PKA. Quantification of single-channel current and Po at -80 mV for each of these 
constructs as well as human and mouse WT-CFTR are shown in Figures 5.12B and 
C. Of the four constructs tested, the hmNBD1/2 construct produced currents and 
showed activity that most closely resembled that of human WT-CFTR. The single-
channel current amplitude recorded from hmNBD1/2 at -80 mV was -0.62 ± 0.01 pA 
(n = 6) representing a 32% reduction in i compared to human WT-CFTR. The Po of 
the hmNBD1/2 construct was recorded as 0.33 ± 0.09 (n = 6) representing a 22% 
reduction compared to human WT CFTR. Visual inspection of the gating behaviour of 
the hmNBD1/2 chimera in Figure 5.12A indicates a pattern of gating that more closely 
resembles that of human WT-CFTR than mouse WT-CFTR, exhibiting bursts of 
channel openings with short intraburst closures and no evidence of the sub-
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conductance O1 level observed for mouse WT-CFTR. This is in contrast however to 
the hmTM1-6 chimeric construct that demonstrated brief channel openings and a sub-
conductance state similar to the O1 state observed for mouse WT-CFTR. The single-
channel current amplitude of the hmTM1-6 chimera was -0.40 ± 0.01 pA at -80 mV (n 
= 3), indicating a 56% reduction in the singe-channel current amplitude compared to 
human WT-CFTR. The Po of the hmTM1-6 chimera was recorded at 0.06 ± 0.02 (n = 
3) (Figure 5.12C). For hmTM5+6, a similar reduction in single-channel current 
amplitude was recorded of -0.39 ± 0.05 pA at -80 mV and a Po of 0.07 ± 7.28 x10-3 (n 
= 4) (Figure 5.12B and C). As shown by the representative trace in Figure 5.12A, 
despite the low Po, the gating behaviour of the hmTM5+6 construct did not 
demonstrate the same brief channel openings observed for mouse WT-CFTR and 
hmTM1-6, and the sub-conductance level was also absent from single-channel 
recordings of this construct. Finally, in comparison to the hmTM5+6 chimera, 
hmTM5+6:9+10 did not show a reduced single-channel current at -80 mV (-0.40 ± 0.02 
pA) (Figure 5.12B), but did result in a 200% increase in Po compared to hmTM5+6 
with a Po of 0.21 ± 0.08 (n = 3) (Figure 5.12C). The Po of the hmTM5+6:9+10 chimera 
therefore represented a 49% reduction compared to the Po of human WT-CFTR. 
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Figure 5.12: Summary of gating properties of human-mouse CFTR chimeras. A Representative 
single-channel recordings of human-mouse CFTR chimeras from excised inside-out membrane 
patches in the presence of a Cl- concentration gradient ([Cl-]int = 147 mM; [Cl-]ext = 10 mM). ATP (1 mM) 
and PKA (75 nM) were continuously present in the intracellular solution. Dotted grey lines represent the 
closed channel level. For the purpose of illustration, recordings have been filtered at 500 Hz and 
digitised at 5 kHz before file size was compressed by 5-fold data reduction. For all experiments, 
temperature was 37 °C and holding potential was -80 mV. B and C Comparison of i and Po for human-
mouse CFTR chimeras. Data are means ± SEM (human, n = 5-10; mouse n = 4; hmNBD1/2, n = 6; 
hmTM1-6, n = 3; hmTM5+6, n = 4; hmTM5+6:9+10, n = 3). 
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5.5 Determining the binding domain of ivacaftor using single-channel 
studies of human-mouse CFTR chimeras 
 
In addition to characterising the single-channel current amplitude and Po of the 
selected human-mouse CFTR chimeras, we tested the effects of ivacaftor on the 
single-channel activity of these constructs. Due to the fact that 10 μM ivacaftor 
inhibited some constructs using the automated whole-cell patch-clamp technique, in 
these experiments we tested ivacaftor at 1 μM and 10 μM. In this way, we controlled 
for the possibility that ivacaftor may inhibit human-mouse CFTR chimeras at higher 
concentrations that may be obscuring possible potentiation effects at lower 
concentrations. 
 
5.5.1 Effect of ivacaftor on whole-domain CFTR chimeras 
Figure 5.13 shows the effects of 1 μM and 10 μM ivacaftor on the single-channel 
activity of the hmNBD1/2 chimera. The spread of the data points shown in Figure 
5.13B highlight the variability of the data collected for the hmNBD1/2 chimera. 
However, despite this variability an increase in Po with increasing ivacaftor 
concentrations was observed for all experiments performed with this construct. This 
increase in activity is demonstrated by the increase in open-channel burst duration 
after addition of 1 and 10 μM ivacaftor shown in the example recordings in Figure 
5.13A. This increase was not found to be significant at 1 μM ivacaftor, where Po 
increased from 0.33 ± 0.07 under control conditions (1 mM ATP + 75 nM PKA) to 0.41 
± 0.11 (n = 5). Increasing the concentration of ivacaftor to 10 μM however increased 
Po further to 0.47 ± 0.11 (n = 5) and this further increase was found to be significant 
when compared to control (Figure 5.13B). 
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Figure 5.13: Effects of ivacaftor on the single-channel activity of the human-mouse NBD1/2 
chimera. A Representative recordings from an excised inside-out membrane patch from a CHO cell 
showing the response of hmNBD1/2 to 1 μM and 10 μM ivacaftor. Other conditions as described for 
Figure 5.12A. B Po for hmNBD1/2 at 1 μM and 10 μM ivacaftor. Data are means ± SEM and individual 
data points are indicated by circles. (n = 4 - 5, * = P < 0.05 vs control, one-way repeated measures 
ANOVA and Dunnett’s multiple comparisons). 
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5.5.2 Effect of ivacaftor on TM-helix CFTR chimeras 
Unfortunately, insufficient data were collected to determine the effect of ivacaftor on 
the hmTM1-6 chimera. However, Figure 5.14 shows the effects of ivacaftor on the 
single-channel activity of the hmTM5+6 chimera. Representative traces showing the 
activity of this CFTR chimera under control conditions and following the addition of 1.0 
μM ivacaftor are shown in Figure 5.14A, whilst quantification of Po at control, 1.0 and 
10 μM ivacaftor are shown in Figure 5.14B. As can be seen in Figure 5.14B, addition 
of ivacaftor at either 1.0 or 10 μM did not result in an increase in the Po recorded for 
the hmTM5+6 chimera. Although only three experiments were successful at 1.0 μM 
ivacaftor, and two at 10 μM ivacaftor, no increase in Po was observed at the tested 
concentrations, with the mean Po recorded as 0.08 ± 0.01 (n = 4) under control 
conditions, 0.07 ± 0.02 (n = 3) after addition of 1.0 μM ivacaftor, and 0.10 ± 0.01 (n = 
2) after addition of 10 μM ivacaftor. 
 
Figure 5.15 shows the effects of 1 and 10 μM ivacaftor on the hmTM5+6:9+10 
construct. At the whole cell level, this construct showed potentiation at 10 μM ivacaftor 
(Figure 5.9E). However, potentiation was not observed to the same level when this 
construct was tested using single-channel patch-clamp recordings. Only three single-
channel experiments were successfully completed using this construct. An increase 
in Po was only observed in two of the three experiments at 1 and 10 μM ivacaftor 
(individual data points in Figure 5.15B) and the mean data did not indicate a 
statistically significant level of potentiation. The mean Po for this construct was 
calculated as 0.19 ± 0.08 under control conditions, increasing to 0.26 ± 0.04 at 1 μM 
ivacaftor and 0.27 ± 0.06 at 10 μM ivacaftor respectively (Figure 5.15B). Whilst the low 
power of this experiment (n = 3) limits the interpretation of these data, the upward 
trend in Po with increasing ivacaftor concentrations observed in two of the three 
experiments suggests that ivacaftor may be potentiating the single-channel activity of 





Figure 5.14: Effects of ivacaftor on the single-channel activity of the human-mouse TM5+6 
chimera. A Representative recordings from an excised inside-out membrane patch from a CHO cell 
show the response of hmTM5+6 to 1 μM ivacaftor. Other conditions as described for Figure 5.12A. B 
Po for hmTM5+6 at 1 μM and 10 μM ivacaftor. Data are means ± SEM except at 10 μM ivacaftor where 





Figure 5.15: Effects of ivacaftor on the single-channel activity of the human-mouse TM5+6:9+10 
chimeras. A Representative recordings from an excised inside-out membrane patch from a CHO cell 
show the response of hmTM5+6:9+10 to 1 μM and 10 μM ivacaftor. Other conditions as described for 
Figure 5.12A. B Po for hmTM5+6:9+10 at 1 μM and 10 μM ivacaftor. Data are means ± SEM (n = 3, P 
> 0.05 vs control, one-way repeated measures ANOVA). 
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5.6 Determining regions of the CFTR protein involved in the 
mechanism of action of ivacaftor 
 
5.6.1 Sequence alterations that affect the response of human CFTR to 
ivacaftor 
Our results from both automated whole-cell patch-clamp and single-channel patch-
clamp experiments suggest that replacement of the human CFTR sequences for TM5 
and TM6 with the mouse equivalent produces a CFTR chimera that does not 
demonstrate potentiation by ivacaftor. We therefore generated a ClustalO sequence 
alignment of both human and mouse WT-CFTR sequences for this region to determine 
which amino acid residues had been altered in the generation of the hmTM5+6 
chimera (Figure 5.16). 
 
Figure 5.16: Sequence alignment of human WT CFTR and hmTM5+6 chimera between residues 
307 and 355. Position of ECL3 is indicated by grey bar from residues 327-334. Residues that have 
been changed to the mouse equivalent in the hmTM5+6 chimera are highlighted in blue. Sequences 
aligned by ClustalO alignment using CLC Sequence Viewer v7.5. 
 
As shown in Figure 5.16, in the generation of the hmTM5+6 chimera only five amino 
acid residues were altered, the changes from the human to the mouse sequences 
being A326T, L327V, K329N, I332V and A349S. Figure 5.17 shows the locations of 
these five residues in the high-resolution cryo-EM structure of human CFTR produced 
by Liu et al. (2017). L327V, K329N, I332V are located within ECL3 adjacent to the 
extracellular entry point to the channel pore, whilst A326T is at the apical end of TM5. 
A349S is located deeper within the CFTR channel pore on TM6 (Figure 5.17). 
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Figure 5.17: Identities and locations of human-mouse sequence alterations involved in 
determining the potentiation of CFTR by ivacaftor. Structure of human CFTR based upon cryo-EM 
data, PDB: 5UAK (Liu et al., 2017). Structure on left of figure represents side view of the CFTR channel, 
structure on right represents view of the channel from the extracellular side. A326T, L327V, K329N, 
and I332V are located at the extracellular side of the CFTR channel, with L327V, K329N, and I332V 
located within ECL3 and A326T forming the extracellular end of TM5. A349S is located within the 




5.7.1. Interpretation of the data collected from automated whole-cell 
patch-clamp studies of human-mouse CFTR chimeras 
In Chapter 4, our data demonstrated that under the experimental conditions used for 
the study of human and mouse CFTR orthologues by single-channel patch-clamp 
recording, mouse WT-CFTR was not potentiated by ivacaftor. This observation 
provided the rationale for using human-mouse CFTR chimeras to investigate structural 
regions of the CFTR protein that may be involved in the mechanism of action of 
ivacaftor. Due to the large number of chimeras to be tested, their systematic study 
using the single-channel patch-clamp technique would have required a time-scale 
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beyond that which was possible in the scope of this project. Furthermore, the 
observations of Cui and co-authors that ivacaftor does potentiate mouse CFTR under 
certain experimental conditions highlighted the need to ensure that the observations 
made in Chapter 4 were not limited to the specific conditions under which these 
experiments had been carried out (Cui & McCarty, 2015; Cui et al., 2016). We were 
therefore keen to test the response of both human and mouse WT-CFTR orthologues 
as well as human-mouse CFTR chimeras using the whole-cell patch-clamp technique, 
and to test these constructs at room temperature as well as at 37 °C. 
 
By working with our industrial partner, the Novartis Institutes for Biomedical Research, 
we were able to design experiments utilising the QPatch HTX high-throughput 
automated patch-clamp platform in their laboratories based in Cambridge, 
Massachusetts, USA. Automated patch-clamp has recently been demonstrated to 
provide comparable results to manual whole-cell patch-clamp techniques, whilst 
producing a higher throughput for data collection (Billet et al., 2017). However, 
previous studies utilising automated whole-cell patch-clamp for the study of CFTR 
have utilised stably transfected cells. Due to the limited time scale of the project, the 
development of stable cell lines for all of the CFTR chimeric constructs we aimed to 
test was not feasible. For this reason, we sought to develop an assay that utilised 
transiently transfected cells that could be cryopreserved, whilst maintaining a 
sufficiently high transfection efficiency for use on the QPatch system. Furthermore, 
due to the absence of fluorescent tagging on our CFTR chimeric constructs, the assay 
design would not be able to utilise cell sorting techniques such as fluorescence 
activated cell sorting (FACS) to sort transfected cells from non-transfected cells. We 
therefore had to develop a transfection protocol that would transfect cells with a 
sufficient level of transfection efficiency to enable cells to be screened using the 
QPatch HTX platform without prior sorting. The MaxCyte STX Scalable Transfection 
System for computer-controlled flow large volume electroporation is a novel 
transfection system that has been developed for large volume, high efficiency 
transfection of cells, including mammalian cell lines (Li et al., 2009). We therefore 
adapted this technique for the transfection of CHO cells with our human-mouse CFTR 
chimeras. 
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As described in Chapter 2, we performed initial optimisation studies to test the optimal 
cDNA concentrations and incubation periods for our CFTR constructs and tested 
these using both the QPatch HTX system and the Nanion SyncroPatch 384PE 
automated patch-clamp platforms. The optimal transfection cDNA quantity and 
incubation period determined during optimisation was 300 μg∙ml-1 and incubation for 
72 hours, determined as a balance between transfection success rate, cell viability 
and magnitude of CFTR-mediated currents recorded. However, despite this 
optimisation stage, large variations were recorded in transfection success rate, 
stability of recordings and magnitude of the CFTR-mediated current for cells 
transfected with the same cDNA plasmid. Additionally, success rate varied 
considerably between different constructs tested. For this reason, the number of 
successful experiments completed for each construct was relatively low, despite 
multiple repeats of the experiment with cells (overall success rate around 25% of cells 
tested). A major limitation introduced into the analysis of these data was the 
subtraction of leak current, which was incorrectly calculated by subtracting the current 
recorded at -30 mV from the maximal outward current record at +80 mV for each 
sweep. As a result of this error, the values recorded for maximal outward current are 
likely to represent an overestimate of the actual outward current that was present. It is 
therefore possible that the magnitude of the effects observed for each CFTR construct 
were smaller than those reported. However, as this stage of the analysis was applied 
consistently for all recordings, trends in the data are unaffected. Nevertheless, it must 
be recognised that the levels of significance reported are based on overestimates in 
the magnitude of the outward currents. Despite these limitations however, the assay 
enabled the rapid testing of all 16 CFTR constructs for their response to 10 μM 
ivacaftor. 
 
The bar chart shown in Figure 5.18 summarises the data for the response of human-
mouse CFTR chimeras to 10 μM ivacaftor shown in Figures 5.3, 5.5, 5.7, 5.9 and 5.11. 
Our whole-cell data indicate that human WT-CFTR was potentiated by 10 μM ivacaftor 
in agreement with the data collected from single-channel recordings of the human WT-
CFTR channel in Chapter 4. However, when testing mouse WT-CFTR using the 
automated whole-cell platform, ivacaftor at 10 μM resulted in an inhibition of the 
channel that was consistent over multiple repetitions of the experiment. Whilst our 
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single-channel data in Chapter 4 had suggested the possibility of a slight inhibitory 
effect of ivacaftor at higher concentrations in the case of some CFTR orthologues, 
inhibition on the scale observed using the QPatch assay was not observed at the 
single-channel level and had not been observed before for the mouse WT-CFTR 
channel. Furthermore, the pattern of activation of mouse WT-CFTR by FSK and 
subsequent inactivation by CFTRinh-172 was different to that observed for other 
constructs as demonstrated by the representative trace shown in Figure 5.4. Overall 
FSK-induced current for mouse WT-CFTR was low in comparison to human WT-
CFTR, at 15.9 ± 3.19 pA/pF (n = 11) compared to 37.7 ± 6.61 pA/pF (n = 13) for human 
WT-CFTR. This lower CFTR-mediated current would be expected from the reduced 
single-channel current and CFTR conductance recorded for mouse WT-CFTR in 
Chapter 4 using the single-channel patch-clamp technique. This difference may also 
result from variation in expression levels for human and mouse CFTR in CHO cells, 
as has been reported previously in other cell lines including NIH 3T3 (Ostedgaard et 
al., 2007). In addition, it is not possible to rule out a reduced transfection efficiency for 
mouse WT-CFTR as a contributing factor to this observation. Furthermore, the rate of 
increase in outward current for mouse WT-CFTR in response to FSK appeared 
reduced in comparison to both human WT-CFTR and the other CFTR chimeric 
constructs tested (Figure 5.4). However, despite these differences, the experiments 
utilising mouse WT-CFTR did not demonstrate potentiation of mouse WT-CFTR in 
response to 10 μM ivacaftor although they showed an increase in current in response 
to FSK that was inhibited by CFTRinh-172. These data, as with the data collected in 
Chapter 4, again appear to contradict previously published data suggesting 
potentiation of mouse WT-CFTR by ivacaftor (Cui & McCarty, 2015; Cui et al., 2016), 
and indicate that at the whole-cell level, mouse CFTR-mediated Cl- currents are not 
potentiated, and may indeed be inhibited by 10 μM ivacaftor. 
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Figure 5.18: Effect of 10 μM ivacaftor on human-mouse CFTR chimeras following activation by 
FSK. Data collected by automated whole-cell patch-clamp of human-mouse CFTR chimeras at 80 mV. 
Data have been corrected for cell size. Error bars represent SEM (n = 4-14, * = P < 0.05 vs control for 
each construct, paired two-way Student’s t-test). 
After testing human and mouse WT-CFTR using automated whole-cell patch-clamp 
recordings, we next focussed on the ivacaftor response of the whole-domain NBD 
CFTR chimeras hmNBD1/2, hmNBD1 and hmNBD2, where one or both of the NBD 
sequences in human CFTR were exchanged for the corresponding sequences from 
mouse CFTR. As shown in Figure 5.18, all three of these NBD chimeras showed 
potentiation by ivacaftor. Given that human WT-CFTR is potentiated by ivacaftor 
whereas mouse WT-CFTR is not, these data suggest that the sequences responsible 
for the observed differences in the ivacaftor response between human and mouse 
CFTR are not located within the NBDs. One potential explanation for this is that the 
binding site, or binding sites for ivacaftor are not located within the NBDs and that 
alteration of the NBD structure of human CFTR therefore does not result in inhibition 
of the ivacaftor response in the case of these NBD chimeras. This observation 
supports data obtained using HDX, which suggests a possible binding site for ivacaftor 
located at residues within TMD2 where this domain is in close proximity to either NBD1 
or NBD2 (Byrnes et al., 2018). Cysteine cross-linking has identified eight interactions 
between residues F1074, L1065, T1064, G1069 and F1068 in ICL4 and W496, M498, 
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F508, V510 and K564 in NBD1, indicating that these residues lie within close proximity 
(He et al., 2008; Serohijos et al., 2008; Zhou et al., 2010; Wang et al., 2011a; Wang 
& Linsdell, 2012; Gao & Hwang, 2016; Zhang & Chen, 2016). Alteration of the NBD 
structure in this region could conceivably alter the interaction of the TMD2 residues 
with ivacaftor if such changes were sufficient to alter the TMD structure at these points. 
However, our data suggest that this is not likely. As shown in Figure 5.19, the residues 
that demonstrate cysteine cross-linking between ICL4 and NBD1 are conserved in 
both human and mouse CFTR. 
 
Figure 5.19: Sequence alignment for human and mouse NBD1. Residues identified as forming 
cross-links following mutation to cysteines are highlighted in red (He et al., 2008; Serohijos et al., 2008; 
Zhou et al., 2010; Wang et al., 2011a; Wang & Linsdell, 2012; Gao & Hwang, 2016; Zhang & Chen, 
2016). Sequences aligned by ClustalO alignment using CLC Sequence Viewer v7.5. 
 
Having established that exchanging the NBD sequences in human CFTR for mouse 
sequences does not prevent potentiation by ivacaftor, we next investigated the effect 
of exchanging the TMD sequences for mouse equivalents. As shown in Figure 5.18 
and in Figures 5.6 and 5.7, exchanging both TMD1 and TMD2 in human CFTR for the 
mouse sequences resulted in a chimera (construct hmTM1-12) that demonstrated 
inhibition of whole-cell current in response to 10 μM ivacaftor, in common with mouse 
WT-CFTR. This observation provides strong support for the action of ivacaftor at the 
level of the TMDs rather than the NBDs and supports the data obtained by Byrnes et 
al. (2018) using HDX. The hmTM1-6 chimera however still demonstrated ivacaftor 
potentiation, whilst the hmTM7-12 chimera did not, with inhibition by ivacaftor not 
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being present for either of these constructs (Figure 5.18). These data appear to 
support a role of TMD2 in the mechanism of action of ivacaftor rather than TMD1. The 
data from Byrnes et al. (2018) suggested binding of ivacaftor at the TMD2 residues in 
close proximity to NBD1 and NBD2, with regions between residues 1055–1064 and 
1070–1074 showing the greatest level of protection from HDX after addition of 
ivacaftor. However, as shown in Figure 5.20, alignment of the human and mouse 
sequences shows that these sequences are highly conserved between human and 
mouse orthologues, with only one sequence alteration, P1072T being located within 
this region. It is therefore possible that the hmTMD7-12 construct may not demonstrate 
functional differences resulting from ivacaftor binding at this site. Byrnes et al. (2018) 
also showed strong protection from HDX occurring at the N-terminal lasso motif in 
TMD1. For this reason, we hypothesised that ivacaftor may be acting either directly or 
through allosteric interactions via alternative regions within the TMDs that were not 
examined by the HDX experiments. 
 
Figure 5.20: Human-Mouse sequence alignment of residues within ICL4 identified as a potential 
ivacaftor-binding site by HDX. Residues that have shown protection from HDX following addition of 
ivacaftor are highlighted in green. Sequences aligned by ClustalO alignment using CLC Sequence 
Viewer v7.5. HDX data are from Byrnes et al. (2018). 
 
The next chimera tested was the hmTM5+6 construct in which the mouse sequences 
for TM5 and TM6 were expressed on the human CFTR background. This construct 
represented the chimera with the smallest number of sequence alterations that was 
tested, with just 5 amino acid residues changed from the human sequence (A326T, 
L327V, K329N, I332V and A349S, Figure 5.16). From the finding that the hmTM1-6 
chimera demonstrated potentiation by ivacaftor, it would be expected that hmTM5+6 
would also similarly show potentiation. However, no potentiation was observed for the 
hmTM5+6 construct, suggesting that the five sequence alterations A326T, L327V, 
K329N, I332V and A349S are sufficient to prevent the potentiation of human CFTR by 
10 μM ivacaftor. Four of these residues, A326T, L327V, K329N and I332V are grouped 
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either in ECL3 or at the external end of TM5 near the extracellular entry point to the 
CFTR pore, whilst the fifth is buried deeper within the protein on TM6 and is likely to 
line the pore itself according to cryo-EM data (Liu et al., 2017). Due to the lack of 
coverage by HDX at ECL3, it is possible that our data highlights a secondary binding 
site for ivacaftor at this region that would not have been detected by the techniques 
employed by Byrnes et al. (2018). However, we cannot rule out the possibility that the 
regions highlighted by our experiments may be required for ivacaftor potentiation via 
allosteric interactions following binding of ivacaftor at another location on the CFTR 
protein. The location of the channel gate in CFTR is thought to correspond to the 
narrow pore region adjacent to residues 338-341 in TM6 (Gao & Hwang, 2015). A349 
is located close to this region within the intracellular vestibule of CFTR. Whilst it is 
therefore unlikely that A349 represents the location of a binding site for ivacaftor, it is 
possible that binding of ivacaftor at a different binding site (such as the location on 
ICL4 suggested by Byrnes et al. (2018)) results in a conformational change in CFTR 
along its longitudinal axis via the region of A349 that leads to favourable opening of 
the channel gate. It is therefore possible that the A349S sequence alteration disrupts 
this pathway of longitudinal movement and prevents the potentiation of CFTR by 
ivacaftor. Further experiments involving the sequence alterations A326T, L327V, 
K329N, I332V and A349S either individually or in combinations would be valuable in 
determining which of these changes are involved in inhibition of ivacaftor potentiation. 
 
Our observations that the hmTM1-6 chimera showed potentiation by ivacaftor, 
whereas the hmTM5+6 chimera did not, suggest that allosteric interactions between 
TM5+6 and other transmembrane helices may facilitate ivacaftor potentiation. We 
therefore tested a range of human-mouse CFTR chimeras where additional mouse 
TM helices were introduced into the protein in addition to TM5 and TM6. As shown in 
Figure 5.18, constructs where mouse TM3+4 or TM9+10 were incorporated into the 
CFTR protein in conjunction with mouse TM5 and TM6 demonstrated ivacaftor 
potentiation. We therefore hypothesise that interactions exist between transmembrane 
helices 3, 4, 9 and 10 and TM5 and TM6 that may reverse the effects of the A326T, 
L327V, K329N, I332V and A349S human-mouse sequence alterations. 
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5.7.2. Interpretation of the data collected from single-channel patch-
clamp studies of human-mouse CFTR chimeras 
Although providing a useful technique for the rapid screening of multiple CFTR 
constructs for potentiation by ivacaftor, the variability inherent in the automated whole-
cell patch-clamp data, potentially resulting from variance in transfection efficiency and 
cDNA expression, limits the interpretation of these data. We therefore aimed to test a 
smaller number of these human-mouse CFTR chimeras using the single-channel 
patch-clamp technique to provide greater insight into the effect of ivacaftor on these 
constructs. The first construct to be tested utilising this approach was the hmNBD1/2 
chimera. The gating behaviour of this chimera was characterised by openings to the 
full open state with a Po that was decreased compared to human WT-CFTR but higher 
than that of mouse WT-CFTR (Figure 5.12). The single-channel current observed for 
the hmNBD1/2 chimeras was midway between that of human and mouse WT-CFTR 
and the O1 sub-conductance state observed for mouse WT-CFTR was not observed 
for hmNBD1/2. These data suggest that the unique gating behaviour of mouse WT-
CFTR highlighted in Chapter 3 results primarily from the properties of the mouse TMD 
sequences. They also likely reflect the close sequence homology between human and 
mouse NBDs. As predicted from the whole-cell patch-clamp experiments, the 
hmNBD1/2 chimera was potentiated by 10 μM ivacaftor. However, although an 
increase was observed at 1 μM ivacaftor this increase was not found to be significant 
(P < 0.05, Figure 5.13). This contrasts considerably with the data collected using 
single-channel patch-clamp for human WT-CFTR, which demonstrated high levels of 
potentiation at ivacaftor concentrations as low as 0.01 μM (Chapter 4, Figure 4.1). 
These data therefore suggest a shift in the efficacy of ivacaftor for the hmNBD1/2 
chimera when compared to human WT-CFTR. However, as ivacaftor was only tested 
at 1.0 and 10 μM in these experiments determination of the KD of the compound for 
this construct requires additional experiments. As mentioned, the interface between 
ICL4 and NBD1 has been proposed as a binding site for ivacaftor (Byrnes et al., 2018). 
Whilst our data obtained using the whole-cell patch-clamp technique appeared to rule 
out the possibility that exchange of the human NBD sequences for the corresponding 
mouse sequences affected this interface, a shift in the efficacy for ivacaftor resulting 
from these changes suggests that this interaction may have been altered in the case 
of the hmNBD1/2 construct. 
 159 
 
The next chimera to be tested at the single-channel level was the hmTM1-6 construct. 
However, unfortunately insufficient data were collected to test the effect of ivacaftor 
on this construct. The limited data that were obtained demonstrated a gating behaviour 
that more closely resembled that of mouse rather than human WT-CFTR (Figure 5.12). 
Both the single-channel conductance and Po of the hmTM1-6 chimera were 
comparable to mouse WT-CFTR (Figure 5.12) and examination of the single-channel 
trace shown in Figure 5.12 appears to demonstrate the presence of the O1 sub-
conductance state observed for mouse WT-CFTR. These data combined with those 
for the hmNBD1/2 chimera highlight the involvement of the TMDs rather than the 
NBDs in determining the unique gating behaviour of mouse WT-CFTR. 
 
In agreement with the whole-cell patch-clamp data collected for the hmTM5+6 
chimera, single-channel data for this construct did not show potentiation in response 
to either 1.0 or 10 μM ivacaftor (Figure 5.14). These data provide further support for 
the involvement of the five mouse sequence alterations in TM5 and TM6 in the 
mechanism of action of ivacaftor, although the number of successful experiments 
carried out using this chimera were small (1.0 μM ivacaftor, n = 3; 10 μM ivacftor, n = 
2). The pattern of gating for this chimera showed similarities with that of mouse WT-
CFTR, with a reduced Po and single-channel current amplitude (Figure 5.12). 
However, this gating pattern appeared to show more defined open bursts than either 
mouse WT-CFTR or the hmTM1-6 chimera (Figure 5.12) with increased interburst 
channel closures. However, a lack of sufficient true single-channel recordings 
obtained with this construct prevented further analysis of the gating behaviour of the 
channel. 
 
The whole-cell patch-clamp data had shown that inclusion of mouse sequences for 
TM9+10 in conjunction with TM5+6 in the hmTM5+6:9+10 chimera resulted in reversal 
of the effect of the mouse TM5+6 sequences on potentiation by ivacaftor. We were 
therefore keen to determine if this effect was also observed at the single-channel level. 
As shown in Figure 5.15, no significant increase in activity was observed for this 
chimera on addition of either 1.0 or 10 μM ivacaftor. However only limited single 
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channel data were collected for this construct, with a pattern of increasing Po with 
increasing concentrations of ivacaftor observed in two out of the three experiments 
completed (Figure 5.15B). Whilst these data do not support potentiation by ivacaftor, 
it is possible that an effect might be observed if sufficient data were collected. From 
our data we therefore conclude that at the single-channel level, inclusion of mouse 
sequences for TM9 and TM10 in conjunction with TM5 and TM6 does not result in 
significant ivacaftor potentiation. However, at the whole-cell level, the expression of 
multiple channels may explain the potentiation observed for the hmTM5+6:9+10 
chimera. 
 
In conclusion, our data have demonstrated the involvement of all or some of the five 
amino acid residues A326, L327, K329, I332 and A349 in determining the response of 
human CFTR to the potentiator ivacaftor. Exchange of all five of these residues for 
their mouse CFTR equivalents is sufficient to prevent potentiation by ivacaftor. Whilst 
it is not possible to determine from these data whether the locations of these five 
residues contribute to a binding site of the ivacaftor molecule, future experiments 
where these residues are exchanged from their human to their mouse equivalents 












6. General discussion 
 
6.1 Species differences in CFTR structure and function 
 
6.1.1 Variations in the structure and gating behaviour of CFTR 
orthologues from diverse species 
As demonstrated by the cladogram shown in Figure 1.7 of Chapter 1, CFTR 
orthologues have evolved across a broad spectrum of species including all species 
within the Gnathostomata superclass (jawed vertebrates) with an additional 
orthologue that lacks the RD reported in lampreys (Bose et al., 2015; Cui et al., 2017). 
Homologies between sequenced CFTR orthologues within the Gnathostomata range 
from 53.9% (zebrafish) to 99.7% (chimpanzee) (Zerbino et al., 2018), yet despite the 
low homology of the zebrafish CFTR compared human CFTR, comparison of the 
human and zebrafish structures obtained by cryo-EM demonstrates a high level of 
structural conservation (Zhang & Chen, 2016; Liu et al., 2017). Conservation of 
residues across species includes several functionally important residues such as the 
R347/D924 salt bridge between TM6 and TM8, TM6 gating residues such as F337 
and T338 as well as many proposed pore-lining residues (Liu et al., 2017). The RD 
shows the lowest level of homology of all of the domains of CFTR (Figure 1.8 and 
Appendix 1), although phosphorylation sites within the RD are more highly conserved. 
This variation is likely to reflect a lower selection pressure on the evolution of this 
domain. However, despite the high levels of homology for functional residues within 
CFTR, many residues differ between CFTR orthologues and may contribute to 
observed differences in function and pharmacology for these orthologues. The varied 
function of CFTR orthologues from diverse species is likely to reflect optimisation of 
the channel according to its specific role in different species. For the purpose of CF 
research however, this library of diverse CFTR orthologues may serve as a useful tool 
for understanding structure-function relationships and investigating the action of small 
molecule modulators of channel function. 
 
In Chapter 3, the single-channel behaviour of human, pig, sheep, ferret, mouse and 
zebrafish CFTR orthologues was characterised. Differences observed in the single-
channel current amplitude and Po for human, sheep and pig WT-CFTR provide a 
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demonstration of how the gating behaviour and single-channel properties of CFTR 
orthologues may differ despite high levels of sequence homology. Sheep WT-CFTR 
for example shares 91% amino acid identity with human WT-CFTR, yet despite this 
high level of homology, sheep WT-CFTR demonstrated a 7% increase in Po and a 
35% increase in single-channel current amplitude compared to human CFTR. By 
contrast however, the more divergent orthologues tested, mouse and zebrafish WT-
CFTR, demonstrated a reduced single-channel current amplitude and lower Po, 
characterised by brief short-lived channel openings and a highly active sub-
conductance state in the case of mouse CFTR. Data from Chapter 5 obtained from 
human-mouse CFTR chimeras demonstrated that in the case of mouse CFTR, this 
reduction in Po of the full open state most likely results from sequence differences in 
the TMDs rather than in the NBDs of the mouse CFTR protein. 
 
As shown in Figure 5.12, the unique gating behaviour of mouse WT-CFTR appears to 
be reproduced by both the hmTM1-6 and the hmTM5+6 CFTR chimeras. These data 
suggest that sequence changes in TMD1, and specifically the five sequence 
alterations A326T, L327V, K329N, I332V and A349S from human to mouse 
sequences may be involved in determining the presence of these brief channel 
openings and the reduced single-channel current amplitude demonstrated by 
divergent CFTR orthologues. One possible hypothesis for this observation is that the 
sequence alterations A326T, L327V, K329N, I332V (Figure 5.17), may alter the 
properties of ECL3 in such a way as to result in interference with the Cl- conduction 
pathway at the extracellular entrance of the CFTR pore, or alter the Cl- sensitivity of 
the CFTR channel. Broadbent et al. (2015) for example have shown that the positively 
charged arginine residue at position 899 in ECL4 is involved in determining sensitivity 
of the CFTR channel to extracellular Cl-. In this same study, exchange of K329 for an 
alanine residue also resulted in a small decrease in the percentage stimulation of 
CFTR by extracellular Cl-, albeit not at statistically significant levels (Broadbent et al., 
2015). However, it is possible that positively charged residues located near the 
extracellular entrance of the CFTR pore play a role in attracting Cl- ions into the 
extracellular CFTR vestibule and may affect conductance. Comparison of the ECL3 
sequences of mouse and zebrafish demonstrate that the zebrafish orthologue does 
not contain the same sequence alterations in this region as mouse. However, other 
sequence alterations are present, including I332N, raising the possibility that 
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expression of polar residues such as asparagine may alter the structural interaction of 
this extracellular region with other regions adjacent to the CFTR pore entrance. 
Further study of the effect of changing individual residues highlighted in our study, 
including K329N may help to determine the role that these residues play in the single-
channel properties of divergent CFTR orthologues such as mouse CFTR and could 
provide insight into the role of such residues in the gating and conductance 
characteristics of CFTR. 
 
As discussed in Chapter 3, our data appears to demonstrate a functional divergence 
in CFTR gating behaviour that is related to evolutionary divergence. The cladogram 
shown in Figure 3.1 demonstrates that human, sheep, pig and ferret CFTR represent 
a divergent evolutionary clade from mouse and zebrafish based on sequence 
similarity. This division appears to correlate with observed divergence in the gating 
properties of these orthologues. Furthermore, ferret CFTR, which represents further 
evolutionary divergence from human, pig and sheep CFTR demonstrates a reduced 
single-channel conductance whilst maintaining a similar Po to human, pig and sheep 
CFTR orthologues. These data therefore appear to support a correlation of CFTR 
function with evolutionary divergence. We have previously suggested that there may 
be a link between CFTR activity and metabolic rate in endothermic species, as 
highlighted by a potential correlation between CFTR conductance and body 
temperature (Bose et al., 2015a).  Although differences in the experimental conditions 
must be accounted for, previously published data suggests that the activity 
conductance values for CFTR orthologues can be ranked in the order chicken > sheep 
> rabbit > Xenopus > human > possum > pig > mouse (Hanrahan et al., 1993; Lansdell 
et al., 1998a; Al-Nakkash & Reinach, 2001; Ostedgaard et al., 2007; Demmers et al., 
2010; Aleksandrov et al., 2012; Cai et al., 2015). When the published values for 
conductance of these orthologues is plotted against mean body temperature, the 
resulting scatter plot can be fitted by linear regression with r2 = 0.51 (Figure 6.1). 
Further study with a greater selection of evolutionarily intermediate CFTR orthologues 




Figure 6.1: Relationship between CFTR single-channel conductance (γ) and mean body 
temperature in endothermic vertebrates. Linear regression (grey line) indicates possibility of a 
positive correlation with an r2 value of 0.51. Figures for mean body temperature sourced from Hanrahan 
et al. (1993), Lansdell et al. (1998a), Al-Nakkash & Reinach (2001), Ostedgaard et al. (2007), Demmers 
et al. (2010), Aleksandrov et al. (2012), and Cai et al. (2015). 
 
6.1.2 Differences in the effect of CF-causing mutations on diverse 
species orthologues of CFTR 
A number of studies have previously highlighted differences in the susceptibility of 
diverse species orthologues of CFTR to CF-causing mutations, with variations 
reported in the impact on gating behaviour, channel processing, maturation and 
thermal stability (Ostedgaard et al., 2007; Fisher et al., 2011; Aleksandrov et al., 2012; 
Cai et al., 2015). Whilst previous studies have demonstrated that mouse F508del-
CFTR does not demonstrate the same level of processing defect as observed for 
human F508del-CFTR, our data demonstrate that both mouse and sheep F508del-
CFTR orthologues demonstrate a reduced susceptibility to the gating defect of the 
F508del mutation. In the case of mouse CFTR, no difference was observed in the 
gating behaviour of mouse F508del-CFTR when compared to WT-CFTR (Figure 3.7). 
Interestingly, this observation contrasts with other studies of the mouse F508del-
CFTR channel using excised membrane patches, which have shown a reduced 
activity compared to mouse WT-CFTR, resulting from an increase in the interburst 
interval (Ostedgaard et al., 2007; Dong et al., 2012). However in these studies, the 
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reduction in Po observed for mouse F508del-CFTR compared to WT-CFTR was much 
smaller than that observed for human F508del-CFTR compared to human WT-CFTR 
(Ostedgaard et al., 2007; Dong et al., 2012). Furthermore, our data demonstrated that 
the mouse F508del-CFTR orthologue unlike human F508del-CFTR shows thermal 
stability at 37 °C (Figure 3.9). Although it was not possible in the current study to 
identify the structural differences between human and mouse CFTR orthologues that 
result in these differences in the F508del phenotype, these observations raise the 
possibility that future studies, potentially utilising human-mouse chimeras that include 
the F508del mutation may highlight regions of the CFTR protein, which may be 
targeted to stabilise the F508del-CFTR protein. 
 
One possible site is the isoleucine residue at position 539, which is altered to a 
threonine residue in the mouse CFTR orthologue. I539T has been shown to act as a 
revertant mutant when expressed in conjunction with the F508del mutation in human 
CFTR (deCarvalho et al., 2002; Aleksandrov et al., 2012) and its presence in the 
mouse sequence may help to explain the differences observed between human and 
mouse F508del-CFTR. However, Dong et al. (2012) have shown previously that whilst 
I539T improves F508del-CFTR processing, it has a negative impact on F508del-
gating. In this same study, Dong et al. (2012) also demonstrated using human-mouse 
CFTR chimeras that inclusion of mouse sequences for ICL3 and ICL4 on a human 
F508del-CFTR background prevents the gating defect of the F508del mutation. This 
protective effect was linked to the human-mouse sequence change P1072T (Dong et 
al., 2012). 
 
6.2 Relevance and implications of species differences in function and 
pharmacology of CFTR orthologues for the use of CF animal models 
 
The differences in phenotype between mouse models of CF and human patients, 
discussed in Chapter 1.7.2, combined with the observed differences between human 
and mouse CFTR pharmacology demonstrated in this study highlights the requirement 
for the development of alternative animal models for CF that more accurately replicate 
the human disease (McCarron et al., 2018). In addition to the development of gut-
corrected and humanised mouse CF models (Zhou et al., 1994; Hodges et al., 2016), 
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alternative animal models, including rat (Tuggle et al., 2014), rabbit (Xu et al., 2016), 
ferret (Sun et al., 2010), pig (Rogers et al., 2008a) and very recently sheep (Fan et al. 
2018). Our data demonstrate that the function and pharmacology of CFTR orthologues 
may differ, despite high levels of sequence homology. This observation therefore 
highlights the importance of characterising functional and pharmacological differences 
between species orthologues prior to the development of animal models in order to 
determine any likely differences in phenotype in-vivo. The ferret model of CF provides 
a good example of the relevance of this research. Ferrets share similarities in lung 
physiology with humans, possessing goblet cells and demonstrating a high expression 
of CFTR in trachea and primary bronchi (Engelhardt et al., 1992; Fisher et al., 2012; 
Keiser et al., 2013; McCarron et al., 2018). In addition, the ferret CFTR orthologue 
shares 92% amino acid identity with the human CFTR orthologue. Combined with the 
economic benefits of ferrets when compared to larger species with a slower growth 
and reproductive rate such as pigs, sheep or primates, these factors make ferrets an 
attractive species for use as CF models. However, our data have demonstrated some 
key differences in the electrophysiological properties of ferret CFTR despite the high 
levels of sequence homology compared to human CFTR. For example, whilst ferret 
CFTR shares similar activity with human CFTR, this orthologue has a lower single-
channel current amplitude and the possibility of current rectification at negative holding 
potentials when studied in the presence of an asymmetrical Cl- gradient (Figure 3.3). 
Whilst ferret CFTR did demonstrate potentiation in response to ivacaftor (Figure 4.5), 
these electrophysiological differences should be considered when using ferret CF 
models for bioelectrical studies. 
 
6.3 Differences in pharmacology between CFTR orthologues 
 
Our data have demonstrated that mouse CFTR (and potentially zebrafish CFTR), are 
not potentiated by ivacaftor (Figure 4.11). Furthermore, we have shown that different 
species orthologues, including sheep and pig CFTR, may demonstrate a reduced 
efficacy for ivacaftor despite sharing high levels of sequence homology with human 
CFTR (Figures 4.3 and 4.4). The observation that non-human species may not 
replicate the human response to certain small molecule modulators is an important 
consideration when using animal models for any disease in the pre-clinical screening 
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for novel pharmaceuticals. In addition, however, our study has demonstrated how 
such differences may provide the basis for studies of structure-function relationships 
and investigations into the mechanism of action of such compounds through the use 
of chimeric proteins. 
 
6.4 Identification of residues involved in the mechanism of action of 
ivacaftor 
 
Our data have highlighted five sequence alterations in the hmTM5+6 chimera, A326, 
L327, K329, I332 and A349, that result in impaired CFTR function compared to human 
WT-CFTR as demonstrated by a reduction in Po and single-channel current amplitude 
compared to human WT-CFTR. Furthermore, we have shown that the resulting CFTR 
channel cannot be potentiated by ivacaftor. As shown in Figure 5.17, four of these 
residues, A326, L327, K329 and I332 are located at the extracellular side of the CFTR 
protein, within ECL3 and the outer part of TM5 adjacent to the extracellular entrance 
to the CFTR pore (Liu et al., 2017). The fifth residue A349 is located within the CFTR 
pore itself, sitting at the intracellular side of the proposed CFTR gate located in the 
region of residues 338 and 341 in TM6 (Gao & Hwang, 2015; Liu et al., 2017). There 
are multiple potential explanations for the effect of changing these residues. Firstly, it 
is possible that these residues correspond to a potential binding site of ivacaftor. In 
their study of the binding sites of ivacaftor using HDX, Byrnes et al. (2018) identified 
regions of the CFTR protein where HDX was protected following addition of ivacaftor, 
therefore demonstrating potential binding sites for the drug (Figure 1.12). The region 
that underwent the greatest degree of protection was located at the intracellular apex 
of ICL4 in TMD2 where this region has been proposed to form a so-called ‘ball and 
socket’ joint with adjacent residues on NBD1, including F508 (Oldham et al., 2008; 
Zhang & Chen, 2016; Byrnes et al., 2018). 
 
In our experiments where the entire human sequence for TMD2, including ICL4, was 
exchanged for the mouse sequence, potentiation by ivacaftor was not observed. 
However, our data unfortunately do not include CFTR constructs where ICL4 residues 
were exchanged in isolation. Furthermore, the proposed binding region within ICL4 
that was proposed by Byrnes et al. (2018) is highly conserved between human and 
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mouse and so the use of a human-mouse chimera for this region may not demonstrate 
differences in function and pharmacology. However, our data do not rule out the 
possibility that ivacaftor does bind at the ICL4/NBD1 interface and may therefore be 
complementary to the data obtained by Byrnes et al. (2018). Interestingly, as 
mentioned in Section 6.1.2, Dong et al. (2012) used human-mouse CFTR chimeras to 
identify the P1072T human to mouse sequence alteration as preventing the gating 
defect of F508del. This residue is located in the proposed ICL4 binding site for 
ivacaftor (Byrnes et al., 2018) (Figure 5.20). The P1072T sequence alteration was 
present in both the hmTM1-12 and hmTM7-12 chimeras, and neither of these 
chimeras demonstrated potentiation in response to ivacaftor when studied using the 
automated whole-cell patch-clamp technique (Figures 5.7 and 5.18). These data 
combined with the studies by Dong et al. (2012) and Byrnes et al. (2018) highlight the 
importance of this region in both the gating of CFTR and the mechanism of action of 
ivacaftor. 
 
In addition to the ICL4 binding site, Byrnes et al. (2018) also identified regions 
corresponding to residues within the lasso motif, ICL1 and ICL3 that showed protection 
to HDX following addition of ivacaftor. These data suggest the possibility that ivacaftor 
may bind to CFTR at multiple locations. Although the five residues that were 
highlighted by our data did not demonstrate protection from HDX, these regions did 
not demonstrate deuterium uptake and so HDX experiments do not rule out the 
possibility of an additional ivacaftor binding site located at the residues identified in 
our study (Byrnes et al., 2018). 
 
Whilst it is possible that the A326, L327, K329, I332 and A349 residues may represent 
an additional binding-site for ivacaftor besides the ICL4/NBD1 region, another 
possibility is that these residues represent structural regions of the protein that are 
involved in the mechanism of action of ivacaftor through allosteric interactions. In 
Chapter 1.8, four potential modes of action for CFTR potentiators were discussed, 
these being enhancement of RD phosphorylation, enhanced ATP-binding at the 
NBDs, promotion of NBD dimerization or facilitation of movement along the 
longitudinal axis of CFTR from the NBDs to the TMDs. Ivacaftor has been shown 
previously to operate independently of ATP (Eckford et al., 2012; Jih & Hwang, 2013) 
and to potentiate CFTR channels that lack either the RD or NBD2 (Bompadre et al., 
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2005; Jih & Hwang, 2013; Yeh et al., 2015). It is therefore likely that the mechanism 
by which ivacaftor potentiates CFTR involves facilitation of the movement of the 
transmembrane helices. Further experiments would be required to determine which of 
the A326, L327, K329, I332 and A349 residues are involved in the action of ivacaftor, 
however from the data collected two hypotheses may be generated. The first is that 
binding of ivacaftor to CFTR facilitates allosteric movement of the residues in ECL3, 
which in turn may facilitate channel gating or entry of Cl- at the extracellular side of the 
CFTR conduction pathway. Alternatively, altering the alanine residue at position 349 
to a serine residue may inhibit the facilitation of transmembrane domain movement by 
ivacaftor. Further experiments would be required to determine the residue or residues 
that are responsible for the differences in pharmacology that have been observed here 
between human and mouse CFTR. 
 
6.5 Implications for future research and development of CF therapies 
 
By identifying regions of the CFTR protein that are involved in the mechanism of action 
of ivacaftor, we have identified potential sites within the CFTR protein that may form 
targets for the development of novel potentiators for the treatment of CF. Ivacaftor 
itself was first characterised in 2009 and approved for patient use by the FDA in 2012 
(Van Goor et al., 2009; Ramsey et al., 2011). At the time of writing, ivacaftor has 
therefore been available to patients for six years, and has proved highly efficacious for 
the treatment of patients carrying class III mutations, providing a proof of concept for 
the treatment of CF using small molecules (Moss et al., 2015). However, for the 
treatment of patients homozygous for mutations that also affect channel processing, 
such as F508del, potentiators like ivacaftor must be used in combination with CFTR 
correctors. Orkambi, which was the first such combination therapy to be licensed, 
showed some benefit to patients carrying the F508del mutation, but the size of this 
benefit was relatively small in most patients compared to the effects observed for 
ivacaftor in patients with class III mutations (4.3 - 6.7% increase in FEV1 compared to 
10.6% observed in G551D patients treated with ivacaftor) (Ramsey et al., 2011; 
Wainwright et al., 2015). Symdeko, which represents the next generation of 
combination therapy, combining ivacaftor with tezacaftor, has demonstrated an 
improved level of tolerance compared to Orkambi (Taylor-Cousar et al., 2017). In 
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addition, results from recent trials for triple combination therapy including the Vertex 
compounds VX-659 and VX-445 have also shown positive effects with improvements 
in FEV1 of 13.3% and 13.8%, respectively (Davies et al., 2018; Keating et al., 2018). 
However, the ongoing development of CFTR potentiators such as QBW251 (Novartis), 
CTP-656 (Concert Pharmaceuticals/Vertex) and GLPG1837 (AbbVie/Galapagos), 
demonstrates the requirement for compounds that show increased efficacy compared 
to ivacaftor. Understanding the mechanism of action of ivacaftor, principally the 
regions of the CFTR protein with which the compound is likely to interact, and regions 
that are involved in the mechanism of action of the drug, therefore helps to provide 
information about potential targets for the development of novel CFTR potentiators. 
The results of this study have highlighted such regions of the CFTR protein that have 
not been identified by previous studies. It is hoped that further experiments focussing 
on the five residues, A326, L327, K329, I332 and A349, may determine the precise 
region of the CFTR protein that is involved in CFTR potentiation by ivacaftor. In turn, 






















Since the identification of the gene encoding CFTR (Riordan et al., 1989), significant 
advances have been made in our knowledge of CF and the development of treatments 
for this disease. One of the major success stories over the past three decades of CF 
research has been the rise in life expectancy for patients with CF. Whereas CF was 
once considered to be a primarily pediatric disease, we have now passed the point 
where the number of adults with CF outnumber the number children, and patients with 
CF can now be expected to reach middle age, have careers, and raise families (Burgel 
et al., 2015). We now have a greater understanding of the role of this protein in 
regulating transepithelial fluid and electrolyte flux, and how impairment of this function 
affects patients with CF. We have a better understanding of the structure of CFTR, 
and recent advances such as the use of cryo-electron microscopy have facilitated the 
determination of the CFTR protein structure at a far higher resolution than was 
previously possible (Liu et al., 2017). Drugs are now available that treat the root cause 
of the disease, targeting mutation-specific defects in CFTR function and offering 
precision medicine to patients with the disease (Fajac & De Boeck, 2017). The 
continued development of combination therapies such as Orkambi and Symdeko, is 
broadening the use of these compounds for a wider range of patients, including 
patients carrying the most common F508del mutation (Fajac & De Boeck, 2017). 
Advances in translational research techniques such as the use of organoids 
developed from patient stem cells, are aiding the prediction of efficacy for the use of 
existing drugs in patients with rare mutations (Cholon & Gentzsch, 2018). New 
techniques in gene therapy are in development, and it is hoped that these therapies 
may hold the key to the eventual cure for this disease (Alton et al., 2016). Yet there is 
still some way to go in the development of a cure for CF and gaining a greater 
understanding of structure-function relationships of CFTR, and how existing drugs 
interact with the CFTR protein, is key to the development of the next generation of CF 
therapeutics. 
 
In this study, we have identified that the mechanism of action of ivacaftor, the first drug 
licensed to treat an underlying defect in the CFTR channel resulting from mutations, 
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involves interactions with the transmembrane helices of CFTR. We have also 
identified key residues within the TMDs of CFTR that are involved in facilitating the 
potentiation of CFTR by ivacaftor. Whilst further research is required to determine the 
exact role that these residues play in the potentiation of CFTR by ivacaftor, it is hoped 
that gaining a better understanding of how this drug interacts with CFTR may aid the 
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Coloured bars indicate boundaries of the lasso motif (LM, red), TMD1 (cyan), NBD1 (magenta), RD 
(grey), TMD2 (green) and NBD2 (purple). Blue bars represent percentage sequence conservation for 






























Residues that differ from human WT-CFTR sequence are highlighted in blue with grey shading. 
Horizontal bars indicate domains and transmembrane helices. Domain boundaries based upon Zhang 
and Chen (2016) Constructed by ClustalO alignment using CLC Sequence Viewer v7.5 (Qiagen). 
